

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

REGENERON PHARMACEUTICALS, INC.,
Petitioner,

v.

NOVARTIS PHARMA AG,
NOVARTIS TECHNOLOGY LLC,
NOVARTIS PHARMACEUTICALS CORPORATION,
Patent Owners.

Case IPR2021-00816
Patent 9,220,631

SECOND DECLARATION OF JAMES L. MULLINS, PH.D.

**Regeneron Exhibit 1103.001
Regeneron v. Novartis
IPR2021-00816**

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. QUALIFICATIONS	2
III. BACKGROUND ON PUBLIC ACCESSIBILITY	2
A. Scope of this Declaration	2
B. Person of Ordinary Skill in the Art	4
C. Library Catalog Records and Other Resources	6
D. Monograph Publications	11
E. Ownership and Date Stamp	12
F. Indexing/Cataloging	13
H. Periodical Publications	15
IV. OPINION REGARDING AUTHENTICITY AND PUBLIC ACCESSIBILITY	16
A. Document A: Ex. 1015 & Ex. 1016: Sandeep Nema and John D. Ludwig, editors, Pharmaceutical Dosage Forms: Parenteral Medications, 3rd edition	16
1. Authentication	16
2. Public Accessibility	19
3. Conclusion	23
B. Document B: Ex. 1214: Shawn Kinney, et al., “A Rational Approach to Determining the Maximum Product Sterility”, Drug Delivery Technology, Volume 9, Number 2	23
1. Authentication	23
2. Public Accessibility	27

3.	Conclusion	32
V.	AVAILABILITY FOR CROSS-EXAMINATION	32
VI.	RIGHT TO SUPPLEMENT	33
VII.	JURAT.....	33

I, Dr. James L. Mullins, declare as follows:

I. INTRODUCTION

1. My name is Dr. James L. Mullins. I have been retained by petitioner Regeneron Pharmaceutical, Inc. (“Regeneron”) to provide opinions on various documents.

2. I am presently Dean Emeritus of Libraries and Esther Ellis Norton Professor Emeritus at Purdue University. My career as a professional and academic/research librarian spanned more than 44 years including library positions at Indiana University, Villanova University, Massachusetts Institute of Technology, and Purdue University. Appendix A is a true and correct copy of my curriculum vitae my background and experience.

3. In 2018, I founded the firm Prior Art Documentation Librarian Services, LLC, located at 106 Berrow, Williamsburg, VA 23188 after purchasing the intellectual property of and as a successor to Prior Art Documentation, LLC located at 711 South RaceStreet, Urbana, IL 61801. Further information about my firm, Prior Art Documentation Librarian Services, LLC (PADLS), is available at www.priorartdoclib.com.

4. I have been retained by Regeneron to offer my opinion on the authenticity and dates of public accessibility of various documents. For this service, I am being paid my usual hourly fee of \$275.00. I have no stake in the outcome of

this proceeding or any related litigation or administrative proceedings, and my compensation in no way depends on the substance of my testimony or the outcome of this proceeding.

II. QUALIFICATIONS

5. My qualifications are laid out in my first declaration (Ex. 1033) and in my CV (Appendix A).

III. BACKGROUND ON PUBLIC ACCESSIBILITY

A. Scope of this Declaration

6. I am not a lawyer, and I am not rendering an opinion on the legal question of whether a particular document is, or is not, a “printed publication” under the law. I am, however, rendering my expert opinion on the authenticity of the document referenced herein and when and how this document was disseminated or otherwise made available to the extent that persons interested and ordinarily skilled in the subject matter or art, exercising reasonable diligence, could have located the document.

7. I am informed by counsel that an item is considered authentic if there is sufficient evidence to support a finding that the item is what it is claimed to be. I am also informed that authenticity can be established based on the contents of the document itself, such as the appearance, content, substance, internal patterns, or other distinctive characteristics of the item.

8. I am informed by counsel that a given reference qualifies as “publicly accessible” if it was disseminated or otherwise made available such that a person interested in and ordinarily skilled in the relevant subject matter could locate it through the exercise of ordinary diligence.

9. While I understand that the determination of public accessibility under the foregoing standard rests on a case-by-case analysis of the facts particular to an individual publication, I also understand that a printed publication is rendered “publicly accessible” if it is cataloged and indexed by a library such that a person interested in the relevant subject matter could locate it (*i.e.*, I understand that cataloging and indexing by a library is sufficient, though there are other ways that a printed publication may qualify as “publicly accessible”). One manner of sufficient indexing is indexing according to subject matter. I understand that it is not necessary to prove someone actually looked at the printed publication in order to show it was publicly accessible by virtue of a library’s cataloging and indexing thereof. I understand that cataloging and indexing by a single library of a single instance of a particular printed publication is sufficient. I understand that, even if access to a library is restricted, a printed publication that has been cataloged and indexed therein is publicly accessible so long as a presumption is raised that the portion of the public concerned with the relevant subject matter would know of the printed publication. I also understand that the cataloging and indexing of information that would guide a

person interested in the relevant subject matter to the printed publication, such as the cataloging and indexing of an abstract for the printed publication, is sufficient to render the printed publication publicly accessible.

10. I understand that evidence showing the specific date when a printed publication became publicly accessible is not necessary. Rather, routine business practices, such as general library cataloging and indexing practices, can be used to establish an approximate date on which a printed publication became publicly accessible.

B. Person of Ordinary Skill in the Art

11. In forming the opinions expressed in this declaration, I have reviewed the documents and appendices referenced herein. These materials are records created in the ordinary course of business by publishers, libraries, indexing services, and others. From my years of experience, I am familiar with the process for creating many of these records, and I know that these records are created by people with knowledge of the information contained within the record. Further, these records are created with the expectation that researchers and other members of the public will use them. All materials cited in this declaration and its appendices are of a type that experts in my field would reasonably rely upon and refer to in forming their opinions.

12. I have been informed by counsel that the subject matter of this proceeding relates to a terminally sterilized pre-filled syringe for intravitreal injection that includes a VEGF-antagonist solution.

13. I have been informed by counsel that, with respect to claims 1-23 of the '631 Patent, a person of ordinary skill would have had at least an advanced degree (Dipl.Ing, M.S., or Ph.D.), with research experience in mechanical engineering, biomedical engineering, materials science, chemistry, or a related field, or at least 2-3 years of professional experience in one or more of those fields. Furthermore, I understand that a POSITA would have had experience with (i) the design of pre-filled syringes; and (ii) sterilization of drug delivery devices, including those containing sterilization sensitive therapeutics. Such sterilization experience would include experience with microbiology. I have further been informed by counsel that, with respect to claims 24-26 of the '631 Patent, a person of ordinary skill would be an ophthalmologist with experience administering VEGF-antagonist drugs to patients via the intravitreal route.

14. I further understand that Novartis has proposed a different definition of POSITA, under which a POSITA would have had an advanced degree (i.e., an M.S., a Ph.D., or equivalent), and at least 2-3 years of professional experience, in mechanical engineering, biomedical engineering, materials science, chemistry, chemical engineering, or a related field, including experience with the design of a

PFS and/or the development of ophthalmologic drug products or drug delivery devices. Such a person would have been a member of a product development team and would have drawn upon not only his or her own skills, but also the specialized skills of team members in complementary fields including ophthalmology, microbiology and toxicology. My opinions do not change and are equally valid under either definition of POSITA.

15. It is my opinion that such a person would have been actively engaged in academic research and learning through study and practice in the field, and possibly through formal instruction through the bibliographic resources relevant to his or her research. By the 2000s, such a person would have had access to a vast array of print resources, including at least the documents referenced below, as well as to a fast-changing set of online resources.

C. Library Catalog Records and Other Resources

16. Although I have previously provided background on library catalog records (*see* Ex. 1033), some additional background on MARC (Machine-Readable Cataloging) formatted records, OCLC, and *WorldCat* is helpful to understand the library catalog records discussed in this declaration. I am fully familiar with the library cataloging standard known as the MARC standard, which is an industry-wide

standard method of storing and organizing library catalog information.¹ MARC practices have been consistent since the MARC format was developed by the Library of Congress in the 1960s, and by the early 1970s became the U.S. national standard for disseminating bibliographic data. By the mid-1970s, MARC format became the international standard, and persists through the present. A MARC-compatible library is one that has a catalog consisting of individual MARC records for each of its items. The underlying MARC format (computer program) underpins the online public access catalog (OPAC) that is available to library users to locate a particular holding of a library. Today, MARC is the primary communications protocol for the transfer and storage of bibliographic metadata in libraries.² The MARC practices discussed below were in place during the late 1990s period relevant to the documents referenced herein.

17. Online Computer Library Center (OCLC) is a not-for-profit worldwide consortium of libraries. Similar to MARC standards, OCLC's practices have been

¹ The full text of the standard is available from the Library of Congress at <http://www.loc.gov/marc/bibliographic/>.

² Almost every major library in the world uses a catalog that is MARC-compatible. See, e.g., *Library of Congress, MARC Frequently Asked Questions (FAQ)*, <https://www.loc.gov/marc/faq.html> (last visited Jan. 24, 2018) (“MARC is the acronym for MACHine-Readable Cataloging. It defines a data format that emerged from a Library of Congress-led initiative that began nearly forty years ago. It provides the mechanism by which computers exchange, use, and interpret bibliographic information, and its data elements make up the foundation of most library catalogs used today.”). MARC is the ANSI/NISO Z39.2-1994 (reaffirmed 2009) standard for Information Interchange Format.

consistent since the 1970s through the present. Accordingly, the OCLC practices discussed below were in place during the period discussed in my opinions section. OCLC was created “to establish, maintain and operate a computerized library network and to promote the evolution of library use, of libraries themselves, and of librarianship, and to provide processes and products for the benefit of library users and libraries, including such objectives as increasing availability of library resources to individual library patrons and reducing the rate of rise of library per-unit costs, all for the fundamental public purpose of furthering ease of access to and use of the ever-expanding body of worldwide scientific, literary and educational knowledge and information.”³ Among other services, OCLC and its members are responsible for maintaining the *WorldCat* database (<http://www.worldcat.org/>), used by libraries throughout the world.

18. Libraries worldwide use the machine-readable MARC format for catalog records. MARC-formatted records include a variety of subject access points based on the content of the document being cataloged. A MARC record for a particular work comprises several fields, each of which contains specific data about the work. Each field is identified by a standardized, unique, three-digit code

³ OCLC Online Computer Library Center, Inc., Amended Articles of Incorporation of OCLC Online Computer Library Center, Inc., Third Article (OCLC, Dublin, Ohio) Revised November 30, 2016, <https://www.oclc.org/content/dam/oclc/membership/articles-of-incorporation.pdf>.

corresponding to the type of data that follows. For example, a work's title is recorded in field 245, the primary author of the work is recorded in field 100, a work's International Standard Book Number ("ISBN") is recorded in field 020, and the work's Library of Congress call number (assigned by Library of Congress) is recorded in field 050. Some fields can contain subfields, which are indicated by letters. For example, a work's publication date is recorded in field 260 under the subfield "c."

19. The MARC Field 040, subfield "a," identifies the library or other entity that created the catalog record in the MARC format. The MARC Field 008 identifies the date when this first MARC record was created.

20. MARC records also include several fields that include subject matter classification information. An overview of MARC record fields is available through the Library of Congress at <http://www.loc.gov/marc/bibliographic/>. For example, 6XX fields are termed "Subject Access Fields."⁴ Among these, for example, is the 650 field; this is the "Subject Added Entry – Topical Term" field. *See* <http://www.loc.gov/marc/bibliographic/bd650.html>. The 650 field is a "[s]ubject added entry in which the entry element is a topical term." *Id.* The 650 field entries "are assigned to a bibliographic record to provide access according to generally accepted thesaurus-building rules (e.g., *Library of Congress Subject Headings*

⁴ *See* <http://www.loc.gov/marc/bibliographic/bd6xx.html>.

(LCSH), *Medical Subject Headings* (MeSH)).” *Id.* Thus, a researcher can easily discover material relevant to a topic of interest with a search using the terms employed in the MARC Fields 6XX.

21. Further, MARC records include call numbers, which themselves include a classification number. For example, the 050 field is dedicated as the “Library of Congress Call Number”⁵ as assigned by the Library of Congress. A defined portion of the Library of Congress Call Number is the classification number, and “source of the classification number is *Library of Congress Classification* and the *LC Classification-Additions and Changes*.” *Id.* Thus, included in the 050 field is a subject matter classification. As an example: TK5105.59 indicates books on computer networks – security measures. When a local library assigns a classification number, most often a Library of Congress derived classification number created by a local library cataloger or it could be a Dewey Decimal classification number for example, 005.8, computer networks – security measures, it appears in the 090 field. In either scenario, the MARC record includes a classification number in the call number field that represents a subject matter classification.

22. The 9XX fields, which are not part of the standard MARC 21 format,⁶ were defined by OCLC for use by the Library of Congress, processing or holding

⁵ See <http://www.loc.gov/marc/bibliographic/bd050.html>.

⁶ See <https://www.oclc.org/bibformats/en/9xx.html>.

notes for a local library, and for internal OCLC use. For example, the 955 field is reserved for use by the Library of Congress to track the progress of a new acquisition from the time it is submitted for Cataloging in Publication (CIP) review until it is published and fully cataloged and publicly available for use within the Library of Congress. Fields 901- 907, 910, and 945-949 have been defined by OCLC for local use and will pass OCLC validation. Fields 905 or 910 are often used by an individual library for internal processing purposes, for example the date of cataloging and/or the initials of the cataloger.

D. Monograph Publications

23. Monograph publications are written on a single topic, presented at length, and distinguished from an article and include books, dissertations, proceedings of a conference, and technical reports. A library typically creates a catalog record when the monograph is acquired by the library. First, it will search OCLC to determine if a record has already been created by the Library of Congress or another OCLC institution. If a record is found in OCLC, the record is downloaded into the library's LMS. The library's LMS typically includes the OPAC (online public access catalog by which researchers locate a particular library holding in a user-friendly format), acquisitions, cataloging, and circulation integrated functions. Once the item is downloaded into the library's LMS, the library adds its identifier to the OCLC database so when a search is completed on *WorldCat*, the library will be

indicated as an owner of the title. Once a record is created in a library's LMS, it is searchable and viewable through the library's OPAC. The record is typically searchable by author, title, and subject heading, at that library and from anywhere in the world through the internet by accessing that library's OPAC. The OPAC also connects with the circulation function of the library which typically indicates whether the record is available, in circulation, etc., with its call number and location in a specific departmental/disciplinary library, if applicable. The OPAC not only provides immediate bibliographic access on site, it also facilitates the interlibrary loan process, which involves loaning a publication from one library to another.

E. Ownership and Date Stamp

24. Every library sets its own practice or policy on whether-or-not to date stamp, but all will have an ownership stamp somewhere in the publication—typically on the cover page, verso of the cover page, or a designated page within the publication, sometimes even on the top, side, or bottom edge of the monograph or periodical. The ownership and date stamp can also vary from one library to another when the stamp is entered on the monograph. It can occur when received in acquisitions after shipment to the library, or it can be at time of cataloging. Therefore, there could be instances when the date of receipt precedes the cataloging date or vice versa.

F. Indexing/Cataloging

25. A researcher may discover material relevant to his or her topic in a variety of ways. One common means of discovery is to search for relevant information in an index of periodical and other publications. Having found relevant material, the researcher will then normally obtain it online, look for it in libraries, or purchase it from the publisher, a bookstore, a document delivery service, or other provider. Sometimes, the date of a document's public accessibility will involve both indexing and library date information. Date information for indexing entries is, however, often unavailable. This is especially true for online indices, including *Wiley Online Library* and *WorldCat*.

26. *WorldCat* is the world's largest public online catalog, maintained by the OCLC, Inc., a not-for-profit international library consortium, and built with the records created by thousands of libraries that are members of OCLC. Prior to *WorldCat*, the OCLC database base was accessible since 1991 through a search engine called *FirstSearch*. *FirstSearch* required access from an OCLC, Inc. member library, therefore, not open access. In 2006, OCLC's *WorldCat* was separated from *FirstSearch* and was made accessible as an open access data base, freely available to anyone in the world.

27. *WorldCat* requires no knowledge of MARC tags and code and does not require a login or password. *WorldCat* is easily accessible through the World Wide

Web to all who wish to search it; there are no restrictions to be a member of a particular community, etc. The date a given catalog record was created (corresponding to the MARC Field 008) appears in some detailed *WorldCat* records as the Date of Entry but not necessarily all. *WorldCat* does not provide a view of the underlying MARC format for a specific *WorldCat* record. In order to see the underlying MARC format the researcher must locate the book in a holding library listed among those shown in *WorldCat*, and search the online public catalog (OPAC) of a holding library. Whereas *WorldCat* records are widely available, the availability of library specific MARC formatted records varies from library to library. When a specific library wishes to make the underlying MARC format available there will be a link from the library's OPAC display, often identified as a MARC record or librarian/staff view.

28. When a MARC record is created by the Library of Congress or an OCLC member institution, the date of creation for that record is automatically populated in the fixed field (008), with characters 00 through 05 in year, month, day format (YYMMDD).⁷ Therefore, the MARC record creation date reflects the date on which the publication associated with the record was first cataloged. Thereafter, the local library's computer system may automatically update the date in field 005

⁷ Some of the newer library catalog systems also include hour, minute, second (HHMMSS).

every time the library updates the MARC record (*e.g.*, to reflect that an item has been moved to a different shelving location within the library, or a reload of the bibliographic data with the introduction of a new library management system that creates and manages the OPAC).

G. Periodical Publications.

29. A library typically creates a catalog record for a periodical publication when the library receives its first issue. When the institution receives subsequent issues/volumes of the periodical, the issues/volumes are generally checked in (often using a date stamp), added to the institution's holding records, and made available very soon thereafter – normally within a few days of receipt or (at most) within a few weeks of receipt.

30. **ProQuest** – ProQuest's collections span six centuries, all disciplines and the diverse content types needed by researchers, providing the world's largest collection of dissertations and theses; three centuries of newspapers; more than 450,000 academic eBooks; collections of important scholarly journals and other content researchers need such as data; and unique digital vaults of primary source materials. ProQuest's renowned abstracting and indexing enables researchers to find sources in their area of study. See <https://about.proquest.com/libraries/academic/>.

31. **Wisconsin TechSearch (WTS)** – WTS offers an array of article delivery and research services to individuals and organizations not affiliated with

the University of Wisconsin or who need the specialized skills of WTS staff in locating and retrieving information. See <https://wts.wisc.edu/>.

IV. OPINION REGARDING AUTHENTICITY AND PUBLIC ACCESSIBILITY

- A. **Document A: Ex. 1015 & Ex. 1016: Sandeep Nema and John D. Ludwig, editors, *Pharmaceutical Dosage Forms: Parenteral Medications*, 3rd edition. Volume 1: *Formulation and Packaging*; Volume 2: *Facility Design, Sterilization and Processing*. Informa Healthcare, 2010. (“Nema”)**

32. I have been asked to opine on a book titled: *Pharmaceutical Dosage Forms: Parenteral Medications*, 3rd edition, edited by Sandeep Nema and John D. Ludwig, published in three volumes, for this declaration, Volume 1 - *Formulation and Packaging*; and Volume 2 - *Facility Design, Sterilization and Processing* have been included in this declaration to authenticate and document public access.

1. Authentication

33. I have evaluated the Nema reference several ways: (1) by assessing scans of a copy provided to me by counsel, Ex. 1015 and Ex. 1016; (2) by assessing scans of a print copy held by the National Library of Medicine (NLM), Attachment A-1 (3) by assessing downloads of Nema available to me as an emeritus faculty member of Purdue University through the Purdue University Libraries, from the *ProQuest Ebook Central*, at this URL: <https://ebookcentral.proquest.com/lib/purdue/detail.action?pq-origsite=primo&docID=584343>.

34. It is available for a fee through *ProQuest Ebook Central* at this URL:

<https://www.taylorfrancis.com/books/edit/10.1201/b17733/pharmaceutical-dosage-forms-sandeep-nema-john-ludwig>.

35. Attachment A-1, obtained by me at my request by Wisconsin TechSearch (WTS) was made from the print copy owned by the National Library of Medicine (NLM). I received Attachment A-1 on March 9, 2022, and it contains scans of Volume 1 of Nema that include: partial back cover with a barcode label that reads “National Library of Medicine” (shown below); spine of the book with a label that reads “2010 L-841 v.1 (shown below); cover of volume 1; front flyleaf with ownership stamp that reads “Property of the National Library of Medicine” (shown below); title page of volume 1; verso of the title page (copyright); Contents [volume 1].



Selected Scans of Volume 1 of Nema (Ex. 1015)

36. Attachment A-1 also contains scans of Volume 2 of Nema that includes: partial back cover with a barcode label that reads “National Library of Medicine” (shown below); spine of the book with a label that reads “2010 L-841 v.2; cover of volume 2 (shown below); front flyleaf- with ownership stamp that reads “Property of the

National Library of Medicine” (shown below); title page of volume 2; verso of the title page (copyright); and Contents [volume 2].



Selected Scans of Volume 2 of Nema (Ex. 1016)

37. All identifying characteristics, such as stamps and notations, on Attachment A-1 are consistent with library practice and procedure that I have observed during my career as a professional librarian, specifically with those items held by the National Library of Medicine (NLM). I have no cause for concern about the authenticity or accuracy of these identifying attributes. In addition, Nema was found within the collection of a library, the National Library of Medicine, one of the most likely locations for an authentic publication to be located.

38. Attachment A-2 is a download of Nema from the *ProQuest Ebook Central* database. I completed this download through Purdue University Libraries on March 26, 2022, as an emeritus faculty member at Purdue at this URL: <https://ebookcentral.proquest.com/lib/purdue/detail.action?pq-origsite=primo&docID=584343>.

39. It is also available for a fee through *ProQuest Ebook Central* at this URL: <https://www.taylorfrancis.com/books/edit/10.1201/b17733/pharmaceutical-dosage-forms-sandeep-nema-john-ludwig>.

40. After comparing Attachment A-1 and A-2, with the corresponding pages of Ex. 1015 and Ex. 1016, I found no difference between Attachment A-1 and Attachment A-2 with Ex. 1015 or Ex.1016.

41. Therefore, upon finding Nema in the National Library of Medicine, and as a download provided through a research library, Purdue University, from the publisher database, *ProQuest Ebook Central*, I have determined that Ex. 1015 and Ex. 1016, Nema, are authentic documents.

42. I conclude and affirm that Nema, Ex. 1015 and Ex. 1016 are authentic documents.

2. Public Accessibility

43. Attachment A-3 is a true and correct copy of the *WorldCat* entry for Nema. I obtained Attachment A-3 by completing a search on *WorldCat* on March 27, 2022, by searching using Maryland (National Library of Medicine) as the geographical location. The National Library of Medicine was second on the list among the 67 libraries that held Nema worldwide.

44. Attachment A-3 shows that Nema is the document associated with this *WorldCat* entry, as verified by authors: Sandeep Nema and John D. Ludwig; title:

Pharmaceutical Dosage Forms. Parenteral Medications; publisher and publication date: Informa Healthcare in 2010; and ISBN: 978420086539 (three volume set).

45. Nema could have been located by searching for the authors: Sandeep Nema and John D. Ludwig; title: *Pharmaceutical Dosage Forms. Parenteral Medications* or by searching the subject headings: *Parenteral solutions*; *Pharmaceutical technology*; and/or *Technology Pharmaceutical*.

46. The search discussed above could have been performed anywhere in the world by anyone who accessed *WorldCat* in 2010, openly accessible on the web at that time, and definitely prior to 2011.

47. Attachment A-4 is a download I made from the National Library of Medicine OPAC (online catalog) on March 27, 2022. The document cataloged in this record is Nema as verified on this record are shown as “Creators”: Sandeep Nema and John D. Ludwig; title: *Pharmaceutical Dosage Forms. Parenteral Medications*; publisher and publication date: Informa Healthcare in 2010; and ISBN: 978420086539 (three volume set). In addition, the National Library of Medicine call number in Attachment A-4: 2010 L841 matches the call number shown in Attachment A-1 in scan of the back cover and spine of the book, 2010 L841.

48. Nema could have been located in the National Library of Medicine OPAC by searching for the authors on this record shown as “Creators”: Sandeep Nema and John D. Ludwig; title: *Pharmaceutical Dosage Forms. Parenteral Medications*;

or by searching the subject headings: *Parenteral solutions*; *Pharmaceutical technology*; and/or *Technology Pharmaceutical*.

49. Attachment A-5 is the MARC record I downloaded from the National Library of Medicine OPAC on March 27, 2022. The MARC format provides information about the processing of Nema by the National Library of Medicine. As mentioned above, the 9XX field in the MARC format is allocated to local libraries to enter information specific to that library. The National Library of Medicine has used several 9XX fields to indicate dates of processing of the item cataloged.

50. Attachment A-6 is a communication to me from Tina Shrader, Acting Head of Cataloging and Metadata Management Section, Technical Services Division, National Library of Medicine dated March 14, 2022. In this communication she clarifies the use of several 9XX fields by the National Library of Medicine catalogers, below is a quote from the communication from Ms. Shrader, Attachment A-6:

NLM has locally defined the MARC 992, 993, 994 fields as follows:

992—Processing Data and Instructions. The date in the \$a represents the date that the item described in the record was sent from Acquisitions to Cataloging. The other subfields contain information about the priority level of the item in our cataloging workflow and the encoding level to be assigned to the final bib record.

993—CAT Action. Records information about the assignment of the item to a cataloger. The date represents when the item was assigned for cataloging.

994—Cataloging Completion. Indicates completion of descriptive and subject cataloging. The date indicates when this work is completed.

There are additional fields that may be tangentially relevant to your question. After cataloging work is completed, most records go through a review process and are not distributed in NLM's MARC files until the 995 Record Authorization/Revision field is coded to indicate the record is authorized for distribution, with the date of authorization. The 999 Processing Status field also contains a code that affects whether the record is distributed.

51. The 992, 993, 994, 995, and 999 MARC Fields indicate the processing and cataloging of Nema after acquisition by the National Library of Medicine. The MARC 992, 993, 994, and 995 fields as shown on Attachment A-5 are as follows:

992	—	pP1eEFa20101116
993	—	aJCYb20101118
994	—	aCDNb20101118
995	—	aAUTHb20100721cREVD20180131
996	—	arev. CIPb20101118

52. In the MARC record above the 992 MARC Field, after the “a” delimiter reads: 20101116, i.e.,: 2010 = 2010; 11 = November; 16 =16th; November 16, 2010, this is the date Nema was received from acquisitions by the cataloging department. The 993 MARC Field after the “b” delimiter reads: 20101118, i.e.,: 2010 = 2010; 11 = November; 18 =18th; November 18, 2010 indicates when Nema was assigned for cataloging. The 994 MARC Field after the “b” delimiter reads: 20101118, i.e.,: 2010 = 2010; 11 = November; 18 =18th; November 18, 2010 indicates when cataloging was completed for Nema.

53. The physical copy of Nema at the National Library of Medicine would have been available for public access, consistent with standard library practice, within one week to ten days after cataloging was completed on November 18, 2010. Therefore, Nema would have been accessible to the public in the National Library of Medicine no later than November 29, 2010.

3. Conclusion

54. I conclude that Nema, Ex. 1015 and Ex. 1016, is an authentic document and would have been publicly accessible in the National Library of Medicine on or about November 29, 2010, well before July, 2011.

B. Document B: Ex. 1214: Shawn Kinney, et al., “A Rational Approach to Determining the Maximum Product Sterility”, *Drug Delivery Technology*, Volume 9, Number 2. February, 2009. Pages: 42-47. (“Kinney”)

55. I have been asked to opine on an article titled: “A Rational Approach to Determining the Maximum Product Sterility” published in *Drug Delivery Technology* in its volume 9, issue number 2, February, 2009 on pages 42-47. In this declaration when “Kinney” is used, it refers not only to the article titled “A Rational Approach to Determining the Maximum Product Sterility” it also can refer, depending upon the context, to *Drug Delivery Technology*, volume 9, issue number 2, February, 2009.

1. Authentication


56. I have evaluated the Kinney reference several ways: (1) by assessing scans of a copy provided to me by counsel, Ex. 1214; (2) by assessing scans of a print copy held by the National Library of Medicine (NLM) provided to me by Wisconsin TechSearch (WTS), Attachment B-1; (3) by assessing scans of a print copy provided to me by Wisconsin TechSearch (WTS) from the British Lending Library, Attachment B-2; (4) by assessing scans of a print copy provided to me by

Wisconsin TechSearch (WTS) from the Butler University Library, Indianapolis, Indiana, Attachment B-3.

57. Attachment B-1, obtained for me at my request by Wisconsin TechSearch (WTS) was made from the print copy owned by the National Library of Medicine (NLM). I received Attachment B-1 on March 14, 2022, and it contains scans of Kinney that includes: cover of *Drug Delivery Technology*, volume 9, number 2, February, 2009 with a stamp in the upper left corner as shown below:




The cover of Attachment B-1 also includes a stamp indicating that the copy is owned by the National Library of Medicine:



58. All identifying characteristics, such as stamps and notations, on Attachment B-1 are consistent with library practice and procedure that I have observed during my career as a professional librarian, specifically with those items held by the National Library of Medicine (NLM). I have no cause for concern about the authenticity or accuracy of these identifying attributes. In addition, Kinney was

found within the collection of a library, the National Library of Medicine, one of the most likely locations for an authentic publication to be located.


59. Attachment B-2, obtained for me at my request by Wisconsin TechSearch (WTS) was made from the print copy owned by the Boston Spa Library of the British Library, United Kingdom. I received Attachment B-1 on March 31, 2022 it contains scans of Kinney that includes: cover of *Drug Delivery Technology*, volume 9, number 2, February, 2009 with a label in the upper right corner as shown as below; periodical information sheet; table of contents; and Kinney article on pages 42-47.



60. All identifying characteristics, such as stamps and notations, on Attachment B-2 are consistent with library practice and procedure that I have observed during my career as a professional librarian. In addition, Kinney was found within the collection of a library, the Boston Spa Center of the British Library of the United Kingdom, one of the most likely locations for an authentic publication to be located.

61. Attachment B-3, obtained for me at my request by Wisconsin TechSearch (WTS) was made from the print copy owned by the Butler University

Library, Indianapolis, Indiana. I received Attachment B-3 on March 18, 2022 and contains scans of Kinney that includes: cover of Drug Delivery Technology, volume 9, number 2, February, 2009; periodical information sheet; table of contents with a stamp that reads “Butler University Libraries FEB 2009” (as shown below); and Kinney article on pages 42-47.



62. All identifying characteristics, such as stamps and notations, on Attachment B-3 are consistent with library practice and procedure that I have observed during my career as a professional librarian. In addition, Kinney was found within the collection of a library, the Butler University Library, a likely locations for an authentic publication to be located.

63. After comparison between Attachment B-1, B-2, and B-3 with the corresponding pages of Ex. 1214, I found no difference between Attachment B-1, Attachment B-2, and Attachment B-3 with Ex. 1214.

64. Therefore, upon finding Kinney in the National Library of Medicine, The Boston Spa Center of the British Library, and the Butler University Library, I have determined that Ex. 1214, Kinney, is an authentic document.

65. I conclude and affirm that Kinney, Ex. 1214 is an authentic document.

2. Public Accessibility

66. Attachments B-4, B-5, and B-6 are true and correct copies of the *WorldCat* entries for Kinney. I obtained Attachment B-4, B-5, and B-6 by completing searches on *WorldCat* on April 3, 2022, by using Maryland (National Library of Medicine) as a geographical location; by using United Kingdom as a geographical location, Boston Spa Center, British Library; and by using Indiana as a geographical location, Butler University.

67. On Attachment B-4 National Library of Medicine was second; on Attachment B-5: The British Library, On Demand (Boston Spa) was fourth; and on Attachment B-6, Butler University was first on the list among the 45 libraries that hold Kinney worldwide.

68. Attachments B-4, B-5, and B-6 show that Kinney is the document associated with these *WorldCat* entries, as verified by title: *Drug Delivery Technology*; and publisher: Drug Delivery Technology, LLC; and ISSN: 1537-2898 (ISSN for print edition).

69. Kinney could have been located by searching for the title: *Drug Delivery Technology* and/or by searching the subject headings: *Drug delivery systems – Periodicals*; *Drug delivery systems*; and/or *Biological Transport*.

70. The search discussed above could have been performed anywhere in the world by anyone who accessed *WorldCat* in 2009, openly accessible on the web at that time, and definitely prior to 2011.

71. Attachment B-7 is a download I made from the National Library of Medicine OPAC (online catalog) on April 3, 2022. The document cataloged in this record is Kinney as verified on this record are shown by title: *Drug Delivery Technology*; publisher: Drug Delivery Technology, LLC. In addition, the National Library of Medicine call number in Attachment B-7: W1 DR514BK, matches the call number shown in Attachment B-1 in the label on the cover of *Drug Delivery Technology*, Volume 9, Number 2. February, 2009.

72. Kinney could have been located in the National Library of Medicine OPAC by searching for the title: *Drug Delivery Technology* and/or by searching the MESH subject headings: *Drug Delivery Systems*; *Biological Transport*; *Drug Industry*; and/or *Technology, Pharmaceutical*. Kinney could have been located in the National Library of Medicine OPAC by searching for the title: *Drug Delivery Technology* and/or by searching the MESH subject headings: *Drug Delivery Systems*; *Biological Transport*; *Drug Industry*; and/or *Technology, Pharmaceutical*.

73. Attachment B-8 is a download I made from the British Library OPAC (online catalog) on April 3, 2022. The document cataloged in this record is Kinney

as verified on this record are shown by title: *Drug Delivery Technology*; publisher: Drug Delivery Technology, LLC.


74. Kinney could have been located in the British Library by searching for the title: *Drug Delivery Technology* and/or by searching the subject headings: *Drug Delivery Systems - Periodicals*; *Biological Transport - Periodicals*; *Drug Industry - Periodicals*; and/or *Technology, Pharmaceutical - Periodicals*.

75. Attachment B-9 is a download I made from the Butler University Library OPAC (online catalog) on April 3, 2022. The document cataloged in this record is Kinney as verified on this record are shown by title: *Drug Delivery Technology*; publisher: Drug Delivery Technology, LLC.


76. Kinney could have been located in the British Library by searching for the title: *Drug Delivery Technology* and/or by searching the Library of Congress subject heading: *Drug Delivery Systems - Periodicals*; and/or *MESH Subject Headings: Drug Delivery Systems; Biological Transport*; and/or *Drug Industry*.

77. The physical copy of Kinney at the National Library of Medicine, British Library and Butler University Library would have been available for public access, consistent with standard library practice, within one week to ten days after receipt as shown on the label (Attachment B-2) or stamp (Attachment B-3).

78. On Attachment B-2, the label, shown below, has a date embedded in it that, more likely than not, 25/02/09, that is the date of receipt of *Drug Delivery Technology*, volume 9, number 2, February 2009, i.e., February 25, 2009.



79. On Attachment B-2, the stamp shown below, has only a month and year, “FEB 2009.”



80. Therefore, the physical copy of Kinney at the British Library and Butler University Library would have been available for public access, consistent with standard library practice, within one week to ten days after receipt as shown on the label (Attachment B-2) or stamp (Attachment B-3). That is, at the British Library by March 6, 2009, and using the end of February, February 28, as the latest date the stamp would have been applied to the print copy held by the Butler Library, of March 10, 2009. The National Library of Medicine print copy did not have a date of receipt

to verify the date of receipt, so it is not used to prove public accessibility, only authenticity.

81. Additional evidence that a publication was known to the research community is a citation to the publication (article, thesis, or paper). Attachment B-10 is an article by: Edwin Chan, et al., titled: “Investigating Liquid Leak from Prefilled Syringes upon Needle Shield Removal: Effect of Air Bubble Pressure,” published in *PDA Journal of Pharmaceutical Science and Technology*, volume 65, number 4, July-August, 2011, pages 363-371. (“Chan”).

82. I downloaded Chan, for a fee, from this link: https://www.researchgate.net/publication/292012903_A_rational_approach_to_determining_the_maximun_allowable_Gas_bubble_inside_a_prefilled_syringe_to_minimize_stopper_movement_protect_product_sterility/citations

83. On page 371 of Chan, is a list of “References”. Number 3 on this list reads as shown below:

3. Kinney, H.; Wagner, A.; Phillips, C. W. A rational approach to determining the maximum allowable gas bubble inside a prefilled syringe to minimize stopper movement and protect product sterility. *Drug Deliv. Technol.* **2009**, *9*, 42– 47.

84. Therefore, having located Kinney in three research libraries with evidence that it was available within two of those libraries, more likely than not, by March 10, 2009, as well as locating a citation to Kinney that was published in a

journal dated July/August 2011, I conclude and affirm that Kinney would have been publicly accessible no later than March 10, 2009, well before July 2011.

3. Conclusion

85. I conclude that Kinney, Ex. 1214 is an authentic document and would have been publicly accessible in the British Library and the Butler University Library National Library on or about March 10, 2009 well before July, 2011.

V. AVAILABILITY FOR CROSS-EXAMINATION

86. In signing this Declaration, I recognize that this Declaration will be filed as evidence in a contested case before the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office. I also recognize that I may be subject to cross-examination in the case and that cross-examination will take place within the United States. If cross-examination is required of me, I will appear for cross-examination within the United States during the time allotted for cross-examination.

VI. RIGHT TO SUPPLEMENT

87. I reserve the right to supplement my opinions in the future to respond to any arguments that the Patent Owner raises and to take into account new information as it becomes available to me.


VII. JURAT

88. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the full knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the U.S. Code.

Dated: April 6, 2022

Respectfully submitted,

Williamsburg, Virginia


James L. Mullins, PhD

ATTACHMENT A-1

NATIONAL LIBRARY OF MEDICINE



NLM 03281906 1

VOLUME

1

Nema Ludwig

Pharmaceutical Dosage Forms: Parenteral Medications
Third Edition Volume 1: Formulation and Packaging

Executive Director,
Therapeutics Pharmaceutical
Louis. Since graduating in 1992
Nema has been involved with
all molecule and protein drugs
first at Mallinckrodt Medical
Co. (Pharmacia), and has led the
development of several
new products. He is active in
the American Pharmaceutical Scientists
Association (APSA), the
Parenteral Drug Association (PDA),
and has given several meetings and focus
group sessions. He holds an adjunct faculty appointment
at the University of Missouri.

He is Vice President, Business
Development and Clinical Supply Planning,
Parenteral Sciences at Pfizer, and
Pfizer's St. Louis Laboratories.
He has a Ph.D. degree in Pharmacy and
Biotechnology from the University of
Missouri and has held numerous research
positions at Burroughs Wellcome
Pharmaceuticals, Inc., and Pfizer. He is
a member of the Association of Pharmaceutical
Scientists, the Parenteral Drug Association
Research Institute, where he has
taught professional training courses
and served as an instructor.

Pharmaceutical Dosage Forms: Parenteral Medications


Third Edition

Volume 1: Formulation and Packaging



2010
L-841
v. 1

ISBN 978-142008643-0



9 781420 086430

informa
healthcare

Regeneron Exhibit 1103.038
Regeneron v. Novartis
IPR2021-00816

Pharmaceutical Dosage Forms: Parenteral Medications

Third Edition

Volume 1: Formulation
and Packaging



informa
healthcare

Edited by
Sandeep Nema
John D. Ludwig

Regeneron Exhibit 1103.039
Regeneron v. Novartis
IPR2021-00816



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

Pharmaceutical Dosage Forms

Parenteral Medications Third Edition

Volume 1 Formulation and Packaging

Edited by

Sandeep Nema

Pfizer, Inc.

Chesterfield, Missouri, U.S.A.

John D. Ludwig

Pfizer, Inc.

Chesterfield, Missouri, U.S.A.

informa

healthcare

New York London

**Regeneron Exhibit 1103.041
Regeneron v. Novartis
IPR2021-00816**

First published in 1984 by Marcel Dekker, Inc., New York, New York.
This edition published in 2010 by Informa Healthcare, Telephone House, 69-77 Paul Street, London EC2A 4LQ, UK.

Simultaneously published in the USA by Informa Healthcare, 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017, USA.

Informa Healthcare is a trading division of Informa UK Ltd. Registered Office: 37-41 Mortimer Street, London W1T 3JH, UK. Registered in England and Wales number 1072954.

©2010 Informa Healthcare, except as otherwise indicated

No claim to original U.S. Government works

Reprinted material is quoted with permission. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, unless with the prior written permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP, UK, or the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA (<http://www.copyright.com/> or telephone 978-750-8400).

Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

This book contains information from reputable sources and although reasonable efforts have been made to publish accurate information, the publisher makes no warranties (either express or implied) as to the accuracy or fitness for a particular purpose of the information or advice contained herein. The publisher wishes to make it clear that any views or opinions expressed in this book by individual authors or contributors are their personal views and opinions and do not necessarily reflect the views/opinions of the publisher. Any information or guidance contained in this book is intended for use solely by medical professionals strictly as a supplement to the medical professional's own judgement, knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures, or diagnoses should be independently verified. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as appropriately to advise and treat patients. Save for death or personal injury caused by the publisher's negligence and to the fullest extent otherwise permitted by law, neither the publisher nor any person engaged or employed by the publisher shall be responsible or liable for any loss, injury or damage caused to any person or property arising in any way from the use of this book.

A CIP record for this book is available from the British Library.

Library of Congress Cataloging-in-Publication Data available on application

ISBN-13: 9781420086430
ISBN-13: 9781420086539 (three-volume set)

Orders may be sent to: Informa Healthcare, Sheepen Place, Colchester, Essex CO3 3LP, UK
Telephone: +44 (0)20 7017 5540
Email: CSDhealthcarebooks@informa.com
Website: <http://informahealthcarebooks.com/>

For corporate sales please contact: CorporateBooksIHC@informa.com
For foreign rights please contact: RightsIHC@informa.com
For reprint permissions please contact: PermissionsIHC@informa.com

Typeset by MPS Limited, A Macmillan Company
Printed and bound in India

Contents

Foreword Michael J. Akers vii

Preface ix

Contributors xiii

1. **Parenteral dosage forms: introduction and historical perspective** 1
John D. Ludwig
2. **Parenteral drug administration: routes of administration and devices** 7
Himanshu Bhattacharjee and Laura A. Thoma
3. **Biopharmaceutics of NCEs and NBEs** 30
Balaji Agoram, Kazuko Sagawa, Ravi M. Shanker, and Satish K. Singh
4. **Preformulation** 57
N. Murti Vemuri
5. **Formulation development of small and large volume injections** 76
Madhav Kamat and Patrick P. DeLuca
6. **Drug solubility and solubilization** 134
Ching-Chiang Su, Lan Xiao, and Michael Hageman
7. **Formulation of depot delivery systems** 158
James J. Cunningham, Marc J. Kirchmeier, and Sachin Mittal
8. **Biophysical and biochemical characterization of peptide and protein drug product** 194
Tapan K. Das and James A. Carroll
9. **Formulation of protein- and peptide-based parenteral products** 222
Gaozhong Zhu and Y. John Wang
10. **Development of ophthalmic formulations** 254
Paramita Bandyopadhyay, Martin J. Coffey, and Mohammad Shauer
11. **Glass containers for parenteral products** 287
Robert Swift
12. **Plastic packaging for parenteral drug delivery** 305
Vinod D. Vilivalam and Frances L. DeGrazio

13. **Elastomeric closures for parenterals** 324
Renaud Janssen
14. **Parenteral product container closure integrity testing** 358
Dana Morton Guazzo
- Index* 389

Pharmaceutical Dosage Forms: Parenteral

Facility Design, Sterilization and Processing

Pharmaceutical Dosage Forms is an authoritative, work on the formulation of parenteral dosage forms, technical considerations with their development. As such, scientists and engineers in the industry and academia, and will also serve as a reference and training tool for quality assurance professionals. This book (the first of two volumes) and then last revised to three volumes, this book covers the plethora of changes and advances in the formulation of these products and routes of administration. The third edition of this book maintains the format of the last edition so popular but with new chapters, revisions to all chapters, and high quality illustrations.

Facility design, environmental control, and operations, sterilization on pharmaceutical water systems, and the attributes of sterile dosage forms such as particulate matter, endotoxin, and the processing of parenteral drug products. The book covers used sterilization methods such as steam, chemical, radiation, and aseptic processing and aseptic processing.

NATIONAL LIBRARY OF MEDICINE

NLM 03281914 2

About the editors

SANDEEP NEMA Ph.D. is Executive Director, Pharmaceutical R&D, BioTherapeutics Pharmaceutical Sciences at Pfizer in St. Louis. Since graduating in 1992 with his doctorate, Dr. Nema has been involved with the development of small molecule and protein drugs via parenteral delivery, first at Mallinckrodt Medical and then at Pfizer (Searle, Pharmacia), and has led the formulation of four launched products. He is active in the American Association of Pharmaceutical Scientists (AAPS) and the Parenteral Drug Association (PDA), where he has chaired several meetings and focus groups. Dr. Nema holds an adjunct faculty appointment at the University of Tennessee.

JOHN D. LUDWIG Ph.D. is Vice President, Business Strategy, Operations, and Clinical Supply Planning, BioTherapeutics Pharmaceutical Sciences at Pfizer, and Site Director for the company's St. Louis Laboratories. Dr. Ludwig received a B.S. degree in Pharmacy and Ph.D. degree in Pharmaceutics from the University of Tennessee, Memphis and has held numerous research and development positions at Burroughs Wellcome Co, Searle, Inc., Pharmacia, Inc., and Pfizer. He is active in the American Association of Pharmaceutical Scientists (AAPS) and the Parenteral Drug Association (PDA) Training and Research Institute, where he has contributed to developing professional training courses and has regularly served as an instructor.

Street, London EC2A 4LQ, UK
ark, NY 10017, USA
care.com

ISBN 978-142008645-4

9 781420 086454

VOLUME
2

Nema
Ludwig

Pharmaceutical Dosage Forms: Parenteral Medicines
Third Edition Volume 2: Facility Design, Sterilization and Processing

2010
L-841
v. 2

Pharmaceutical Dosage Forms: Parenteral Third Edition Volume 2: Sterilization and Processing



informa
healthcare

Regeneron Exhibit 1103.045
Regeneron v. Novartis
IPR2021-00816

Pharmaceutical Dosage Forms: Parenteral Medications

Third Edition

Volume 2: Facility Design,
Sterilization and Processing



informa
healthcare

Edited by
Sandeep Nema
John D. Ludwig

Regeneron Exhibit 1103.046
Regeneron v. Novartis
IPR2021-00816



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

Pharmaceutical Dosage Forms

Parenteral Medications Third Edition

Volume 2 Facility Design, Sterilization and Processing

Edited by

Sandeep Nema

Pfizer, Inc.

Chesterfield, Missouri, U.S.A.

John D. Ludwig

Pfizer, Inc.

Chesterfield, Missouri, U.S.A.

informa
healthcare

New York London

**Regeneron Exhibit 1103.048
Regeneron v. Novartis
IPR2021-00816**

First published in 1984 by Marcel Dekker, Inc., New York, New York.
This edition published in 2010 by Informa Healthcare, Telephone House, 69-77 Paul Street, London EC2A 4LQ, UK.

Simultaneously published in the USA by Informa Healthcare, 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017, USA.

Informa Healthcare is a trading division of Informa UK Ltd. Registered Office: 37-41 Mortimer Street, London W1T 3JH, UK. Registered in England and Wales number 1072954.

©2010 Informa Healthcare, except as otherwise indicated

No claim to original U.S. Government works

Reprinted material is quoted with permission. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, unless with the prior written permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP, UK, or the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA (<http://www.copyright.com/> or telephone 978-750-8400).

Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

This book contains information from reputable sources and although reasonable efforts have been made to publish accurate information, the publisher makes no warranties (either express or implied) as to the accuracy or fitness for a particular purpose of the information or advice contained herein. The publisher wishes to make it clear that any views or opinions expressed in this book by individual authors or contributors are their personal views and opinions and do not necessarily reflect the views/opinions of the publisher. Any information or guidance contained in this book is intended for use solely by medical professionals strictly as a supplement to the medical professional's own judgement, knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures, or diagnoses should be independently verified. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as appropriately to advise and treat patients. Save for death or personal injury caused by the publisher's negligence and to the fullest extent otherwise permitted by law, neither the publisher nor any person engaged or employed by the publisher shall be responsible or liable for any loss, injury or damage caused to any person or property arising in any way from the use of this book.

A CIP record for this book is available from the British Library.

Library of Congress Cataloging-in-Publication Data available on application

ISBN-13: 9781420086454
ISBN-13: 9781420086539 (three-volume set)

Orders may be sent to: Informa Healthcare, Sheepen Place, Colchester, Essex CO3 3LP, UK
Telephone: +44 (0)20 7017 5540
Email: CSDhealthcarebooks@informa.com
Website: <http://informahealthcarebooks.com/>

For corporate sales please contact: CorporateBooksIHC@informa.com
For foreign rights please contact: RightsIHC@informa.com
For reprint permissions please contact: PermissionsIHC@informa.com

Typeset by MPS Limited, A Macmillan Company
Printed and bound in India

Contents

Foreword Michael J. Akers vii

Preface ix

Contributors xiii

1. **Aseptic manufacturing facility design** 1
Mark Caldwell, Bob Helt, Beth Holden, Francesca McBride, and Kevin Schreier
2. **Personnel and their impact on clean room operations** 56
Jeanne Moldenhauer
3. **The fundamentals of an environmental control program** 80
William H. Miele
4. **Water systems for parenteral facilities** 91
Joseph J. Manfredi
5. **Particulate matter: subvisible** 114
D. Scott Aldrich
6. **Endotoxin testing** 146
Michael E. Dawson
7. **The compendial sterility tests** 187
Scott V.W. Sutton
8. **Industrial sterilization technologies: principles and overview** 195
Anne F. Booth
9. **Steam sterilization** 221
James Agalloco
10. **Gas, vapor, and liquid chemical sterilization** 241
James Agalloco
11. **Dry heat depyrogenation and sterilization** 255
Deborah Havlik and Kevin Trupp
12. **Radiation sterilization** 268
Barry P. Fairand and Dusan Razem


13. **Filters and filtration** 297
Maik W. Jornitz and Theodore H. Meltzer
 14. **Processing of small volume parenterals and large volume parenterals** 334
Donald A. Eisenhauer, Roland Schmidt, Christine Martin, and Steven G. Schultz
 15. **Freeze-drying: principles and practice** 353
Steven L. Nail and Larry A. Gatlin
- Index* 383

ATTACHMENT A-2

Pharmaceutical Dosage Forms: Parenteral Medications

Third Edition

Volume 1: Formulation
and Packaging



informa
healthcare

Edited by
Sandeep Nema
John D. Ludwig

Regeneron Exhibit 1103.053
Regeneron v. Novartis
IPR2021-00816



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Copyright © 2010, Taylor & Francis Group. All rights reserved.

Nema, S., Ludwig, J. D., & Ludwig, J. D. (Eds.). (2010). *Pharmaceutical dosage forms : Parenteral medications, third edition*. 3 volume set. Taylor & Francis Group.
Created from purdue on 2022-03-27 20:44:43.

Regeneron Exhibit 1103.054
Regeneron v. Novartis
IPR2021-00816

Pharmaceutical Dosage Forms

Copyright © 2010. Taylor & Francis Group. All rights reserved.

Nema, S., Ludwig, J. D., & Ludwig, J. D. (Eds.). (2010). *Pharmaceutical dosage forms : Parenteral medications*, third edition. 3 volume set. Taylor & Francis Group.
Created from purdue on 2022-03-27 20:29:05.

Regeneron Exhibit 1103.055
Regeneron v. Novartis
IPR2021-00816

Pharmaceutical Dosage Forms

Parenteral Medications Third Edition

Volume 1 Formulation and Packaging

Edited by

Sandeep Nema

Pfizer, Inc.

Chesterfield, Missouri, U.S.A.

John D. Ludwig

Pfizer, Inc.

Chesterfield, Missouri, U.S.A.

informa
healthcare

New York London

Copyright © 2010. Taylor & Francis Group. All rights reserved.

Pharmaceutical Dosage Forms : Parenteral Medications, Third Edition. 3 Volume Set, edited by Sandeep Nema, et al., Taylor & Francis Group, 2010.
ProQuest Ebook Central, <http://ebookcentral.proquest.com/lib/purdue/detail.action?docID=584343>.
Created from purdue on 2022-03-27 20:36:34.

Regeneron Exhibit 1103.056
Regeneron v. Novartis
IPR2021-00816

First published in 1984 by Marcel Dekker, Inc., New York, New York.
This edition published in 2010 by Informa Healthcare, Telephone House, 69-77 Paul Street, London EC2A 4LQ, UK.

Simultaneously published in the USA by Informa Healthcare, 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017, USA.

Informa Healthcare is a trading division of Informa UK Ltd. Registered Office: 37-41 Mortimer Street, London W1T 3JH, UK. Registered in England and Wales number 1072954.

©2010 Informa Healthcare, except as otherwise indicated

No claim to original U.S. Government works

Reprinted material is quoted with permission. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, unless with the prior written permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP, UK, or the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA (<http://www.copyright.com/> or telephone 978-750-8400).

Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

This book contains information from reputable sources and although reasonable efforts have been made to publish accurate information, the publisher makes no warranties (either express or implied) as to the accuracy or fitness for a particular purpose of the information or advice contained herein. The publisher wishes to make it clear that any views or opinions expressed in this book by individual authors or contributors are their personal views and opinions and do not necessarily reflect the views/opinions of the publisher. Any information or guidance contained in this book is intended for use solely by medical professionals strictly as a supplement to the medical professional's own judgement, knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures, or diagnoses should be independently verified. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as appropriately to advise and treat patients. Save for death or personal injury caused by the publisher's negligence and to the fullest extent otherwise permitted by law, neither the publisher nor any person engaged or employed by the publisher shall be responsible or liable for any loss, injury or damage caused to any person or property arising in any way from the use of this book.

A CIP record for this book is available from the British Library.

Library of Congress Cataloging-in-Publication Data available on application

ISBN-13: 9781420086430

ISBN-13: 9781420086539 (three-volume set)

Orders may be sent to: Informa Healthcare, Sheepen Place, Colchester, Essex CO3 3LP, UK

Telephone: +44 (0)20 7017 5540

Email: CSDhealthcarebooks@informa.com

Website: <http://informahealthcarebooks.com/>

For corporate sales please contact: CorporateBooksIHC@informa.com

For foreign rights please contact: RightsIHC@informa.com

For reprint permissions please contact: PermissionsIHC@informa.com

Typeset by MPS Limited, A Macmillan Company

Foreword

I was a faculty member at the University of Tennessee and a colleague of Dr. Kenneth Avis when he conceived, organized, and edited (along with H.A. Lieberman and L. Lachman) the first edition of this book series that was published in 1984. It was so well received by the pharmaceutical science community that an expanded three-volume second edition was published in 1992. Dr. Avis did not survive long enough to oversee a third edition, and it was questionable whether a third edition would ever be published until two of his graduate students, Drs. Nema and Ludwig, took it upon themselves to carry on Dr. Avis' tradition.

Their oversight of this third edition is work that their mentor would be highly pleased and proud of. From 29 chapters in the second edition to 43 chapters in this new edition, this three-volume series comprehensively covers both the traditional subjects in parenteral science and technology as well as new and expanded subjects. For example, separate chapter topics in this edition not found in previous editions include solubility and solubilization, depot delivery systems, biophysical and biochemical characterization of peptides and proteins, container-closure integrity testing, water systems, endotoxin testing, focused chapters on different sterilization methods, risk assessment in aseptic processing, visual inspection, advances in injection devices, RNAi delivery, regulatory considerations for excipients, techniques to evaluate pain on injection, product specifications, extractables and leachables, process analytical technology, and quality by design.

The editors have done an outstanding job of convincing so many top experts in their fields to author these 43 chapters. The excellent reputations of the authors and editors of this book will guarantee superb content of each chapter. There is no other book in the world that covers the breadth and depth of parenteral science and technology better than this one. In my opinion, the editors have achieved their primary objectives—publishing a book that contains current and emerging sterile product development and manufacturing information, and maintaining the high standard of quality that readers would expect.

*Michael J. Akers
Baxter BioPharma Solutions
Bloomington, Indiana, U.S.A.*

Preface

Pharmaceutical Dosage Forms: Parenteral Medications was originally published in 1984 and immediately accepted as a definitive reference in academic institutions and the pharmaceutical industry. The second edition was published in 1993. The ensuing years have produced incredible technological advancement. Classic small-molecule drugs are now complemented by complex molecules such as monoclonal antibodies, antibody fragments, aptamers, antisense, RNAi therapeutics, and DNA vaccines. There have been significant innovations in delivery devices, analytical techniques, in-silico modeling, and manufacturing and control technologies. In addition, the global regulatory environment has shifted toward greater emphasis on science-based risk assessment as evidenced by the evolving cGMPs, quality by design (QbD), process analytical technology (PAT), continuous processing, real time release, and other initiatives. The rapidly changing landscape in the parenteral field was the primary reason we undertook the challenging task of updating the three volumes. Our objectives were to (i) revise the text with current and emerging sterile product development and manufacturing science and (ii) maintain the high standard of quality the readers expect.

The third edition not only reflects enhanced content in all the chapters, but also more than half of the chapters are new underscoring the rapidly advancing technology. We have divided the volumes into logical subunits—volume 1 addresses formulation and packaging aspects; volume 2, facility design, sterilization and processing; and volume 3, regulations, validation and future directions. The authors invited to contribute chapters are established leaders with proven track records in their specialty areas. Hence, the textbook is authoritative and contains much of the collective experience gained in the (bio)pharmaceutical industry over the last two decades. *We are deeply grateful to all the authors who made this work possible.*

Volume 1 begins with a historical perspective of injectable drug therapy and common routes of administration. Formulation of small molecules and large molecules is presented in depth, including ophthalmic dosage forms. Parenteral packaging options are discussed relative to glass and plastic containers, as well as elastomeric closures. A definitive chapter is provided on container closure integrity.

Volume 2 presents chapters on facility design, cleanroom operations, and control of the environment. A chapter discussing pharmaceutical water systems is included. Key quality attributes of sterile dosage forms are discussed, including particulate matter, endotoxin, and sterility testing. The most widely used sterilization techniques as well as processing technologies are presented. Volume 2 concludes with an in-depth chapter on lyophilization.

Volume 3 focuses on regulatory requirements, risk-based process design, specifications, QbD, and extractables/leachables. In addition, we have included chapters on parenteral administration devices, siRNA delivery systems, injection site pain assessment, and control, PAT, and rapid microbiology test methods. Volume 3 concludes with a forward-looking chapter discussing the future of parenteral product manufacturing.

These three volumes differ from other textbooks in that they provide a learned review on developing parenteral dosage forms for *both* small molecules and biologics. Practical guidance is provided, in addition to theoretical aspects, for how to bring a drug candidate forward from discovery, through preclinical and clinical development, manufacturing, validation, and eventual registration.

The editors wish to thank Judy Clarkston and Lynn O'Toole-Bird (Pfizer, Inc.) for their invaluable assistance and organizational support during this project, and Sherri Niziolek and Bianca Turnbull (Informa Healthcare) for patiently leading us through the publishing process.

We also acknowledge the assistance of Pfizer, Inc. colleagues Lin Chen and Min Huang for reviewing several of the chapters.

We would like to express special gratitude to the late Kenneth E. Avis (University of Tennessee College of Pharmacy) for his dedication to teaching and sharing practical knowledge in the area of parenteral medications to so many students over the years, including us. Finally, we acknowledge the contributions of Dr Avis, Leon Lachman, and Herbert A. Lieberman who edited the earlier editions of this book series.

*Sandeep Nema
John D. Ludwig*

*We dedicate this work to those who have inspired us.
To my parents Walter and Ruth Ludwig and my wife Sue Ludwig
To my parents Hari and Pratibha Nema and my wife Tina Busch-Nema*

Contents

Foreword Michael J. Akers vii

Preface ix

Contributors xiii

1. **Parenteral dosage forms: introduction and historical perspective** 1
John D. Ludwig
2. **Parenteral drug administration: routes of administration and devices** 7
Himanshu Bhattacharjee and Laura A. Thoma
3. **Biopharmaceutics of NCEs and NBEs** 30
Balaji Agoram, Kazuko Sagawa, Ravi M. Shanker, and Satish K. Singh
4. **Preformulation** 57
N. Murthi Vemuri
5. **Formulation development of small and large volume injections** 76
Madhav Kamat and Patrick P. DeLuca
6. **Drug solubility and solubilization** 134
Ching-Chiang Su, Lan Xiao, and Michael Hageman
7. **Formulation of depot delivery systems** 158
James J. Cunningham, Marc J. Kirchmeier, and Sachin Mittal
8. **Biophysical and biochemical characterization of peptide and protein drug product** 194
Tapan K. Das and James A. Carroll
9. **Formulation of protein- and peptide-based parenteral products** 222
Gaozhong Zhu and Y. John Wang
10. **Development of ophthalmic formulations** 254
Paramita Bandyopadhyay, Martin J. Coffey, and Mohannad Sharwer
11. **Glass containers for parenteral products** 287
Robert Swift
12. **Plastic packaging for parenteral drug delivery** 305
Vinod D. Viliyalam and Frances L. DeGrazio

13. Elastomeric closures for parenterals	324
<i>Renaud Janssen</i>	
14. Parenteral product container closure integrity testing	358
<i>Dana Morton Guazzo</i>	
<i>Index</i>	389

Contributors

Balaji Agoram Pfizer, Inc., Sandwich, U.K.

Paramita Bandyopadhyay Bausch & Lomb, Rochester, New York, U.S.A.

Himanshu Bhattacharjee Department of Pharmaceutical Sciences, College of Pharmacy,
University of Tennessee Health Science Center, Memphis, Tennessee, U.S.A.

James A. Carroll BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Chesterfield,
Missouri, U.S.A.

Martin J. Coffey Bausch & Lomb, Rochester, New York, U.S.A.

James J. Cunningham Pharmaceutical Research and Development Sciences, Merck Research
Laboratories, West Point, Pennsylvania, U.S.A.

Tapan K. Das BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Chesterfield, Missouri, U.S.A.

Frances L. DeGrazio West Pharmaceutical Services, Inc., Lionville, Pennsylvania, U.S.A.

Patrick P. DeLuca Pharmaceutical Sciences, University of Kentucky College of Pharmacy,
Lexington, Kentucky, U.S.A.

Dana Morton Guazzo RxPax, LLC, Bridgewater, New Jersey, U.S.A.

Michael Hageman Bristol-Myers Squibb Research, Princeton, New Jersey, U.S.A.

Renaud Janssen Helvoet Pharma, Alken, Belgium

Madhav Kamat Biopharmaceutics R&D, Bristol-Myers Squibb Company, New Brunswick, New
Jersey, U.S.A.

Marc J. Kirchmeier Vaccine Formulation Development, Variation Biotechnologies, Inc.,
Cambridge, Massachusetts, U.S.A.

John D. Ludwig BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Chesterfield,
Missouri, U.S.A.

Sachin Mittal Pharmaceutical Research and Development Sciences, Merck Research Laboratories,
West Point, Pennsylvania, U.S.A.

Kazuko Sagawa Pfizer Global R&D, Groton, Connecticut, U.S.A.

Ravi M. Shanker Pfizer Global R&D, Groton, Connecticut, U.S.A.

Mohannad Shawer Bausch & Lomb, Rochester, New York, U.S.A.

Satish K. Singh BioTherapeutics Pharmaceutical Sciences, Pfizer, Inc., Chesterfield, Missouri, U.S.A.

Ching-Chiang Su Bristol-Myers Squibb Research, Princeton, New Jersey, U.S.A.

Robert Swift Amgen, Inc., Thousand Oaks, California, U.S.A.

Laura A. Thoma Department of Pharmaceutical Sciences, College of Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, U.S.A.

N. Murti Vemuri Sanofi-Aventis, Bridgewater, New Jersey, U.S.A.

Vinod D. Vilivalam West Pharmaceutical Services, Inc., Lionville, Pennsylvania, U.S.A.

Y. John Wang Genentech, South San Francisco, California, U.S.A.


Lan Xiao Bristol-Myers Squibb Research, Princeton, New Jersey, U.S.A.

Gaozhong Zhu Shire Human Genetic Therapies, Inc., Cambridge, Massachusetts, U.S.A.

Pharmaceutical Dosage Forms: Parenteral Medications

Third Edition

Volume 2: Facility Design,
Sterilization and Processing



 CRC Press
Taylor & Francis Group

Edited by
Sandeep Nema
John D. Ludwig

Copyright © 2010, Taylor & Francis Group. All rights reserved.

Pharmaceutical Dosage Forms : Parenteral Medications, Third Edition, 3 Volume Set, edited by Sandeep Nema, et al., Taylor & Francis Group, 2010.
ProQuest Ebook Central, <http://ebookcentral.proquest.com/lib/purdue/detail.action?docID=584343>.
Created from purdue on 2022-03-27 20:28:21.

Regeneron Exhibit 1103.066
Regeneron v. Novartis
IPR2021-00816



Taylor & Francis

Taylor & Francis Group

<http://taylorandfrancis.com>

Copyright © 2010. Taylor & Francis Group. All rights reserved.

Nema, S., Ludwig, J. D., & Ludwig, J. D. (Eds.). (2010). *Pharmaceutical dosage forms : Parenteral medications*, third edition. 3 volume set. Taylor & Francis Group.
Created from purdue on 2022-03-27 20:29:36.

Regeneron Exhibit 1103.067
Regeneron v. Novartis
IPR2021-00816

Pharmaceutical Dosage Forms

Copyright © 2010. Taylor & Francis Group. All rights reserved.

Nema, S., Ludwig, J. D., & Ludwig, J. D. (Eds.). (2010). *Pharmaceutical dosage forms : Parenteral medications, third edition*. 3 volume set. Taylor & Francis Group.
Created from purdue on 2022-03-27 20:29:36.

Regeneron Exhibit 1103.068
Regeneron v. Novartis
IPR2021-00816

Pharmaceutical Dosage Forms

Parenteral Medications Third Edition

Volume 2 Facility Design, Sterilization and Processing

Edited by

Sandeep Nema

Pfizer, Inc.

Chesterfield, Missouri, U.S.A.

John D. Ludwig

Pfizer, Inc.

Chesterfield, Missouri, U.S.A.

Copyright © 2010. Taylor & Francis Group. All rights reserved.



CRC Press

Taylor & Francis Group

Boca Raton London New York

CRC Press is an imprint of the
Taylor & Francis Group, an Informa business

Nema, S., Ludwig, J. D., & Ludwig, J. D. (Eds.). (2010). Pharmaceutical dosage forms : Parenteral medications, third edition. 3 volume set. Taylor & Francis Group.
Created from purdue on 2022-03-27 20:30:14.

**Regeneron Exhibit 1103.069
Regeneron v. Novartis
IPR2021-00816**

First published in 1984 by Marcel Dekker, Inc., New York, New York.
This edition published in 2010 by Informa Healthcare, Telephone House, 69-77 Paul Street, London EC2A 4LQ, UK.

Simultaneously published in the USA by Informa Healthcare, 52 Vanderbilt Avenue, 7th Floor, New York, NY 10017, USA.

Informa Healthcare is a trading division of Informa UK Ltd. Registered Office: 37-41 Mortimer Street, London W1T 3JH, UK. Registered in England and Wales number 1072954.

©2010 Informa Healthcare, except as otherwise indicated

No claim to original U.S. Government works

Reprinted material is quoted with permission. Although every effort has been made to ensure that all owners of copyright material have been acknowledged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omissions brought to our attention.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, unless with the prior written permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP, UK, or the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA (<http://www.copyright.com/> or telephone 978-750-8400).

Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

This book contains information from reputable sources and although reasonable efforts have been made to publish accurate information, the publisher makes no warranties (either express or implied) as to the accuracy or fitness for a particular purpose of the information or advice contained herein. The publisher wishes to make it clear that any views or opinions expressed in this book by individual authors or contributors are their personal views and opinions and do not necessarily reflect the views/opinions of the publisher. Any information or guidance contained in this book is intended for use solely by medical professionals strictly as a supplement to the medical professional's own judgement, knowledge of the patient's medical history, relevant manufacturer's instructions and the appropriate best practice guidelines. Because of the rapid advances in medical science, any information or advice on dosages, procedures, or diagnoses should be independently verified. This book does not indicate whether a particular treatment is appropriate or suitable for a particular individual. Ultimately it is the sole responsibility of the medical professional to make his or her own professional judgements, so as appropriately to advise and treat patients. Save for death or personal injury caused by the publisher's negligence and to the fullest extent otherwise permitted by law, neither the publisher nor any person engaged or employed by the publisher shall be responsible or liable for any loss, injury or damage caused to any person or property arising in any way from the use of this book.

A CIP record for this book is available from the British Library.

Library of Congress Cataloging-in-Publication Data available on application

ISBN-13: 9781420086454

ISBN-13: 9781420086539 (three-volume set)

Orders may be sent to: Informa Healthcare, Sheepen Place, Colchester, Essex CO3 3LP, UK

Telephone: +44 (0)20 7017 5540

Email: CSDhealthcarebooks@informa.com

Website: <http://informahealthcarebooks.com/>

For corporate sales please contact: CorporateBooksIHC@informa.com

For foreign rights please contact: RightsIHC@informa.com

For reprint permissions please contact: PermissionsIHC@informa.com

Typeset by MPS Limited, A Macmillan Company

Foreword

I was a faculty member at the University of Tennessee and a colleague of Dr. Kenneth Avis when he conceived, organized, and edited (along with H.A. Lieberman and L. Lachman) the first edition of this book series that was published in 1984. It was so well received by the pharmaceutical science community that an expanded three-volume second edition was published in 1992. Dr. Avis did not survive long enough to oversee a third edition, and it was questionable whether a third edition would ever be published until two of his graduate students, Drs. Nema and Ludwig, took it upon themselves to carry on Dr. Avis' tradition.

Their oversight of this third edition is work that their mentor would be highly pleased and proud of. From 29 chapters in the second edition to 43 chapters in this new edition, this three-volume series comprehensively covers both the traditional subjects in parenteral science and technology as well as new and expanded subjects. For example, separate chapter topics in this edition not found in previous editions include solubility and solubilization, depot delivery systems, biophysical and biochemical characterization of peptides and proteins, container-closure integrity testing, water systems, endotoxin testing, focused chapters on different sterilization methods, risk assessment in aseptic processing, visual inspection, advances in injection devices, RNAi delivery, regulatory considerations for excipients, techniques to evaluate pain on injection, product specifications, extractables and leachables, process analytical technology, and quality by design.

The editors have done an outstanding job of convincing so many top experts in their fields to author these 43 chapters. The excellent reputations of the authors and editors of this book will guarantee superb content of each chapter. There is no other book in the world that covers the breadth and depth of parenteral science and technology better than this one. In my opinion, the editors have achieved their primary objectives—publishing a book that contains current and emerging sterile product development and manufacturing information, and maintaining the high standard of quality that readers would expect.

*Michael J. Akers
Baxter BioPharma Solutions
Bloomington, Indiana, U.S.A.*

Preface

Pharmaceutical Dosage Forms: Parenteral Medications was originally published in 1984 and immediately accepted as a definitive reference in academic institutions and the pharmaceutical industry. The second edition was published in 1993. The ensuing years have produced incredible technological advancement. Classic small-molecule drugs are now complemented by complex molecules such as monoclonal antibodies, antibody fragments, aptamers, antisense, RNAi therapeutics, and DNA vaccines. There have been significant innovations in delivery devices, analytical techniques, in-silico modeling, and manufacturing and control technologies. In addition, the global regulatory environment has shifted toward greater emphasis on science-based risk assessment as evidenced by the evolving cGMPs, quality by design (QbD), process analytical technology (PAT), continuous processing, real time release, and other initiatives. The rapidly changing landscape in the parenteral field was the primary reason we undertook the challenging task of updating the three volumes. Our objectives were to (i) revise the text with current and emerging sterile product development and manufacturing science and (ii) maintain the high standard of quality the readers expect.

The third edition not only reflects enhanced content in all the chapters, but also more than half of the chapters are new underscoring the rapidly advancing technology. We have divided the volumes into logical subunits—volume 1 addresses formulation and packaging aspects; volume 2, facility design, sterilization and processing; and volume 3, regulations, validation and future directions. The authors invited to contribute chapters are established leaders with proven track records in their specialty areas. Hence, the textbook is authoritative and contains much of the collective experience gained in the (bio)pharmaceutical industry over the last two decades. *We are deeply grateful to all the authors who made this work possible.*

Volume 1 begins with a historical perspective of injectable drug therapy and common routes of administration. Formulation of small molecules and large molecules is presented in depth, including ophthalmic dosage forms. Parenteral packaging options are discussed relative to glass and plastic containers, as well as elastomeric closures. A definitive chapter is provided on container closure integrity.

Volume 2 presents chapters on facility design, cleanroom operations, and control of the environment. A chapter discussing pharmaceutical water systems is included. Key quality attributes of sterile dosage forms are discussed, including particulate matter, endotoxin, and sterility testing. The most widely used sterilization techniques as well as processing technologies are presented. Volume 2 concludes with an in-depth chapter on lyophilization.

Volume 3 focuses on regulatory requirements, risk-based process design, specifications, QbD, and extractables/leachables. In addition, we have included chapters on parenteral administration devices, siRNA delivery systems, injection site pain assessment, and control, PAT, and rapid microbiology test methods. Volume 3 concludes with a forward-looking chapter discussing the future of parenteral product manufacturing.

These three volumes differ from other textbooks in that they provide a learned review on developing parenteral dosage forms for *both* small molecules and biologics. Practical guidance is provided, in addition to theoretical aspects, for how to bring a drug candidate forward from discovery, through preclinical and clinical development, manufacturing, validation, and eventual registration.

The editors wish to thank Judy Clarkston and Lynn O'Toole-Bird (Pfizer, Inc.) for their invaluable assistance and organizational support during this project, and Sherri Niziolek and Bianca Turnbull (Informa Healthcare) for patiently leading us through the publishing process.

We also acknowledge the assistance of Pfizer, Inc. colleagues Lin Chen and Min Huang for reviewing several of the chapters.

We would like to express special gratitude to the late Kenneth E. Avis (University of Tennessee College of Pharmacy) for his dedication to teaching and sharing practical knowledge in the area of parenteral medications to so many students over the years, including us. Finally, we acknowledge the contributions of Dr Avis, Leon Lachman, and Herbert A. Lieberman who edited the earlier editions of this book series.

*Sandeep Nema
John D. Ludwig*

*We dedicate this work to those who have inspired us.
To my parents Walter and Ruth Ludwig and my wife Sue Ludwig
To my parents Hari and Pratibha Nema and my wife Tina Busch-Nema*

Copyright © 2010, Taylor & Francis Group. All rights reserved.

Nema, S., Ludwig, J. D., & Ludwig, J. D. (Eds.). (2010). *Pharmaceutical dosage forms : Parenteral medications*, third edition. 3 volume set. Taylor & Francis Group.
Created from purdue on 2022-03-27 20:44:43.

**Regeneron Exhibit 1103.074
Regeneron v. Novartis
IPR2021-00816**

Contents

<i>Foreword</i>	Michael J. Akers	vii
<i>Preface</i>		ix
<i>Contributors</i>		xiii

1. Aseptic manufacturing facility design	1
<i>Mark Caldwell, Bob Helt, Beth Holden, Francesca McBride, and Kevin Schreier</i>	
2. Personnel and their impact on clean room operations	56
<i>Jeanne Moldenhauer</i>	
3. The fundamentals of an environmental control program	80
<i>William H. Miele</i>	
4. Water systems for parenteral facilities	91
<i>Joseph J. Manfredi</i>	
5. Particulate matter: subvisible	114
<i>D. Scott Aldrich</i>	
6. Endotoxin testing	146
<i>Michael E. Dawson</i>	
7. The compendial sterility tests	187
<i>Scott V.W. Sutton</i>	
8. Industrial sterilization technologies: principles and overview	195
<i>Anne F. Booth</i>	
9. Steam sterilization	221
<i>James Agalloco</i>	
10. Gas, vapor, and liquid chemical sterilization	241
<i>James Agalloco</i>	
11. Dry heat depyrogenation and sterilization	255
<i>Deborah Havlik and Kevin Trupp</i>	
12. Radiation sterilization	268
<i>Barry P. Fairand and Dusan Razem</i>	

13. **Filters and filtration** 297
Maik W. Jornitz and Theodore H. Meltzer
14. **Processing of small volume parenterals and large volume parenterals** 334
Donald A. Eisenhauer, Roland Schmidt, Christine Martin, and Steven G. Schultz
15. **Freeze-drying: principles and practice** 353
Steven L. Nail and Larry A. Gatlin
- Index* 383

Contributors

- James Agalloco** Agalloco & Associates, Belle Mead, New Jersey, U.S.A.
- D. Scott Aldrich** Ultramikro, LLC, Richland, Michigan, U.S.A.
- Anne F. Booth** Booth Scientific, Inc., Hendersonville, North Carolina, U.S.A.
- Mark Caldwell** Jacobs Engineering Group, Inc., Conshohocken, Pennsylvania, U.S.A.
- Michael E. Dawson** Associates of Cape Cod, Inc., Falmouth, Massachusetts, U.S.A.
- Donald A. Eisenhauer** Abbott Laboratories, North Chicago, Illinois, U.S.A.
- Barry P. Fairand** Sterigenics International, Dublin, Ohio, U.S.A.
- Larry A. Gatlin** PK, LLC, Groton, Connecticut, U.S.A.
- Deborah Havlik** R&D Microbiology, Hospira, Inc., Lake Forest, Illinois, U.S.A.
- Bob Helt** Jacobs Engineering Group, Inc., Conshohocken, Pennsylvania, U.S.A.
- Beth Holden** Jacobs Engineering Group, Inc., Conshohocken, Pennsylvania, U.S.A.
- Maik W. Jornitz** Sartorius Stedim North America, Inc., Bohemia, New York, U.S.A.
- Joseph J. Manfredi** GMP Systems, Inc., Fairfield, New Jersey, U.S.A.
- Christine Martin** Abbott GmbH & Co. KG, Ludwigshafen, Germany
- Francesca McBride** Jacobs Engineering Group, Inc., Conshohocken, Pennsylvania, U.S.A.
- Theodore H. Meltzer** Capitola Consultancy, Bethesda, Maryland, U.S.A.
- William H. Miele** Pfizer Global Manufacturing, Kalamazoo, Michigan, U.S.A.
- Jeanne Moldenhauer** Excellent Pharma Consulting, Mundelein, Illinois, U.S.A.
- Steven L. Nail** Baxter Pharmaceutical Solutions, Bloomington, Indiana, U.S.A.
- Dusan Razem** Ruder Boskovic Institute, Zagreb, Croatia
- Roland Schmidt** Abbott GmbH & Co. KG, Ludwigshafen, Germany
- Kevin Schreier** Jacobs Engineering Group, Inc., Conshohocken, Pennsylvania, U.S.A.

Steven G. Schultz Abbott Laboratories, North Chicago, Illinois, U.S.A.

Scott V. W. Sutton Microbiology Network, Inc., Rochester, New York, U.S.A.

Kevin Trupp Global Sterilization Engineering, Hospira, Inc., Lake Forest, Illinois, U.S.A.

ATTACHMENT A-3



Search WorldCat

Search

[Advanced Search](#) [Find a Library](#)

[<< Return to Search Results](#)

[Cite/Export](#)

[Print](#)

[E-mail](#)

[Share](#)

[Permalink](#)

[Add to list](#)

[Add tags](#)

[Write a review](#)

Rate this item: 1 2 3 4 5



Pharmaceutical dosage forms. Parenteral medications

Author: [Sandeep Nema](#); [John D Ludwig](#)

Publisher: London ; New York : Informa Healthcare, 2010.

Edition/Format: Print book : English : 3rd ed. [View all editions and formats](#)

Summary: "A historical perspective of injectable drug therapy, common routes of administration, and biopharmaceutics of NCEs and NBEs. - An in-depth discussion on the preformulation and formulation of small and large molecules, including ophthalmic dosage forms. - A presentation of parenteral primary packaging options - glass and plastic containers, as well as elastomeric closures. - A definitive chapter on container-closure [Read more...](#)

Rating: (not yet rated) [0 with reviews - Be the first.](#)

Subjects: [Parenteral solutions.](#)
[Pharmaceutical technology.](#)
[Technology, Pharmaceutical](#)
[View all subjects](#)

More like this [Similar Items](#)

Get a Copy

[Find a copy in the library](#)

[AbeBooks](#) \$218.17

[Amazon](#) \$475.00

Find a copy in the library

Enter your location:

Submit a complete postal address for best results.

Displaying libraries 1-6 out of 67 for all 30 editions (Maryland, USA)

Show libraries holding [just this edition](#)

[« First](#) [< Prev](#) [1](#) [2](#) [3](#) [Next >](#) [Last >>](#)

Library	Held formats	Distance	
1. Howard University Washington, DC 20059 United States	Book	22 miles MAP IT	Library info Ask a librarian Add to favorites
2. National Library of Medicine Bethesda, MD 20894 United States	Book	25 miles MAP IT	Library info Add to favorites
3. Institute for Defense Analyses Library IDA Library Alexandria, VA 22311 United States	Book	30 miles MAP IT	Library info Add to favorites
4. Temple University Libraries Charles Library Philadelphia, PA 19122 United States	Book	102 miles MAP IT	Library info Ask a librarian Add to favorites
5. Princeton University Library Princeton, NJ 08544 United States	Book	139 miles MAP IT	Library info Add to favorites
6. The New School New School Libraries & Archives New York, NY 10011 United States	Book	183 miles MAP IT	Library info Ask a librarian Add to favorites

[« First](#) [< Prev](#) [1](#) [2](#) [3](#) [Next >](#) [Last >>](#)

Details

Document Type: Book

All Authors / Contributors: [Sandeep Nema](#); [John D Ludwig](#)

Find more information about:

ISBN: 9781420086539 1420086537 9781420086430 142008643X 9781420086454 1420086456 9781420086478 1420086472

OCLC Number: 1201395937

Notes: Éd. rev. de: Pharmaceutical dosage forms, parenteral medications. 2nd ed., rev. and expanded. c1992-1993.

Description: 3 v. : ill. (certains en coul.) ; 27 cm.

Contents: V. 1. Formulation and packaging --
v. 2. Facility design, sterilization and processing --
v. 3. Regulations, validation and the future.

Other Titles: Parenteral medications
Pharmaceutical dosage forms, parenteral medications.

Responsibility: edited by Sandeep Nema [and] John D. Ludwig.

Abstract:

"A historical perspective of injectable drug therapy, common routes of administration, and biopharmaceutics of NCEs and NBEs. - An in-depth discussion on the preformulation and formulation of small and large molecules, including ophthalmic dosage forms. - A presentation of parenteral primary packaging options - glass and plastic containers, as well as elastomeric closures. - A definitive chapter on container-closure integrity. - New chapters on solubility and solubilization, formulation of depot delivery systems and biophysical/biochemical characterization of proteins"--Résumé de l'éditeur.

Reviews

User-contributed reviews

[Add a review](#) and share your thoughts with other readers. Be the first.

Tags

[Add tags](#) for "Pharmaceutical dosage forms. Parenteral medications". Be the first.

Similar Items

Related Subjects: (5)

[Parenteral solutions.](#)

[Pharmaceutical technology.](#)

[Technology, Pharmaceutical](#)

[Solutions \(Pharmacie\) -- Administration parentérale.](#)

[Techniques pharmaceutiques.](#)

ATTACHMENT A-4



BOOK

Pharmaceutical dosage forms. Parenteral medications.



Nema, Sandeep.; Ludwig, John D.

New York : Informa Healthcare; 2010

Library Catalog ; MMS ID 9915362393406676; ISBN 9781420086539 (3 v. set); ISBN 9781420086430 (v. 1 : hb); ISBN 9781420086454 (v. 2 : hb); ISBN 9781420086478 (v. 3 : hb); NLM ID 101536239

Available at NLM General Collection (2010 L-841) >

TOP

SEND TO

GET IT

DETAILS

LINKS

Send to



Get It

Please sign in to check if there are other options. [Sign in](#)

BACK TO LOCATIONS

LOCATION ITEMS

NLM

Available , General Collection 2010 L-841

Summary holdings: v.1-3

Item in place (0 requests) v. 3 2010
Loanable



Item in place (0 requests) v. 2 2010
Loanable



Item in place (0 requests) v. 1 2010
Loanable



Details

**Regeneron Exhibit 1103.085
Regeneron v. Novartis
IPR2021-00816**

SEND TO

GET IT

DETAILS

LINKS

Details

Title(s)	Pharmaceutical dosage forms. Parenteral medications.
Other Title	Parenteral medications
	Pharmaceutical dosage forms, parenteral medications.
Creator(s)	Nema, Sandeep. > Ludwig, John D. >
Edition	3rd ed. / edited by Sandeep Nema, John D. Ludwig.
Publisher	New York : Informa Healthcare 2010
Country	United States
Language	English
Description	3 v. : ill.
Identifier(s)	LC : 2010030765 ISBN : 9781420086539 (3 v. set) ISBN : 9781420086430 (v. 1 : hb) ISBN : 9781420086454 (v. 2 : hb) ISBN : 9781420086478 (v. 3 : hb)
MESH Subjects	Infusions, Parenteral -- standards > Dosage Forms -- standards > Drug Delivery Systems -- methods > Pharmaceutical Preparations -- administration & dosage > Quality Control >
Summary	"A historical perspective of injectable drug therapy, common routes of administration, and biopharmaceutics of NCEs and NBEs. - An in-depth discussion on the preformulation and formulation of small and large molecules, including ophthalmic dosage forms . - A presentation of parenteral primary packaging options - glass and plastic containers, as well as elastomeric closures. - A definitive chapter on container-closure integrity. - New chapters on solubility and solubilization, formulation of depot delivery systems and biophysical/biochemical characterization of proteins"--Provided by publisher.
Notes	Rev. ed. of: Pharmaceutical dosage forms, parenteral medications. 2nd ed., rev. and expanded. c1992-1993.
Contents	v. 1. Formulation and packaging -- v. 2. Facility design, sterilization and processing -- v. 3. Regulations, validation and the future.
NLM Unique ID	101536239
MMS ID	9915362393406676
Source	Library Catalog

Links

[View and download the MARC record](#) ☑ >

[Display Source Record](#) ☑ >

ATTACHMENT A-5

Screen scrape from National Library of Medicine OPAC completed by JLM on March 27, 2022.

NLM MMS_ID 9915362393406676

- [Download MARCXML](#)
- [Download MARC21](#)

LDR	02430pam a2200529 a 4500
001	9915362393406676
005	20211203233520.0
008	100720s2010 nyua b 001 0 eng
010	__ a 2010030765
020	__ a9781420086539 (3 v. set)
020	__ a9781420086430 (v. 1 : hb)
020	__ a9781420086454 (v. 2 : hb)
020	__ a9781420086478 (v. 3 : hb)
035	__ 9101536239
040	__ aDNLMcDNLM
041	0_ aeng
042	__ apcc
044	__ 9United States
060	00 aWB 354
245	00 aPharmaceutical dosage forms.pParenteral medications.
246	13 aParenteral medications
250	__ a3rd ed. /bedited by Sandeep Nema, John D. Ludwig.
260	__ aNew York :bInforma Healthcare,c2010.
300	__ a3 v. :bill.
336	__ atextbtxt2rdacontent
337	__ aunmediatedbn2rdamedia
338	__ avolumebnc2rdacarrier
500	__ aRev. ed. of: Pharmaceutical dosage forms, parenteral medications. 2nd ed., rev. and expanded. c1992-1993.
504	__ aIncludes bibliographical references and index.
505	0_ av. 1. Formulation and packaging -- v. 2. Facility design, sterilization and processing -- v. 3. Regulations, validation and the future.
520	__ a"A historical perspective of injectable drug therapy, common routes of administration, and biopharmaceutics of NCEs and NBEs. - An in-depth discussion on the preformulation and formulation of small and large molecules, including ophthalmic dosage forms. - A presentation of parenteral primary packaging options - glass and plastic containers, as well as elastomeric closures.

	- A definitive chapter on container-closure integrity. - New chapters on solubility and solubilization, formulation of depot delivery systems and biophysical/biochemical characterization of proteins"--Provided by publisher.
650	12 a Infusions, Parenteral x standards
650	22 a Dosage Forms x standards
650	22 a Drug Delivery Systems x methods
650	22 a Pharmaceutical Preparations x administration & dosage
650	22 a Quality Control
700	1_ a Nema, Sandeep.
700	1_ a Ludwig, John D.
730	0_ a Pharmaceutical dosage forms, parenteral medications.
935	_ a (DNLM)1536239-nlmdb
992	_ p P1 e EF a 20101116
993	_ a JCY b 20101118
994	_ a CDN b 20101118
995	_ a AUTH b 20100721 c REV d 20180131
996	_ a rev. CIP b 20101118
997	_ a ONIX
999	_ a AUTH

ATTACHMENT A-6

MULLINS, JAMES L.

To: Shrader, Tina (NIH/NLM) [E]
Subject: RE: Response from NLM re: 992, 993, 994 MARC fields

James L Mullins, PhD
Dean Emeritus of Libraries and
Esther Ellis Norton Professor Emeritus
jmullins@purdue.edu
Jlmullins1@cox.net
765 479 4956
205 St Cuthbert
Williamsburg, VA 23188

From: Shrader, Tina (NIH/NLM) [E] <tina.shrader@nih.gov>
Sent: Monday, March 14, 2022 7:36 AM
To: MULLINS, JAMES L. <jmullins@purdue.edu>; jlmullins1@cox.net
Cc: Marill, Jennifer (NIH/NLM) [E] <marillj@mail.nlm.nih.gov>
Subject: Response from NLM re: 992, 993, 994 MARC fields

Dr. Mullins,

I'm responding on behalf of Jennifer Marill to the voice mail you left on Friday. Diane Boehr retired last year, and I'm currently filling in as Acting Head of our Cataloging and Metadata Management Section.

NLM has locally defined the MARC 992, 993, 994 fields as follows:

992—Processing Data and Instructions. The date in the \$a represents the date that the item described in the record was sent from Acquisitions to Cataloging. The other subfields contain information about the priority level of the item in our cataloging workflow and the encoding level to be assigned to the final bib record.

993—CAT Action. Records information about the assignment of the item to a cataloger. The date represents when the item was assigned for cataloging.

994—Cataloging Completion. Indicates completion of descriptive and subject cataloging. The date indicates when this work is completed.

There are additional fields that may be tangentially relevant to your question. After cataloging work is completed, most records go through a review process and are not distributed in NLM's MARC files until the 995 Record Authorization/Revision field is coded to indicate the record is authorized for distribution, with the date of authorization. The 999 Processing Status field also contains a code that affects whether the record is distributed.

Please don't hesitate to contact me by email or phone (301-827-1633) if you have other questions.

Tina Shrader (she/her)
Acting Head
Cataloging and Metadata Management Section
Technical Services Division
National Library of Medicine

ATTACHMENT B-1


Drug delivery technology.
DUP - General Collection
W1 DR514BK
v. 9, no. 2
Feb. 2009

Drug Delivery[®] Technology

February 2009 Vol 9 No 2

www.drugdeliverytech.com

Delivering Therapeutic siRNA



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

The science & business of drug development in specialty pharma, biotechnology, and drug delivery



Madhu Hariharan, PhD

Orally Dissolving Film Strips: The Final Evolution of Orally Dissolving Dosage Forms



Frank Y. Xie, PhD


Systemic Delivery of Therapeutic siRNA: Opportunities & Challenges



Maria J. Gutierrez, MD

A Spring-Powered Device for Subcutaneous, Intramuscular & Intradermal Injections Using an Auto-Disable Syringe

IN THIS ISSUE



INTERVIEW WITH
PRO-PHARMACEUTICALS'
CHIEF EXECUTIVE OFFICER

DAVID PLATT

Diabetes Management 30
Daniel Rupp

Prefilled Syringe Gas Bubbles 42
Shawn Kinney, PhD

Nanoparticles & Cancer 48
Maulik A. Acharya

Particle Size Optimization 53
Thomai Panagiotou, PhD

FEATURING

SPECIALTY PHARMA
Strategies in Business Development

Central Lab Strategies 64
Cindy H. Dubin

Survying Big Pharma 70
Josef Bossart, PhD

Regeneron Exhibit 1103.093
Regeneron v. Novartis
IPR2021-00816



We specialize in providing formulations with technologies that enable you to customize your pharmaceutical product. Our suite of technologies allows you to optimize your active's performance and enhance patient compliance.

These technologies include:

- **ApiSol™** – Bioavailability enhancement technology.
- **ApiCap™** – Capsule delivery platform which offers a wide range of release profiles suitable for both poorly and well absorbed APIs, as well as combination products.
- **ApiTab™** – A tablet delivery platform offering a wide range of release profiles including immediate, delayed, targeted, pulsed, sustained release or combinations thereof.
- **ApiMelt™** – Rapid oral dissolving tablet technology.
- **ApiMask™** – Taste masking technology that effectively masks the bitter taste of oral products.



Contact us to see how we can assist you with your product development needs!

954-241-4340 • www.azopdogroup.com/DDT • development@apicross.com

Drug Delivery Technology **FREE** **SUBSCRIPTION** **OFFER**

Keep abreast of the marketplace with the industry's only publication entirely devoted to drug delivery and development.

Go to www.drugdeliverytech.com
and click on *Subscription Services*

Once on the website you can also subscribe
to our eNewsletter!

For more information contact Ralph Vitaro at 973-299-1200
or e-mail him at rvitaro@drugdeliverytech.com

Drug Delivery

Technology

February 2009 Vol 9 No 2

PUBLISHER/PRESIDENT
Ralph Vitaro

EXECUTIVE EDITORIAL DIRECTOR
Dan Marino, MSc
dmarino@drugdeliverytech.com

CREATIVE DIRECTOR
Shalamar Q. Eagel

CONTROLLER
Debbie Carrillo

CONTRIBUTING EDITORS
Cindy H. Dubin
Debra Bingham
Jason McKinnie

TECHNICAL OPERATIONS
Mark Newland

EDITORIAL SUPPORT
Nicholas D. Vitaro

ADMINISTRATIVE SUPPORT
Kathleen Kenny

Corporate/Editorial Office
219 Changebridge Road, Montville, NJ 07045
Tel: (973) 299-1200
Fax: (973) 299-7937
www.drugdeliverytech.com

Advertising Sales Offices

East & Midwest

Victoria Geis - Account Executive
Cheryl S. Stratos - Account Executive
103 Oronoco Street, Suite 200
Alexandria, VA 22314
Tel: (703) 212-7735
Fax: (703) 548-3733
E-mail: vgeis@drugdeliverytech.com
E-mail: cstratos@drugdeliverytech.com

West Coast

Warren De Graff
Western Regional Manager
818 5th Avenue, Suite 301
San Rafael, CA 94901
Tel: (415) 721-0644
Fax: (415) 721-0665
E-mail: wjdegtraff@drugdeliverytech.com

International

Ralph Vitaro
219 Changebridge Road
Montville, NJ 07045
Tel: (973) 299-1200
Fax: (973) 299-7937
E-mail: rvitaro@drugdeliverytech.com

Mailing List Rental

Candy Brecht
Tel: (703) 706-0383
Fax: (703) 549-6057
E-mail: cbrecht@mgilists.com

All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept responsibility for the accuracy of information supplied herein or for any opinion expressed. Drug Delivery Technology (ISSN 1944-818X) is published 10 times in 2009, January, February, March, April, May, June, July/August, September, October, and November/December by Drug Delivery Technology LLC, 219 Changebridge Road, Montville, NJ 07045. Subscription rates: \$99.00 for 1 year in the United States, Canada, and Mexico. \$153.00 for 1 year outside the United States, Canada, and Mexico. All subscriptions are payable in US funds, drawn on US banks. Send payment to: Drug Delivery Technology LLC Subscription Department, 219 Changebridge Road, Montville, NJ 07045. Single copies (prepaid) \$15.00, US, Canada, and Mexico; \$24.00 in all other countries. Add \$5.00 per order for shipping and handling. Periodicals Postage Paid at Montville, NJ 07045-9998 and additional mailing offices. Postmaster: please send address changes to Drug Delivery Technology, 219 Changebridge Road, Montville, NJ 07045. All rights reserved under the US International and Pan-American Copyright Conventions. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopy, recording, or information storage and retrieval system, without written permission from the publisher. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Drug Delivery Technology LLC for libraries and other users registered with the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923; phone: (978) 750-8400, fax: (978) 750-4470.

Regeneron Exhibit 1103.094
Regeneron v. Novartis
IPR2021-00816

Therapeutic siRNA

“Compared to the local siRNA deliveries that were used in many early siRNA clinical trials, systemic siRNA delivery faces more challenges and hurdles that have slowed down the expansion of siRNA therapeutics. With increasing efforts dedicated to the development of more efficient systemic siRNA delivery technologies, it is conceivable the key delivery hurdles could be overcome and the potential of RNAi-based therapeutics may be realized in a not too distant future.”



Table Of Contents

- 24** *Orally Dissolving Film Strips (ODFS): The Final Evolution of Orally Dissolving Dosage Forms*
Madhu Hariharan, PhD, and B. Artie Bogue, PhD, focus their discussion mainly on films for oral delivery of drug to the GI tract as well as address other prospective manifestations of this dosage form.
- 30** *Continued Drug Delivery Opportunities in Diabetes Management*
Frost & Sullivan Analyst Daniel Ruppert asks the question of whether there is still an opportunity for an inhaled diabetes drug.
- 32** *Systemic Delivery of Therapeutic siRNA: Opportunities & Challenges*
Frank Y. Xie, PhD; Qing Zhou, PhD; Ying Liu, MS; Samuel Zalipsky, PhD; and Xiaodong Yang, MD, PhD; provides an overview of the critical steps in the development of siRNA therapeutics, from the selection of siRNA specific for the target of interest to the development of novel formulations for efficient in vivo systemic delivery of siRNA therapeutics.
- 38** *Speeding Drugs With Non-Traditional Delivery Mechanisms to Market*
Robert R. Andrews, MS, MBA, and Russell L. Newton, MS, provide guidance on how to overcome the most commonly encountered issues in developing non-traditionally delivered drugs.
- 42** *A Rational Approach to Determining the Maximum Allowable Gas Bubble Inside a Prefilled Syringe to Minimize Stopper Movement & Protect Product Sterility*
Shawn Kinney, PhD; Andrea Wagner, PhD; and Christian W. Phillips make the case that reducing or eliminating the bubble inside a prefilled syringe is a preferred means for ensuring product sterility while enhancing the benefits of a prefilled syringe.
- 48** *Nanoparticles in Cancer Research: A Novel Drug Delivery & Pharmacological Approach*
Priyal Patel, Maulik A. Acharya, and Jayvadan Patel, PhD, provide a balanced update on exciting pharmacological and potentially toxicological developments of nanoparticles in cancer research.

Central Lab Strategies

"The best trial plans will fail if they cannot enroll patients. Through feasibility, we help clients select the inclusion and exclusion criteria, model enrollment, incorporate feedback from investigators, consultants, epidemiologists, and analyze prescription and insurance data. The triangulation of this data gives us information to improve country selection, site identification, and enrollment forecasts, as well as identify back-up strategies and alternative plans, tailored to the client's needs."

Table Of Contents

- 53 ***Achieving Optimal Particle Size Distribution in Inhalation Therapy***
Thomai (Mimi) Panagiotou, PhD, addresses many of the concerns medical device manufacturers and their pharmaceutical partners have when attempting to achieve the correct particle size for an inhalation device.
- 61 ***The Untapped Potential of Carbohydrates in Drug Discovery & Development***
Executive Summary: David Platt, CEO of Pro-Pharmaceuticals, says carbohydrate molecules have been shown to play an important role in major diseases, including cancer, cardiovascular disease, Alzheimer's disease, inflammatory disease, and viral infections.
- 64 ***How Your Central Lab Can Keep Clinical Trials Flexible & Cost Effective***
Contributor Cindy H. Dubin poses questions to central lab executives about how improved forecasting methods and alternative foreign locations could result in better data generated during clinical trials.
- 70 ***Drug Delivery Prospects for the Next Decade: An Informal Survey of Big Pharma***
Josef Bossart, PhD, conducted an informal survey with Big Pharma personnel to get their sense of how drug delivery fits into their plans now and for the next decade.

DEPARTMENTS

Market News & Trends	12
Advanced Delivery Devices	18
A Spring-Powered Device for Subcutaneous, Intramuscular & Intradermal Injections Using an Auto-Disable Syringe	
Technology Showcase	58
External Delivery	74
But Mom & Dad... You Promised	

PREFILLED SYRINGES

A Rational Approach to Determining the Maximum Allowable Gas Bubble Inside a Prefilled Syringe to Minimize Stopper Movement & Protect Product Sterility

By: Shawn Kinney, PhD; Andrea Wagner, PhD; and Christian W. Phillips

ABSTRACT


Prefilled syringes are a fast-growing alternative to vials in the parenteral product market due to the many advantages they offer relative to vials. These include reduced overfill requirements, ease of use, more accurate dosing, decreased waste, and enhanced product differentiation.

Conventional syringe-filling processes typically leave a large air bubble in a syringe that can negatively impact product sterility and package integrity. Using a series of equations and hypothetical scenarios, this article will demonstrate the potential impact of a bubble on stopper movement during periods of reduced atmospheric pressure. It will also propose a rational approach for determining the maximum allowable size of a gas bubble inside a prefilled syringe taking into account several critical factors. After weighing some of the alternatives for limiting stopper movement during shipping as well as one additional benefit of bubble-free filling, this article will make the case that reducing or eliminating the bubble inside a prefilled syringe is a preferred means for ensuring product sterility while enhancing the benefits of a prefilled syringe.

INTRODUCTION

The internal environments of a glass vial and a glass syringe have a number of features in common, as shown in Figure 1. Both presentations are essentially glass cylinders that are sealed by an elastomeric closure, or stopper, and both contain a gaseous headspace, or bubble. However, there is one noteworthy difference. A vial's stopper is held in place by a crimp, while a syringe's stopper is designed

to move in order to allow injection of the drug product. This freedom of movement, when coupled with a gas bubble (which is not intrinsic to a syringe but is a byproduct of sub-optimal filling processes) can potentially cause significant challenges with regard to package integrity and product sterility, particularly when the syringe is exposed to repeated changes in atmospheric pressure, such as during shipping. Reducing or eliminating the



bubble inside the syringe would limit stopper movement, potentially enhancing sterility assurance of the product.¹

In a preliminary study of the impact of a bubble on stopper movement in a prefilled syringe, three syringes were placed inside a Hypak vacuum chamber. One syringe contained a 2.5-mm bubble, one a 5.0-mm bubble, and yet another contained no bubble at all. Next, a vacuum was pulled at 8 inches of mercury and then again at 15 inches while the syringes were closely monitored for signs of stopper movement. The procedure was then repeated five more times, with a new set of syringes each time, to substantiate the initial findings, which included the following:

- In the syringes containing a bubble, the stopper was seen rising into non-sterile areas of the syringe barrel each time the vacuum was pulled.
- In the syringes containing no gas bubble, however, the stopper was not seen rising at all.
- The size of the bubble inside the syringe made a difference in the amount of stopper movement. The syringes filled with a 2.5-mm bubble experienced less movement than the syringes filled with a 5.0-mm bubble. When the vacuum was released and the pressure returned to original levels, the stoppers in the syringes containing a bubble returned to their original position with no indication that they had moved.

Due to the difficulty of controlling for all of the variables that affect stopper movement in a prefilled syringe, a series of equations were devised to show, on a theoretical level, the relationship between the size of the gas bubble and stopper movement. Using Boyle's Law, the amount of expansion or contraction a gas bubble inside a prefilled syringe undergoes due to changes in pressure, and the amount of stopper movement that occurs as a result of that expansion and contraction was

TABLE 1

Gas Bubble Size	$H_{sb} = 6.2$ mm Approximate Elevation (1,000s ft)	$H_{sb} = 4.3$ mm Approximate Elevation (1,000's ft)
0.5 mm	21	19
1.0 mm	16	14
2.5 mm	13	7
5.0 mm	7	<5

Approximate elevation (in feet above sea level) at which a stopper will have moved 1/5 H_{sb} .

calculated.


Plugging these calculations into a hypothetical situation in which a syringe is shipped multiple times from the manufacturer to the end-user, a rational approach was developed for determining the maximum allowable size of a gas bubble inside a prefilled syringe. Among the factors taken into account were stopper height, the elevations to which a syringe will likely be exposed and the consequent changes in pressure which it will undergo, as well as the number of times a syringe will be subjected to reduced atmospheric pressure.


STERILE BARRIER HEIGHT: H_{SB}

In a prefilled syringe, a sterile barrier is created in which the stopper is in intimate contact with the glass barrel of

the syringe, as shown in Figure 2. The sterile barrier height, or H_{sb} , spans the entire distance from the uppermost to the lowermost point of stopper contact and represents the limit of upward stopper movement, which the stopper can undergo before product sterility is potentially compromised.

A gas bubble sealed inside a prefilled syringe acts like a spring, expanding and contracting with changes in temperature or external ambient pressure. If the external ambient temperature increases or pressure decreases, the gas bubble expands, pushing the stopper up until the pressure in the syringe is equivalent to the external pressure. When the external ambient pressure and/or temperature return to their original levels, the gas bubble in the syringe contracts until the pressure in the syringe is equal to the external pressure. This causes the stopper to return to its





original position, leaving no visible evidence that the stopper has moved (Figure 3).²

If the stopper in a syringe moves more than the distance of H_{sb} , it can pull microorganisms or contaminants from the non-sterile portion of the syringe into the drug product, potentially causing a sterility failure. This same phenomenon could occur when a stopper moves less than the distance of H_{sb} if it moves multiple times and the sum of all stopper movements exceeds H_{sb} , as demonstrated in Figure 4.

PRESSURE & THE VOLUME OF A GAS BUBBLE

The amount of change in the volume of a gas bubble is relatively small over the reasonable temperatures to which a syringe might be exposed (total range of approximately 40°C); however, the volume change due to pressure changes alone can be significant, as demonstrated in the calculations that appear further on.

Assuming that temperature remains constant, the amount of expansion or contraction a gas bubble inside a prefilled

syringe undergoes due to pressure changes can be calculated using Boyle's Law (Equation 1).

Equation 1.

$$P_1V_1 = P_2V_2$$

Where P_1 = pressure condition 1, V_1 = volume condition 1, P_2 = pressure condition 2, and V_2 = volume condition 2. The volume (V) of a cylinder, such as a syringe, is given by Equation 2.

Equation 2.

$$V = \pi r^2 h$$

Where r = internal radius of the syringe barrel, and h = height of the gas bubble/air gap (assuming the bubble spans the entire diameter of the syringe). If Equation 2 is substituted for V in Equation 1, and both sides are divided by πr^2 , the result is as Equation 3.

Equation 3.

$$P_1h_1 = P_2h_2$$

Where P_1 = pressure condition 1, h_1 = height condition 1, P_2 = pressure condition 2, and h_2 = height condition 2. Thus in Equation 4, the theoretical height of the gas space in the syringe at a given external pressure can be determined based on the initial conditions (condition 1).²

Equation 4.

$$h_2 = P_1h_1/P_2$$

The percentage of total stopper movement beyond the initial sterility barrier (H_{sb}) can be calculated by subtracting the initial height (H_1) from the height calculated in Equation 4 (H_2) and dividing the result by H_{sb} , as shown in Equation 5.

Equation 5.

$$\text{Percent } H_{sb} = 100 * (H_2 - H_1) / H_{sb}$$

Figures 5b and 5c show the percentage of H_{sb} that a stopper will move in syringes with an H_{sb} of 6.2 and 4.3 mm, respectively, and initial bubble sizes ranging from 0.5 mm to 5 mm, the most common size range for a bubble. The points on the x axis in Figures 5b and 5c represent feet of elevation rather than absolute pressure to demonstrate the effect that reduced pressure (due to changes in elevation) will have on a syringe. These points were determined using a conversion of 1 inch Hg vacuum equal to 1000 feet of elevation (Figure 5a).

The y axis in Figures 5b and 5c represents the percentage of H_{sb} , which the stopper in a syringe will move, while the red line at 100% shows the point at which the stopper will enter a non-sterile area of the syringe, potentially compromising product sterility.

In the example in Figure 5b, in which H_{sb} is 6.2 mm and the initial bubble size is 2.5 mm, the stopper travels in excess of one stopper height in a single exposure to an elevation of approximately 23,000 feet. When the initial bubble is 5.0 mm, the stopper travels in excess of one stopper height in a single exposure to an elevation of approximately 20,000 feet.²

Because the cargo hold of an airplane is generally maintained at a pressure equal to 8,000 feet of elevation, and ground elevations during shipment do not often exceed 10,000 feet, a stopper is not likely to move more than H_{sb} in a single exposure. However, during shipment, a syringe could possibly be exposed to reduced pressure on several occasions which, taken together, increases the potential for total stopper movement to exceed H_{sb} .

Consider, for example, a syringe that is shipped from a CMO's manufacturing site to the sponsor company's facility to a distribution center and finally to the end-user's site, for a total of three shipments. It is possible that one or more legs of the product's journey could involve more than one flight, creating additional opportunities for the stopper to rise and fall. Under those conditions, it is conceivable that a syringe could be exposed to changes in pressure on five occasions, resulting in five up and down stopper movements. In that case, a stopper would only need to rise $1/5 H_{sb}$ each time to potentially pull non-sterile material, such as silicon, or other contaminants into the product causing a sterility failure.


Table I shows the approximate elevations at which the stopper would exceed $1/5$ of H_{sb} given several different sized bubbles. To prevent stopper movement as a result of changes in ambient pressure, syringes should ideally be filled without any gas bubbles. However, in practice, most syringe filling equipment does not have the capability to remove all of the gas in a syringe. When that is the case, the maximum acceptable size of a gas bubble for a given stopper in a prefilled syringe should be determined.

This can be done by factoring in the differential pressure changes to which a syringe will likely be exposed, the number of times it will be subjected to reduced pressure, and the height of the sterile barrier.

DETERMINING THE MAXIMUM SIZE OF A GAS BUBBLE

Using the aforementioned equations, the size of the bubble that will lead to a movement of the stopper equal to $1/5$ of H_{sb} can be calculated at a number of different elevations. For example, Figure 6 shows the results of calculations performed using elevations of 8,000 and 12,000 feet with a range of H_{sb} from 1 to 15 mm. In situations where H_{sb} is 4.0 and elevation is 8,000 feet, the maximum acceptable size of the gas bubble is approximately 2.0 mm. When the elevation reaches 12,000 feet, however, the maximum acceptable size of the gas bubble decreases to approximately 1.6

mm.² The aforementioned analysis is a worst-case scenario and does not take into account frictional forces and break loose forces. Frictional forces caused by the stopper rubbing against the syringe, and the break loose force, which is required to start the stopper moving, should reduce stopper movement. Break loose forces, which increase over the life of the syringe, would improve resistance to stopper movement the longer the product was in transit, requiring greater force to initiate the movement of the stopper. However, it is not unreasonable to assume that a newly filled prefilled glass syringe with silicon has very little break loose force. In fact, we have confirmed in our laboratories that standard, commercially available glass syringes and elastomeric stoppers with silicon show actual stopper movement that is approximately 75% of that which has been theoretically calculated in this article. We did not perform an extensive study of all factors that could affect glide and breakloose forces; therefore, we have used theoretical calculations to demonstrate



several worst-case scenarios for stopper movement.

The aforementioned analysis is also based on the assumption that pressures are controlled at consistent levels throughout shipment when, in fact, the actual magnitude of reduced/increased pressure to which syringes are exposed is generally not known. Cargo is shipped by a variety of carriers, many of whom may not consistently control, measure, or report changes in pressure. Atmospheric pressure in a cargo hold could rise and fall during flight, and the drug

manufacturer would not be aware of it upon inspection at the final destination.

There are alternative means to prevent contamination due to stopper movement other than reducing the size of the gas bubble or increasing H_{sb} . For example, the stopper can be locked in place with a device placed inside the barrel, or the entire syringe can be sealed inside a sterile container (protecting the sterility of the barrel above the stopper), or the syringe can be placed in a holder that secures the plunger rod in place. However, each of these approaches adds cost and requires additional packaging and does not provide the added benefits of a bubble-free syringe.

FIGURE 5A


Elevation	" Hg Vac.	psi	torr
0	0	14.7	760
8,000	8"	10.7	555
10,000	10"	9.8	506
12,000	12"	8.9	455
15,000	15"	7.3	379
18,000	18"	5.9	302
25,000	25"	2.4	125
27,000	27"	1.4	74

Conversion of 1-inch Hg vacuum equal to 1000 feet of elevation.

ELIMINATING PRODUCT LOSS

One added benefit of a bubble-free syringe is the reduction in the amount of product inadvertently lost during use. In a side-by-side analysis, 15 syringes were filled with gas bubbles of varying sizes, while 15 syringes were filled with no bubble. As the tip caps on each set of syringes were removed, the needles were watched for any sign of dripping or product leaks. In the set that were filled with a bubble, product was observed leaking from needle over 75% of the time when the tip cap was removed. Conversely, in the needles that were bubble-free, no product was seen leaking from the needle any time the tip caps were removed (Figure 7).²


This is because in a bubble-free syringe, there is no expansion and contraction of the bubble as a result of the small vacuum that is created when the tip cap is removed. Without a drip, there is added assurance that the end-user will receive the entire deliverable dose. There is also less risk that the administrator or end-user will be exposed to cytotoxic or potent compounds, as well as a reduction in product wasted.



CONCLUSION

Although, on the surface, syringes may appear very similar to vials, the freedom of stopper movement in a prefilled syringe, coupled with a gas bubble, will result in challenges to package integrity and product sterility when the syringe is exposed to changes in atmospheric pressure. A gas bubble is not intrinsic to a syringe but is the result of a sub-optimal filling process and therefore, can be reduced or eliminated using alternative filling methods.

Manufacturers go to great lengths to monitor and control the temperature to which products are exposed during shipping. Yet the same attention has not been paid to changes in differential pressures to which a product is exposed. Given that a number of today's parenteral products are shipped several times before reaching the end-user, undergoing several changes in atmospheric pressure and several potential



movements of the stopper, such attention is warranted. Just as exposure to elevated temperatures may impact the shelf-life and efficacy of products, exposure to reduced pressure may potentially impact the sterility and safety of an injectable product in a prefilled syringe if one is not aware of the importance of reduced bubble size and stopper design.

In this discussion, we have proposed one way to determine the maximum acceptable size of a gas bubble that can be left inside a syringe based on stopper height as well as other variables. There are alternative ways to protect prefilled syringes from contamination due to stopper movement, but these require additional packaging and do not offer the added benefits of a bubble-free syringe, such as enhanced dosing accuracy and safety as well as reduced waste due to the elimination of a product drip at the needle when the tip cap is removed.³


As prefilled syringes continue to find favor as an alternative to vials for many of

today's parenteral products, reduced gas bubble filling should likewise become increasingly popular as an alternative to traditional filling methods and may one day become the industry standard.

REFERENCES


1. Harrison B, Rios M. Big shot: developments in prefilled syringes. *Pharm Technol.* 2007;31(3):50-56.
2. Kinney SD. Considerations on the size of the gas bubble in a prefilled syringe. Paper presented at the PDA Universe of the Prefilled Syringe Show in Berlin, Germany, November 27-28, 2007.
3. Kinney SD. Innovative Solutions Seminar. New Brunswick, NJ, October 30, 2007.

FIGURE 6



The data demonstrates that smaller gas bubbles and stoppers with larger H_{sb} reduce the risk of stopper movement exceeding $1/5 H_{sb}$.

FIGURE 7



Gas bubbles in traditionally filled syringes, like the syringe on the bottom in this photo, can cause product to drip from the needle when the needle sheath or tip cap is removed. In a bubble-free syringe, like the one pictured on the top, there is no drip, decreasing waste and improving dosing accuracy and safety.

BIOGRAPHIES

Dr. Shawn D. Kinney, President of Hyaluron Contract Manufacturing (HCM), founded HCM in 1999 to provide aseptic manufacturing and filling services to the pharmaceutical, biotech, and medical device industries. Dr. Kinney earned his PhD in Chemistry from the University of Massachusetts at Amherst, a Masters in Medicinal Chemistry from Northeastern University, and a BS in Chemistry from the University of Massachusetts at North Dartmouth. Dr. Kinney has worked at Anika Therapeutics, Wyeth-Ayerst, and Millipore and has more than 20 years of experience in the pharmaceutical industry. He has extensive experience in the development of sterile formulation and filling processes, including viscous and difficult-to-fill products. Prior to founding HCM, he was responsible for the sterile formulation and filling of hyaluronate into prefilled syringes in his role as VP of Operations at Anika Therapeutics. Recently, Dr. Kinney has pioneered a new technology in online vacuum filling and stoppering (Bubble-Free Filling®) and has been granted a patent. He continues to oversee HCM's expansion and leadership in the aseptic contract manufacturing industry. He can be reached at shawn@hyaluron.com or (781) 270-7900, ext. 218.

Dr. Andrea Wagner is the Vice President of Business Development at HCM, a position she has held for 7 years. Prior to joining HCM, she was employed by the New Jersey Institute of Technology in the capacity of Senior Scientist in a national training program. Simultaneously, she worked as a Manager at Thermo Fisher Scientific as a Manager in business development of pharmaceutical applications for their XRF Analyzers. After earning her PhD in Toxicology, she managed a center devoted to innovative testing technologies in the Chemistry Department at Tufts University in Massachusetts. Dr. Wagner also earned her a MS in Analytical Chemistry and her BS in Chemistry. She can be reached at andrea@hyaluron.com or (781) 270-7900, ext. 106.

Christian W. Phillips is the Director of Process Engineering, at HCM. Mr. Phillips has 14 years of experience in R&D, Process Development, Tech Transfer, and Manufacturing environments suited for the introduction of novel biotherapeutics and generics, including fill/finish applications. Prior to HCM, Mr. Phillips was employed by Transkaryotic Therapies (now Shire HGS). Mr. Phillips earned his a BS in Biology from St. Michael's College and is the co-inventor with Shawn Kinney of HCM's Bubble-Free Filling® technology. He can be reached at cphillips@hyaluron.com or (781) 270-7900, ext. 181.

ATTACHMENT B-2

Drug Delivery Technology

7842723 25/02/09 BOSTON SPA LS23 7BQ
 DRUG DELIVERY TECHNOLOGY.
 3629.104900
 Volume 9: Number 2 (2009)
 ETOC

1

February 2009 Vol 9 No 2

www.drugdeliverytech.com

Delivering Therapeutic siRNA

LOAN BAN

EXPIRES 25 AUG 2009

IN THIS ISSUE



INTERVIEW WITH
 PRO-PHARMACEUTICALS'
 CHIEF EXECUTIVE OFFICER

DAVID PLATT

Diabetes Management 30
 Daniel Ruppard

Prefilled Syringe Gas Bubbles 42
 Shawn Kinney, PhD

Nanoparticles & Cancer 48
 Maulik A. Acharya

Particle Size Optimization 53
 Thomai Panagiotou, PhD

FEATURING

SPECIALTY PHARMA
 Strategies for Business Development

Central Lab Strategies 64
 Cindy H. Dubin

Survying Big Pharma 70
 Josef Bossart, PhD

The science & business of drug development in specialty pharma, biotechnology, and drug delivery



Madhu Hariharan, PhD

Orally Dissolving Film Strips: The Final Evolution of Orally Dissolving Dosage Forms



Frank Y. Xie, PhD

Systemic Delivery of Therapeutic siRNA: Opportunities & Challenges



Maria J. Gutierrez, MD

A Spring-Powered Device for Subcutaneous, Intramuscular & Intradermal Injections Using an Auto-Disable Syringe

Regeneron Exhibit 1103.104
 Regeneron v. Novartis
 IPR2021-00816



We specialize in providing formulations with technologies that enable you to customize your pharmaceutical product. Our suite of technologies allows you to optimize your active's performance and enhance patient compliance.

These technologies include:

- **ApiSol™** – Bioavailability enhancement technology.
- **ApiCap™** – Capsule delivery platform which offers a wide range of release profiles suitable for both poorly and well absorbed APIs, as well as combination products.
- **ApiTab™** – A tablet delivery platform offering a wide range of release profiles including immediate, delayed, targeted, pulsed, sustained release or combinations thereof.
- **ApiMelt™** – Rapid oral dissolving tablet technology.
- **ApiMask™** – Taste masking technology that effectively masks the bitter taste of oral products.

An Azopharma Company
Azopharma
Pharmaceuticals

Contact us to see how we can assist you with your product development needs!

954-241-4340 • www.azopdogroup.com/DDT • development@apicross.com

Drug Delivery Technology **FREE** SUBSCRIPTION OFFER

Keep abreast of the marketplace with the industry's only publication entirely devoted to drug delivery and development.

Go to www.drugdeliverytech.com and click on Subscription Services

Once on the website you can also subscribe to our eNewsletter!

For more information contact Ralph Vitaro at 973-299-1200 or e-mail him at rvitaro@drugdeliverytech.com

Drug Delivery Technology

February 2009 Vol 9 No 2

PUBLISHER/PRESIDENT
Ralph Vitaro

EXECUTIVE EDITORIAL DIRECTOR
Dan Marino, MSc
dmarino@drugdeliverytech.com

CREATIVE DIRECTOR
Shalamar Q. Eagel

CONTROLLER
Debbie Carrillo

CONTRIBUTING EDITORS
Cindy H. Dubin
Debra Bingham
Jason McKinnie

TECHNICAL OPERATIONS
Mark Newland

EDITORIAL SUPPORT
Nicholas D. Vitaro

ADMINISTRATIVE SUPPORT
Kathleen Kenny

Corporate/Editorial Office
219 Changebridge Road, Montville, NJ 07045
Tel: (973)299-1200
Fax: (973) 299-7937
www.drugdeliverytech.com

Advertising Sales Offices

East & Midwest

Victoria Geis - Account Executive
Cheryl S. Stratos - Account Executive
103 Oronoco Street, Suite 200
Alexandria, VA 22314
Tel: (703) 212-7735
Fax: (703) 548-3733
E-mail: vgeis@drugdeliverytech.com
E-mail: cstratos@drugdeliverytech.com

West Coast

Warren De Graff
Western Regional Manager
818 5th Avenue, Suite 301
San Rafael, CA 94901
Tel: (415) 721-0644
Fax: (415) 721-0665
E-mail: wjdegraff@drugdeliverytech.com

International

Ralph Vitaro
219 Changebridge Road
Montville, NJ 07045
Tel: (973) 299-1200
Fax: (973) 299-7937
E-mail: rvitaro@drugdeliverytech.com

Mailing List Rental

Candy Brecht
Tel: (703) 706-0383
Fax: (703) 549-6057
E-mail: cbrecht@mgilists.com

All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept responsibility for the accuracy of information supplied herein or for any opinion expressed. Drug Delivery Technology (ISSN 1944-818X) is published 10 times in 2009, January, February, March, April, May, June, July/August, September, October, and November/December by Drug Delivery Technology LLC, 219 Changebridge Road, Montville NJ 07045. Subscription rates: \$99.00 for 1 year in the United States, Canada, and Mexico. \$153.00 for 1 year outside the United States, Canada, and Mexico. All subscriptions are payable in US funds, drawn on US banks. Send payment to: Drug Delivery Technology LLC Subscription Department, 219 Changebridge Road, Montville NJ 07045. Single copies (prepaid) \$15.00, US, Canada, and Mexico; \$24.00 in all other countries. Add \$5.00 per order for shipping and handling. Periodicals Postage Paid at Montville, NJ 07045-9998 and additional mailing offices. Postmaster: please send address changes to Drug Delivery Technology, 219 Changebridge Road, Montville NJ 07045. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopy, recording, or information storage and retrieval system, without written permission from the publisher. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Drug Delivery Technology LLC for libraries and other users registered with the Copyright Clearance, 222 Rosewood Drive, Danvers, MA 01923; phone: (978) 750-8400, fax: (978) 750-4470.

Regeneron Exhibit 1103.105
Regeneron v. Novartis
IPR2021-00816

Therapeutic siRNA

“Compared to the local siRNA deliveries that were used in many early siRNA clinical trials, systemic siRNA delivery faces more challenges and hurdles that have slowed down the expansion of siRNA therapeutics. With increasing efforts dedicated to the development of more efficient systemic siRNA delivery technologies, it is conceivable the key delivery hurdles could be overcome and the potential of RNAi-based therapeutics may be realized in a not too distant future.”

Table Of Contents

- 24 ***Orally Dissolving Film Strips (ODFS): The Final Evolution of Orally Dissolving Dosage Forms***
Madhu Hariharan, PhD, and B. Arlie Bogue, PhD, focus their discussion mainly on films for oral delivery of drug to the GI tract as well as address other prospective manifestations of this dosage form.
- 30 ***Continued Drug Delivery Opportunities in Diabetes Management***
Frost & Sullivan Analyst Daniel Ruppar asks the question of whether there is still an opportunity for an inhaled diabetes drug.
- 32 ***Systemic Delivery of Therapeutic siRNA: Opportunities & Challenges***
Frank Y. Xie, PhD; Qing Zhou, PhD; Ying Liu, MS; Samuel Zalipsky, PhD; and Xiaodong Yang, MD, PhD; provides an overview of the critical steps in the development of siRNA therapeutics, from the selection of siRNA specific for the target of interest to the development of novel formulations for efficient in vivo systemic delivery of siRNA therapeutics.
- 38 ***Speeding Drugs With Non-Traditional Delivery Mechanisms to Market***
Robert R. Andrews, MS, MBA, and Russell L. Newton, MS, provide guidance on how to overcome the most commonly encountered issues in developing non-traditionally delivered drugs.
- 42 ***A Rational Approach to Determining the Maximum Allowable Gas Bubble Inside a Prefilled Syringe to Minimize Stopper Movement & Protect Product Sterility***
Shawn Kinney, PhD; Andrea Wagner, PhD; and Christian W. Phillips make the case that reducing or eliminating the bubble inside a prefilled syringe is a preferred means for ensuring product sterility while enhancing the benefits of a prefilled syringe.
- 48 ***Nanoparticles in Cancer Research: A Novel Drug Delivery & Pharmacological Approach***
Priyal Patel, Maulik A. Acharya, and Jayvadan Patel, PhD, provide a balanced update on exciting pharmacological and potentially toxicological developments of nanoparticles in cancer research.

Central Lab Strategies

"The best trial plans will fail if they cannot enroll patients. Through feasibility, we help clients select the inclusion and exclusion criteria, model enrollment, incorporate feedback from investigators, consultants, epidemiologists, and analyze prescription and insurance data. The triangulation of this data gives us information to improve country selection, site identification, and enrollment forecasts, as well as identify back-up strategies and alternative plans, tailored to the client's needs."

Table Of Contents

- 53 ***Achieving Optimal Particle Size Distribution in Inhalation Therapy***
Thomai (Mimi) Panagiotou, PhD, addresses many of the concerns medical device manufacturers and their pharmaceutical partners have when attempting to achieve the correct particle size for an inhalation device.
- 61 ***The Untapped Potential of Carbohydrates in Drug Discovery & Development***
Executive Summary: David Platt, CEO of Pro-Pharmaceuticals, says carbohydrate molecules have been shown to play an important role in major diseases, including cancer, cardiovascular disease, Alzheimer's disease, inflammatory disease, and viral infections.
- 64 ***How Your Central Lab Can Keep Clinical Trials Flexible & Cost Effective***
Contributor Cindy H. Dubin poses questions to central lab executives about how improved forecasting methods and alternative foreign locations could result in better data generated during clinical trials.
- 70 ***Drug Delivery Prospects for the Next Decade: An Informal Survey of Big Pharma***
Josef Bossart, PhD, conducted an informal survey with Big Pharma personnel to get their sense of how drug delivery fits into their plans now and for the next decade.

DEPARTMENTS

Market News & Trends	12
Advanced Delivery Devices	18
A Spring-Powered Device for Subcutaneous, Intramuscular & Intradermal Injections Using an Auto-Disable Syringe	
Technology Showcase	58
External Delivery	74
But Mom & Dad... You Promised	

PREFILLED SYRINGES

A Rational Approach to Determining the Maximum Allowable Gas Bubble Inside a Prefilled Syringe to Minimize Stopper Movement & Protect Product Sterility

By: Shawn Kinney, PhD; Andrea Wagner, PhD; and Christian W. Phillips

ABSTRACT


Prefilled syringes are a fast-growing alternative to vials in the parenteral product market due to the many advantages they offer relative to vials. These include reduced overfill requirements, ease of use, more accurate dosing, decreased waste, and enhanced product differentiation.

Conventional syringe-filling processes typically leave a large air bubble in a syringe that can negatively impact product sterility and package integrity. Using a series of equations and hypothetical scenarios, this article will demonstrate the potential impact of a bubble on stopper movement during periods of reduced atmospheric pressure. It will also propose a rational approach for determining the maximum allowable size of a gas bubble inside a prefilled syringe taking into account several critical factors. After weighing some of the alternatives for limiting stopper movement during shipping as well as one additional benefit of bubble-free filling, this article will make the case that reducing or eliminating the bubble inside a prefilled syringe is a preferred means for ensuring product sterility while enhancing the benefits of a prefilled syringe.

INTRODUCTION

The internal environments of a glass vial and a glass syringe have a number of features in common, as shown in Figure 1. Both presentations are essentially glass cylinders that are sealed by an elastomeric closure, or stopper, and both contain a gaseous headspace, or bubble. However, there is one noteworthy difference. A vial's stopper is held in place by a crimp, while a syringe's stopper is designed

to move in order to allow injection of the drug product. This freedom of movement, when coupled with a gas bubble (which is not intrinsic to a syringe but is a byproduct of sub-optimal filling processes) can potentially cause significant challenges with regard to package integrity and product sterility, particularly when the syringe is exposed to repeated changes in atmospheric pressure, such as during shipping. Reducing or eliminating the



Comparison of a vial and a syringe. Both are essentially glass tubes sealed with an elastomeric closure and contain a gas headspace.

bubble inside the syringe would limit stopper movement, potentially enhancing sterility assurance of the product.¹

In a preliminary study of the impact of a bubble on stopper movement in a prefilled syringe, three syringes were placed inside a Hypak vacuum chamber. One syringe contained a 2.5-mm bubble, one a 5.0-mm bubble, and yet another contained no bubble at all. Next, a vacuum was pulled at 8 inches of mercury and then again at 15 inches while the syringes were closely monitored for signs of stopper movement. The procedure was then repeated five more times, with a new set of syringes each time, to substantiate the initial findings, which included the following:

- In the syringes containing a bubble, the stopper was seen rising into non-sterile areas of the syringe barrel each time the vacuum was pulled.
- In the syringes containing no gas bubble, however, the stopper was not seen rising at all.
- The size of the bubble inside the syringe made a difference in the amount of stopper movement. The syringes filled with a 2.5-mm bubble experienced less movement than the syringes filled with a 5.0-mm bubble. When the vacuum was released and the pressure returned to original levels, the stoppers in the syringes containing a bubble returned to their original position with no indication that they had moved.

Due to the difficulty of controlling for all of the variables that affect stopper movement in a prefilled syringe, a series of equations were devised to show, on a theoretical level, the relationship between the size of the gas bubble and stopper movement. Using Boyle's Law, the amount of expansion or contraction a gas bubble inside a prefilled syringe undergoes due to changes in pressure, and the amount of stopper movement that occurs as a result of that expansion and contraction was

Gas Bubble Size	H _{sb} = 6.2 mm Approximate Elevation (1,000's ft)	H _{sb} = 4.3 mm Approximate Elevation (1,000's ft)
0.5 mm	21	19
1.0 mm	16	14
2.5 mm	13	7
5.0 mm	7	<5

Approximate elevation (in feet above sea level) at which a stopper will have moved 1/5 H_{sb}.

calculated.


Plugging these calculations into a hypothetical situation in which a syringe is shipped multiple times from the manufacturer to the end-user, a rational approach was developed for determining the maximum allowable size of a gas bubble inside a prefilled syringe. Among the factors taken into account were stopper height, the elevations to which a syringe will likely be exposed and the consequent changes in pressure which it will undergo, as well as the number of times a syringe will be subjected to reduced atmospheric pressure.


STERILE BARRIER HEIGHT: H_{SB}

In a prefilled syringe, a sterile barrier is created in which the stopper is in intimate contact with the glass barrel of

the syringe, as shown in Figure 2. The sterile barrier height, or H_{sb}, spans the entire distance from the uppermost to the lowermost point of stopper contact and represents the limit of upward stopper movement, which the stopper can undergo before product sterility is potentially compromised.

A gas bubble sealed inside a prefilled syringe acts like a spring, expanding and contracting with changes in temperature or external ambient pressure. If the external ambient temperature increases or pressure decreases, the gas bubble expands, pushing the stopper up until the pressure in the syringe is equivalent to the external pressure. When the external ambient pressure and/or temperature return to their original levels, the gas bubble in the syringe contracts until the pressure in the syringe is equal to the external pressure. This causes the stopper to return to its





original position, leaving no visible evidence that the stopper has moved (Figure 3).²

If the stopper in a syringe moves more than the distance of H_{sb} , it can pull microorganisms or contaminants from the non-sterile portion of the syringe into the drug product, potentially causing a sterility failure. This same phenomenon could occur when a stopper moves less than the distance of H_{sb} if it moves multiple times and the sum of all stopper movements exceeds H_{sb} , as demonstrated in Figure 4.

PRESSURE & THE VOLUME OF A GAS BUBBLE

The amount of change in the volume of a gas bubble is relatively small over the reasonable temperatures to which a syringe might be exposed (total range of approximately 40°C); however, the volume change due to pressure changes alone can be significant, as demonstrated in the calculations that appear further on.

Assuming that temperature remains constant, the amount of expansion or contraction a gas bubble inside a prefilled

syringe undergoes due to pressure changes can be calculated using Boyle's Law (Equation 1).

Equation 1.

$$P_1V_1 = P_2V_2$$

Where P_1 = pressure condition 1, V_1 = volume condition 1, P_2 = pressure condition 2, and V_2 = volume condition 2. The volume (V) of a cylinder, such as a syringe, is given by Equation 2.

Equation 2.

$$V = \pi r^2 h$$

Where r = internal radius of the syringe barrel, and h = height of the gas bubble/air gap (assuming the bubble spans the entire diameter of the syringe). If Equation 2 is substituted for V in Equation 1, and both sides are divided by πr^2 , the result is as Equation 3.

Equation 3.

$$P_1h_1 = P_2h_2$$

Where P_1 = pressure condition 1, h_1 = height condition 1, P_2 = pressure condition 2, and h_2 = height condition 2. Thus in Equation 4, the theoretical height of the gas space in the syringe at a given external pressure can be determined based on the initial conditions (condition 1).²

Equation 4.

$$h_2 = P_1h_1/P_2$$

The percentage of total stopper movement beyond the initial sterility barrier (H_{sb}) can be calculated by subtracting the initial height (H_1) from the height calculated in Equation 4 (H_2) and dividing the result by H_{sb} , as shown in Equation 5.

Equation 5.

$$\text{Percent } H_{sb} = 100 * (H_2 - H_1) / H_{sb}$$

Figures 5b and 5c show the percentage of H_{sb} that a stopper will move in syringes with an H_{sb} of 6.2 and 4.3 mm, respectively, and initial bubble sizes ranging from 0.5 mm to 5 mm, the most common size range for a bubble. The points on the x axis in Figures 5b and 5c represent feet of elevation rather than absolute pressure to demonstrate the effect that reduced pressure (due to changes in elevation) will have on a syringe. These points were determined using a conversion of 1 inch Hg vacuum equal to 1000 feet of elevation (Figure 5a).

The y axis in Figures 5b and 5c represents the percentage of H_{sb} , which the stopper in a syringe will move, while the red line at 100% shows the point at which the stopper will enter a non-sterile area of the syringe, potentially compromising product sterility.

In the example in Figure 5b, in which H_{sb} is 6.2 mm and the initial bubble size is 2.5 mm, the stopper travels in excess of one stopper height in a single exposure to an elevation of approximately 23,000 feet. When the initial bubble is 5.0 mm, the stopper travels in excess of one stopper height in a single exposure to an elevation of approximately 20,000 feet.²

Because the cargo hold of an airplane is generally maintained at a pressure equal to 8,000 feet of elevation, and ground elevations during shipment do not often exceed 10,000 feet, a stopper is not likely to move more than H_{sb} in a single exposure. However, during shipment, a syringe could possibly be exposed to reduced pressure on several occasions which, taken together, increases the potential for total stopper movement to exceed H_{sb} .

Consider, for example, a syringe that is shipped from a CMO's manufacturing site to the sponsor company's facility to a distribution center and finally to the end-user's site, for a total of three shipments. It is possible that one or more legs of the product's journey could involve more than one flight, creating additional opportunities for the stopper to rise and fall. Under those conditions, it is conceivable that a syringe could be exposed to changes in pressure on five occasions, resulting in five up and down stopper movements. In that case, a stopper would only need to rise $1/5 H_{sb}$ each time to potentially pull non-sterile material, such as silicon, or other contaminants into the product causing a sterility failure.


Table 1 shows the approximate elevations at which the stopper would exceed $1/5$ of H_{sb} given several different sized bubbles. To prevent stopper movement as a result of changes in ambient pressure, syringes should ideally be filled without any gas bubbles. However, in practice, most syringe filling equipment does not have the capability to remove all of the gas in a syringe. When that is the case, the maximum acceptable size of a gas bubble for a given stopper in a prefilled syringe should be determined.

This can be done by factoring in the differential pressure changes to which a syringe will likely be exposed, the number of times it will be subjected to reduced pressure, and the height of the sterile barrier.

DETERMINING THE MAXIMUM SIZE OF A GAS BUBBLE

Using the aforementioned equations, the size of the bubble that will lead to a movement of the stopper equal to $1/5$ of H_{sb} can be calculated at a number of different elevations. For example, Figure 6 shows the results of calculations performed using elevations of 8,000 and 12,000 feet with a range of H_{sb} from 1 to 15 mm. In situations where H_{sb} is 4.0 and elevation is 8,000 feet, the maximum acceptable size of the gas bubble is approximately 2.0 mm. When the elevation reaches 12,000 feet, however, the maximum acceptable size of the gas bubble decreases to approximately 1.6

mm.² The aforementioned analysis is a worst-case scenario and does not take into account frictional forces and break loose forces. Frictional forces caused by the stopper rubbing against the syringe, and the break loose force, which is required to start the stopper moving, should reduce stopper movement. Break loose forces, which increase over the life of the syringe, would improve resistance to stopper movement the longer the product was in transit, requiring greater force to initiate the movement of the stopper. However, it is not unreasonable to assume that a newly filled prefilled glass syringe with silicon has very little break loose force. In fact, we have confirmed in our laboratories that standard, commercially available glass syringes and elastomeric stoppers with silicon show actual stopper movement that is approximately 75% of that which has been theoretically calculated in this article. We did not perform an extensive study of all factors that could affect glide and breakloose forces; therefore, we have used theoretical calculations to demonstrate



several worst-case scenarios for stopper movement.

The aforementioned analysis is also based on the assumption that pressures are controlled at consistent levels throughout shipment when, in fact, the actual magnitude of reduced/increased pressure to which syringes are exposed is generally not known. Cargo is shipped by a variety of carriers, many of whom may not consistently control, measure, or report changes in pressure. Atmospheric pressure in a cargo hold could rise and fall during flight, and the drug

manufacturer would not be aware of it upon inspection at the final destination.


There are alternative means to prevent contamination due to stopper movement other than reducing the size of the gas bubble or increasing H_{sb} . For example, the stopper can be locked in place with a device placed inside the barrel, or the entire syringe can be sealed inside a sterile container (protecting the sterility of the barrel above the stopper), or the syringe can be placed in a holder that secures the plunger rod in place. However, each of these approaches adds cost and requires additional packaging and does not provide the added benefits of a bubble-free syringe.

FIGURE 5A

Elevation	" Hg Vac.	psi	torr
0	0	14.7	760
8,000	8"	10.7	555
10,000	10"	9.8	506
12,000	12"	8.9	455
15,000	15"	7.3	379
18,000	18"	5.9	302
25,000	25"	2.4	125
27,000	27"	1.4	74


Conversion of 1-inch Hg vacuum equal to 1000 feet of elevation.

FIGURE 5B



Percentage of H_{sb} that the stopper will move as a function of elevation and initial bubble size when H_{sb} is 6.2 mm.

FIGURE 5C



Percentage of H_{sb} that the stopper will move as a function of elevation and initial bubble size when H_{sb} is 4.3 mm.

ELIMINATING PRODUCT LOSS

One added benefit of a bubble-free syringe is the reduction in the amount of product inadvertently lost during use. In a side-by-side analysis, 15 syringes were filled with gas bubbles of varying sizes, while 15 syringes were filled with no bubble. As the tip caps on each set of syringes were removed, the needles were watched for any sign of dripping or product leaks. In the set that were filled with a bubble, product was observed leaking from needle over 75% of the time when the tip cap was removed. Conversely, in the needles that were bubble-free, no product was seen leaking from the needle any time the tip caps were removed (Figure 7).²

This is because in a bubble-free syringe, there is no expansion and contraction of the bubble as a result of the small vacuum that is created when the tip cap is removed. Without a drip, there is added assurance that the end-user will receive the entire deliverable dose. There is also less risk that the administrator or end-user will be exposed to cytotoxic or potent compounds, as well as a reduction in product wasted.

CONCLUSION

Although, on the surface, syringes may appear very similar to vials, the freedom of stopper movement in a prefilled syringe, coupled with a gas bubble, will result in challenges to package integrity and product sterility when the syringe is exposed to changes in atmospheric pressure. A gas bubble is not intrinsic to a syringe but is the result of a sub-optimal filling process and therefore, can be reduced or eliminated using alternative filling methods.

Manufacturers go to great lengths to monitor and control the temperature to which products are exposed during shipping. Yet the same attention has not been paid to changes in differential pressures to which a product is exposed. Given that a number of today's parenteral products are shipped several times before reaching the end-user, undergoing several changes in atmospheric pressure and several potential

movements of the stopper, such attention is warranted. Just as exposure to elevated temperatures may impact the shelf-life and efficacy of products, exposure to reduced pressure may potentially impact the sterility and safety of an injectable product in a prefilled syringe if one is not aware of the importance of reduced bubble size and stopper design.

In this discussion, we have proposed one way to determine the maximum acceptable size of a gas bubble that can be left inside a syringe based on stopper height as well as other variables. There are alternative ways to protect prefilled syringes from contamination due to stopper movement, but these require additional packaging and do not offer the added benefits of a bubble-free syringe, such as enhanced dosing accuracy and safety as well as reduced waste due to the elimination of a product drip at the needle when the tip cap is removed.³

As prefilled syringes continue to find favor as an alternative to vials for many of


today's parenteral products, reduced gas bubble filling should likewise become increasingly popular as an alternative to traditional filling methods and may one day become the industry standard.

REFERENCES

1. Harrison B, Rios M. Big shot: developments in prefilled syringes. *Pharm Technol.* 2007;31(3):50-56.
2. Kinney SD. Considerations on the size of the gas bubble in a prefilled syringe. Paper presented at the PDA Universe of the Prefilled Syringe Show in Berlin, Germany, November 27-28, 2007.
3. Kinney SD. Innovative Solutions Seminar. New Brunswick, NJ, October 30, 2007.

FIGURE 6

**Allowable Gas Bubble Size vs. Hsb
5 Exposures to Increased Elevation**



The data demonstrates that smaller gas bubbles and stoppers with larger Hsb reduce the risk of stopper movement exceeding 1/5 Hsb.

FIGURE 7



Gas bubbles in traditionally filled syringes, like the syringe on the bottom in this photo, can cause product to drip from the needle when the needle sheath or tip cap is removed. In a bubble-free syringe, like the one pictured on the top, there is no drip, decreasing waste and improving dosing accuracy and safety.

BIOGRAPHIES

Dr. Shawn D. Kinney, President of Hyaluron Contract Manufacturing (HCM), founded HCM in 1999 to provide aseptic manufacturing and filling services to the pharmaceutical, biotech, and medical device industries. Dr. Kinney earned his PhD in Chemistry from the University of Massachusetts at Amherst, a Masters in Medicinal Chemistry from Northeastern University, and a BS in Chemistry from the University of Massachusetts at North Dartmouth. Dr. Kinney has worked at Anika Therapeutics, Wyeth-Ayerst, and Millipore and has more than 20 years of experience in the pharmaceutical industry. He has extensive experience in the development of sterile formulation and filling processes, including viscous and difficult-to-fill products. Prior to founding HCM, he was responsible for the sterile formulation and filling of hyaluronate into prefilled syringes in his role as VP of Operations at Anika Therapeutics. Recently, Dr. Kinney has pioneered a new technology in online vacuum filling and stoppering (Bubble-Free Filling®) and has been granted a patent. He continues to oversee HCM's expansion and leadership in the aseptic contract manufacturing industry. He can be reached at shawn@hyaluron.com or (781) 270-7900, ext. 218.

Dr. Andrea Wagner is the Vice President of Business Development at HCM, a position she has held for 7 years. Prior to joining HCM, she was employed by the New Jersey Institute of Technology in the capacity of Senior Scientist in a national training program. Simultaneously, she worked as a Manager at Thermo Fisher Scientific as a Manager in business development of pharmaceutical applications for their XRF Analyzers. After earning her PhD in Toxicology, she managed a center devoted to innovative testing technologies in the Chemistry Department at Tufts University in Massachusetts. Dr. Wagner also earned her a MS in Analytical Chemistry and her BS in Chemistry. She can be reached at andrea@hyaluron.com or (781) 270-7900, ext. 106.

Christian W. Phillips is the Director of Process Engineering, at HCM. Mr. Phillips has 14 years of experience in R&D, Process Development, Tech Transfer, and Manufacturing environments suited for the introduction of novel biotherapeutics and generics, including fill/finish applications. Prior to HCM, Mr. Phillips was employed by Transkaryotic Therapies (now Shire HGS). Mr. Phillips earned his a BS in Biology from St. Michael's College and is the co-inventor with Shawn Kinney of HCM's Bubble-Free Filling® technology. He can be reached at cphillips@hyaluron.com or (781) 270-7900, ext. 181.

ATTACHMENT B-3

Drug Delivery[®] Technology

February 2009 Vol 9 No 2

www.drugdeliverytech.com

Delivering Therapeutic siRNA

IN THIS ISSUE



INTERVIEW WITH
PRO-PHARMACEUTICALS'
CHIEF EXECUTIVE OFFICER

DAVID PLATT

**Diabetes
Management** 30
Daniel Ruppap

**Prefilled Syringe
Gas Bubbles** 42
Shawn Kinney, PhD

**Nanoparticles &
Cancer** 48
Maulik A. Acharya

**Particle Size
Optimization** 53
Thomai Panagiotou, PhD

FEATURING

SPECIALTY 
Strategies for Business Development
PHARMA

**Central Lab
Strategies** 64
Cindy H. Dubin

**Surveying
Big Pharma** 70
Josef Bossart, PhD

The science & business of drug development in specialty pharma, biotechnology, and drug delivery



**Madhu
Hariharan,
PhD**

Orally Dissolving Film
Strips: The Final
Evolution of Orally
Dissolving Dosage
Forms



**Frank Y. Xie,
PhD**

Systemic Delivery of
Therapeutic siRNA:
Opportunities &
Challenges



**Maria J.
Gutierrez, MD**

A Spring-Powered
Device for
Subcutaneous,
Intramuscular &
Intradermal Injections
Using an Auto-Disable
Syringe

Regeneron Exhibit 1103.115
Regeneron v. Novartis
IPR2021-00816



We specialize in providing formulations with technologies that enable you to customize your pharmaceutical product. Our suite of technologies allows you to optimize your active's performance and enhance patient compliance.

These technologies include:

- **ApiSol™** – Bioavailability enhancement technology.
- **ApiCap™** – Capsule delivery platform which offers a wide range of release profiles suitable for both poorly and well absorbed APIs, as well as combination products.
- **ApiTab™** – A tablet delivery platform offering a wide range of release profiles including immediate, delayed, targeted, pulsed, sustained release or combinations thereof.
- **ApiMelt™** – Rapid oral dissolving tablet technology.
- **ApiMask™** – Taste masking technology that effectively masks the bitter taste of oral products.



Contact us to see how we can assist you with your product development needs!

954-241-4340 • www.azopdogroup.com/DDT • development@apicross.com

Drug Delivery Technology **FREE** **SUBSCRIPTION** **OFFER**

Keep abreast of the marketplace with the industry's only publication entirely devoted to drug delivery and development.

Go to www.drugdeliverytech.com and click on Subscription Services

Once on the website you can also subscribe to our eNewsletter!

For more information contact Ralph Vitaro at 973-299-1200 or e-mail him at rvitaro@drugdeliverytech.com

Drug Delivery Technology

February 2009 Vol 9 No 2

PUBLISHER/PRESIDENT
Ralph Vitaro

EXECUTIVE EDITORIAL DIRECTOR
Dan Marino, MSc
dmarino@drugdeliverytech.com

CREATIVE DIRECTOR
Shalamar Q. Eigel

CONTROLLER
Debbie Carrillo

CONTRIBUTING EDITORS
Cindy H. Dubin
Debra Bingham
Jason McKinnie

TECHNICAL OPERATIONS
Mark Newland

EDITORIAL SUPPORT
Nicholas D. Vitaro

ADMINISTRATIVE SUPPORT
Kathleen Kenny

Corporate/Editorial Office
219 Changebridge Road, Montville, NJ 07045
Tel: (973) 299-1200
Fax: (973) 299-7937
www.drugdeliverytech.com

Advertising Sales Offices

East & Midwest

Victoria Geis - Account Executive
Cheryl S. Stratos - Account Executive
103 Oranoco Street, Suite 200
Alexandria, VA 22314
Tel: (703) 212-7735
Fax: (703) 548-3733
E-mail: vgeis@drugdeliverytech.com
E-mail: cstratos@drugdeliverytech.com

West Coast

Warren De Graff
Western Regional Manager
818 5th Avenue, Suite 301
San Rafael, CA 94901
Tel: (415) 721-0644
Fax: (415) 721-0665
E-mail: wjdegtraff@drugdeliverytech.com

International

Ralph Vitaro
219 Changebridge Road
Montville, NJ 07045
Tel: (973) 299-1200
Fax: (973) 299-7937
E-mail: rvitaro@drugdeliverytech.com

Mailing List Rental

Candy Brecht
Tel: (703) 706-0383
Fax: (703) 549-6057
E-mail: cbrecht@mgilists.com

All editorial submissions are handled with reasonable care, but the publishers assume no responsibility for the safety of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but publishers cannot accept responsibility for the accuracy of information supplied herein or for any opinion expressed. Drug Delivery Technology (ISSN 1944-812X) is published 10 times in 2009, January, February, March, April, May, June, July/August, September, October, and November/December by Drug Delivery Technology LLC, 219 Changebridge Road, Montville NJ 07045. Subscription rates: \$99.00 for 1 year in the United States, Canada, and Mexico; \$153.00 for 1 year outside the United States, Canada, and Mexico. All subscriptions are payable in US funds, drawn on US banks. Send payment to: Drug Delivery Technology LLC Subscription Department, 219 Changebridge Road, Montville NJ 07045. Single copies (prepaid) \$15.00, US, Canada, and Mexico; \$24.00 in all other countries. Add \$5.00 per order for shipping and handling. Periodicals Postage Paid at Montville, NJ 07045-9998 and additional mailing offices. Postmaster: please send address changes to Drug Delivery Technology, 219 Changebridge Road, Montville NJ 07045. All rights reserved under the US International and Pan-American Copyright Conventions. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including by photocopy, recording or information storage and retrieval system, without written permission from the publisher. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Drug Delivery Technology LLC for libraries and other users registered with the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923; phone: (978) 750-8400, fax: (978) 750-4470.

Regeneron Exhibit 1103.116
Regeneron v. Novartis
IPR2021-00816

Therapeutic siRNA



FEB 2009

“Compared to the local siRNA deliveries that were used in many early siRNA clinical trials, systemic siRNA delivery faces more challenges and hurdles that have slowed down the expansion of siRNA therapeutics. With increasing efforts dedicated to the development of more efficient systemic siRNA delivery technologies, it is conceivable the key delivery hurdles could be overcome and the potential of RNAi-based therapeutics may be realized in a not too distant future.”




Table Of Contents

- 24** *Orally Dissolving Film Strips (ODFS): The Final Evolution of Orally Dissolving Dosage Forms*
Madhu Hariharan, PhD, and B. Artie Bogue, PhD, focus their discussion mainly on films for oral delivery of drug to the GI tract as well as address other prospective manifestations of this dosage form.
- 30** *Continued Drug Delivery Opportunities in Diabetes Management*
Frost & Sullivan Analyst Daniel Ruppar asks the question of whether there is still an opportunity for an inhaled diabetes drug.
- 32** *Systemic Delivery of Therapeutic siRNA: Opportunities & Challenges*
Frank Y. Xie, PhD; Qing Zhou, PhD; Ying Liu, MS; Samuel Zalipsky, PhD; and Xiaodong Yang, MD, PhD; provides an overview of the critical steps in the development of siRNA therapeutics, from the selection of siRNA specific for the target of interest to the development of novel formulations for efficient in vivo systemic delivery of siRNA therapeutics.
- 38** *Speeding Drugs With Non-Traditional Delivery Mechanisms to Market*
Robert R. Andrews, MS, MBA, and Russell L. Newton, MS, provide guidance on how to overcome the most commonly encountered issues in developing non-traditionally delivered drugs.
- 42** *A Rational Approach to Determining the Maximum Allowable Gas Bubble Inside a Prefilled Syringe to Minimize Stopper Movement & Protect Product Sterility*
Shawn Kinney, PhD; Andrea Wagner, PhD; and Christian W. Phillips make the case that reducing or eliminating the bubble inside a prefilled syringe is a preferred means for ensuring product sterility while enhancing the benefits of a prefilled syringe.
- 48** *Nanoparticles in Cancer Research: A Novel Drug Delivery & Pharmacological Approach*
Priyal Patel, Maulik A. Acharya, and Jayvadan Patel, PhD, provide a balanced update on exciting pharmacological and potentially toxicological developments of nanoparticles in cancer research.

Central Lab Strategies

"The best trial plans will fail if they cannot enroll patients. Through feasibility, we help clients select the inclusion and exclusion criteria, model enrollment, incorporate feedback from investigators, consultants, epidemiologists, and analyze prescription and insurance data. The triangulation of this data gives us information to improve country selection, site identification, and enrollment forecasts, as well as identify back-up strategies and alternative plans, tailored to the client's needs."

p.64

Table Of Contents

- 53 ***Achieving Optimal Particle Size Distribution in Inhalation Therapy***
Thomai (Mimi) Panagiotou, PhD, addresses many of the concerns medical device manufacturers and their pharmaceutical partners have when attempting to achieve the correct particle size for an inhalation device.
- 61 ***The Untapped Potential of Carbohydrates in Drug Discovery & Development***
Executive Summary: David Platt, CEO of Pro-Pharmaceuticals, says carbohydrate molecules have been shown to play an important role in major diseases, including cancer, cardiovascular disease, Alzheimer's disease, inflammatory disease, and viral infections.
- 64 ***How Your Central Lab Can Keep Clinical Trials Flexible & Cost Effective***
Contributor Cindy H. Dubin poses questions to central lab executives about how improved forecasting methods and alternative foreign locations could result in better data generated during clinical trials.
- 70 ***Drug Delivery Prospects for the Next Decade: An Informal Survey of Big Pharma***
Josef Bossart, PhD, conducted an informal survey with Big Pharma personnel to get their sense of how drug delivery fits into their plans now and for the next decade.

DEPARTMENTS

Market News & Trends	12
Advanced Delivery Devices	18
A Spring-Powered Device for Subcutaneous, Intramuscular & Intradermal Injections Using an Auto-Disable Syringe	
Technology Showcase	58
External Delivery	74
But Mom & Dad... You Promised	

PREFILLED SYRINGES

A Rational Approach to Determining the Maximum Allowable Gas Bubble Inside a Prefilled Syringe to Minimize Stopper Movement & Protect Product Sterility

By: Shawn Kinney, PhD; Andrea Wagner, PhD; and Christian W. Phillips

ABSTRACT


Prefilled syringes are a fast-growing alternative to vials in the parenteral product market due to the many advantages they offer relative to vials. These include reduced overfill requirements, ease of use, more accurate dosing, decreased waste, and enhanced product differentiation.

Conventional syringe-filling processes typically leave a large air bubble in a syringe that can negatively impact product sterility and package integrity. Using a series of equations and hypothetical scenarios, this article will demonstrate the potential impact of a bubble on stopper movement during periods of reduced atmospheric pressure. It will also propose a rational approach for determining the maximum allowable size of a gas bubble inside a prefilled syringe taking into account several critical factors. After weighing some of the alternatives for limiting stopper movement during shipping as well as one additional benefit of bubble-free filling, this article will make the case that reducing or eliminating the bubble inside a prefilled syringe is a preferred means for ensuring product sterility while enhancing the benefits of a prefilled syringe.

INTRODUCTION

The internal environments of a glass vial and a glass syringe have a number of features in common, as shown in Figure 1. Both presentations are essentially glass cylinders that are sealed by an elastomeric closure, or stopper, and both contain a gaseous headspace, or bubble. However, there is one noteworthy difference. A vial's stopper is held in place by a crimp, while a syringe's stopper is designed

to move in order to allow injection of the drug product. This freedom of movement, when coupled with a gas bubble (which is not intrinsic to a syringe but is a byproduct of sub-optimal filling processes) can potentially cause significant challenges with regard to package integrity and product sterility, particularly when the syringe is exposed to repeated changes in atmospheric pressure, such as during shipping. Reducing or eliminating the



This material may be protected by Copyright law (Title 17 U.S. Code)

bubble inside the syringe would limit stopper movement, potentially enhancing sterility assurance of the product.¹

In a preliminary study of the impact of a bubble on stopper movement in a prefilled syringe, three syringes were placed inside a Hypak vacuum chamber. One syringe contained a 2.5-mm bubble, one a 5.0-mm bubble, and yet another contained no bubble at all. Next, a vacuum was pulled at 8 inches of mercury and then again at 15 inches while the syringes were closely monitored for signs of stopper movement. The procedure was then repeated five more times, with a new set of syringes each time, to substantiate the initial findings, which included the following:

- In the syringes containing a bubble, the stopper was seen rising into non-sterile areas of the syringe barrel each time the vacuum was pulled.
- In the syringes containing no gas bubble, however, the stopper was not seen rising at all.
- The size of the bubble inside the syringe made a difference in the amount of stopper movement. The syringes filled with a 2.5-mm bubble experienced less movement than the syringes filled with a 5.0-mm bubble. When the vacuum was released and the pressure returned to original levels, the stoppers in the syringes containing a bubble returned to their original position with no indication that they had moved.

Due to the difficulty of controlling for all of the variables that affect stopper movement in a prefilled syringe, a series of equations were devised to show, on a theoretical level, the relationship between the size of the gas bubble and stopper movement. Using Boyle's Law, the amount of expansion or contraction a gas bubble inside a prefilled syringe undergoes due to changes in pressure, and the amount of stopper movement that occurs as a result of that expansion and contraction was

TABLE 1

Gas Bubble Size	H _{sb} = 6.2 mm Approximate Elevation (1,000s ft)	H _{sb} = 4.3 mm Approximate Elevation (1,000's ft)
0.5 mm	21	19
1.0 mm	16	14
2.5 mm	13	7
5.0 mm	7	<5

Approximate elevation (in feet above sea level) at which a stopper will have moved 1/5 H_{sb}.

calculated.


Plugging these calculations into a hypothetical situation in which a syringe is shipped multiple times from the manufacturer to the end-user, a rational approach was developed for determining the maximum allowable size of a gas bubble inside a prefilled syringe. Among the factors taken into account were stopper height, the elevations to which a syringe will likely be exposed and the consequent changes in pressure which it will undergo, as well as the number of times a syringe will be subjected to reduced atmospheric pressure.


STERILE BARRIER HEIGHT: H_{SB}

In a prefilled syringe, a sterile barrier is created in which the stopper is in intimate contact with the glass barrel of

the syringe, as shown in Figure 2. The sterile barrier height, or H_{sb}, spans the entire distance from the uppermost to the lowermost point of stopper contact and represents the limit of upward stopper movement, which the stopper can undergo before product sterility is potentially compromised.

A gas bubble sealed inside a prefilled syringe acts like a spring, expanding and contracting with changes in temperature or external ambient pressure. If the external ambient temperature increases or pressure decreases, the gas bubble expands, pushing the stopper up until the pressure in the syringe is equivalent to the external pressure. When the external ambient pressure and/or temperature return to their original levels, the gas bubble in the syringe contracts until the pressure in the syringe is equal to the external pressure. This causes the stopper to return to its





original position, leaving no visible evidence that the stopper has moved (Figure 3).²

If the stopper in a syringe moves more than the distance of H_{sb} , it can pull microorganisms or contaminants from the non-sterile portion of the syringe into the drug product, potentially causing a sterility failure. This same phenomenon could occur when a stopper moves less than the distance of H_{sb} if it moves multiple times and the sum of all stopper movements exceeds H_{sb} , as demonstrated in Figure 4.

PRESSURE & THE VOLUME OF A GAS BUBBLE

The amount of change in the volume of a gas bubble is relatively small over the reasonable temperatures to which a syringe might be exposed (total range of approximately 40°C); however, the volume change due to pressure changes alone can be significant, as demonstrated in the calculations that appear further on.

Assuming that temperature remains constant, the amount of expansion or contraction a gas bubble inside a prefilled

syringe undergoes due to pressure changes can be calculated using Boyle's Law (Equation 1).

Equation 1.

$$P_1V_1 = P_2V_2$$

Where P_1 = pressure condition 1, V_1 = volume condition 1, P_2 = pressure condition 2, and V_2 = volume condition 2. The volume (V) of a cylinder, such as a syringe, is given by Equation 2.

Equation 2.

$$V = \pi r^2 h$$

Where r = internal radius of the syringe barrel, and h = height of the gas bubble/air gap (assuming the bubble spans the entire diameter of the syringe). If Equation 2 is substituted for V in Equation 1, and both sides are divided by πr^2 , the result is as Equation 3.

Equation 3.

$$P_1h_1 = P_2h_2$$

Where P_1 = pressure condition 1, h_1 = height condition 1, P_2 = pressure condition 2, and h_2 = height condition 2. Thus in Equation 4, the theoretical height of the gas space in the syringe at a given external pressure can be determined based on the initial conditions (condition 1).²

Equation 4.

$$h_2 = P_1h_1/P_2$$

The percentage of total stopper movement beyond the initial sterility barrier (H_{sb}) can be calculated by subtracting the initial height (H_1) from the height calculated in Equation 4 (H_2) and dividing the result by H_{sb} , as shown in Equation 5.

Equation 5.

$$\text{Percent } H_{sb} = 100 * (H_2 - H_1) / H_{sb}$$

Figures 5b and 5c show the percentage of H_{sb} that a stopper will move in syringes with an H_{sb} of 6.2 and 4.3 mm, respectively, and initial bubble sizes ranging from 0.5 mm to 5 mm, the most common size range for a bubble. The points on the x axis in Figures 5b and 5c represent feet of elevation rather than absolute pressure to demonstrate the effect that reduced pressure (due to changes in elevation) will have on a syringe. These points were determined using a conversion of 1 inch Hg vacuum equal to 1000 feet of elevation (Figure 5a).

The y axis in Figures 5b and 5c represents the percentage of H_{sb} which the stopper in a syringe will move, while the red line at 100% shows the point at which the stopper will enter a non-sterile area of the syringe, potentially compromising product sterility.

In the example in Figure 5b, in which H_{sb} is 6.2 mm and the initial bubble size is 2.5 mm, the stopper travels in excess of one stopper height in a single exposure to an elevation of approximately 23,000 feet. When the initial bubble is 5.0 mm, the stopper travels in excess of one stopper height in a single exposure to an elevation of approximately 20,000 feet.²

Because the cargo hold of an airplane is generally maintained at a pressure equal to 8,000 feet of elevation, and ground elevations during shipment do not often exceed 10,000 feet, a stopper is not likely to move more than H_{sb} in a single exposure. However, during shipment, a syringe could possibly be exposed to reduced pressure on several occasions which, taken together, increases the potential for total stopper movement to exceed H_{sb} .

Consider, for example, a syringe that is shipped from a CMO's manufacturing site to the sponsor company's facility to a distribution center and finally to the end-user's site, for a total of three shipments. It is possible that one or more legs of the product's journey could involve more than one flight, creating additional opportunities for the stopper to rise and fall. Under those conditions, it is conceivable that a syringe could be exposed to changes in pressure on five occasions, resulting in five up and down stopper movements. In that case, a stopper would only need to rise $1/5 H_{sb}$ each time to potentially pull non-sterile material, such as silicon, or other contaminants into the product causing a sterility failure.


Table 1 shows the approximate elevations at which the stopper would exceed $1/5$ of H_{sb} given several different sized bubbles. To prevent stopper movement as a result of changes in ambient pressure, syringes should ideally be filled without any gas bubbles. However, in practice, most syringe filling equipment does not have the capability to remove all of the gas in a syringe. When that is the case, the maximum acceptable size of a gas bubble for a given stopper in a prefilled syringe should be determined.

This can be done by factoring in the differential pressure changes to which a syringe will likely be exposed, the number of times it will be subjected to reduced pressure, and the height of the sterile barrier.

DETERMINING THE MAXIMUM SIZE OF A GAS BUBBLE

Using the aforementioned equations, the size of the bubble that will lead to a movement of the stopper equal to $1/5$ of H_{sb} can be calculated at a number of different elevations. For example, Figure 6 shows the results of calculations performed using elevations of 8,000 and 12,000 feet with a range of H_{sb} from 1 to 15 mm. In situations where H_{sb} is 4.0 and elevation is 8,000 feet, the maximum acceptable size of the gas bubble is approximately 2.0 mm. When the elevation reaches 12,000 feet, however, the maximum acceptable size of the gas bubble decreases to approximately 1.6

mm.² The aforementioned analysis is a worst-case scenario and does not take into account frictional forces and break loose forces. Frictional forces caused by the stopper rubbing against the syringe, and the break loose force, which is required to start the stopper moving, should reduce stopper movement. Break loose forces, which increase over the life of the syringe, would improve resistance to stopper movement the longer the product was in transit, requiring greater force to initiate the movement of the stopper. However, it is not unreasonable to assume that a newly filled prefilled glass syringe with silicon has very little break loose force. In fact, we have confirmed in our laboratories that standard, commercially available glass syringes and elastomeric stoppers with silicon show actual stopper movement that is approximately 75% of that which has been theoretically calculated in this article. We did not perform an extensive study of all factors that could affect glide and breakloose forces; therefore, we have used theoretical calculations to demonstrate



several worst-case scenarios for stopper movement.

The aforementioned analysis is also based on the assumption that pressures are controlled at consistent levels throughout shipment when, in fact, the actual magnitude of reduced/increased pressure to which syringes are exposed is generally not known. Cargo is shipped by a variety of carriers, many of whom may not consistently control, measure, or report changes in pressure. Atmospheric pressure in a cargo hold could rise and fall during flight, and the drug

manufacturer would not be aware of it upon inspection at the final destination.


There are alternative means to prevent contamination due to stopper movement other than reducing the size of the gas bubble or increasing H_{sb} . For example, the stopper can be locked in place with a device placed inside the barrel, or the entire syringe can be sealed inside a sterile container (protecting the sterility of the barrel above the stopper), or the syringe can be placed in a holder that secures the plunger rod in place. However, each of these approaches adds cost and requires additional packaging and does not provide the added benefits of a bubble-free syringe.

FIGURE 5A

Elevation	" Hg Vac.	psi	torr
0	0	14.7	760
8,000	8"	10.7	555
10,000	10"	9.8	506
12,000	12"	8.9	455
15,000	15"	7.3	379
18,000	18"	5.9	302
25,000	25"	2.4	125
27,000	27"	1.4	74


Conversion of 1-inch Hg vacuum equal to 1000 feet of elevation.

FIGURE 5B



Percentage of H_{sb} that the stopper will move as a function of elevation and initial bubble size when H_{sb} is 6.2 mm.

FIGURE 5C



Percentage of H_{sb} that the stopper will move as a function of elevation and initial bubble size when H_{sb} is 4.3 mm.

ELIMINATING PRODUCT LOSS

One added benefit of a bubble-free syringe is the reduction in the amount of product inadvertently lost during use. In a side-by-side analysis, 15 syringes were filled with gas bubbles of varying sizes, while 15 syringes were filled with no bubble. As the tip caps on each set of syringes were removed, the needles were watched for any sign of dripping or product leaks. In the set that were filled with a bubble, product was observed leaking from needle over 75% of the time when the tip cap was removed. Conversely, in the needles that were bubble-free, no product was seen leaking from the needle any time the tip caps were removed (Figure 7).²

This is because in a bubble-free syringe, there is no expansion and contraction of the bubble as a result of the small vacuum that is created when the tip cap is removed. Without a drip, there is added assurance that the end-user will receive the entire deliverable dose. There is also less risk that the administrator or end-user will be exposed to cytotoxic or potent compounds, as well as a reduction in product wasted.

CONCLUSION

Although, on the surface, syringes may appear very similar to vials, the freedom of stopper movement in a prefilled syringe, coupled with a gas bubble, will result in challenges to package integrity and product sterility when the syringe is exposed to changes in atmospheric pressure. A gas bubble is not intrinsic to a syringe but is the result of a sub-optimal filling process and therefore, can be reduced or eliminated using alternative filling methods.

Manufacturers go to great lengths to monitor and control the temperature to which products are exposed during shipping. Yet the same attention has not been paid to changes in differential pressures to which a product is exposed. Given that a number of today's parenteral products are shipped several times before reaching the end-user, undergoing several changes in atmospheric pressure and several potential

movements of the stopper, such attention is warranted. Just as exposure to elevated temperatures may impact the shelf-life and efficacy of products, exposure to reduced pressure may potentially impact the sterility and safety of an injectable product in a prefilled syringe if one is not aware of the importance of reduced bubble size and stopper design.

In this discussion, we have proposed one way to determine the maximum acceptable size of a gas bubble that can be left inside a syringe based on stopper height as well as other variables. There are alternative ways to protect prefilled syringes from contamination due to stopper movement, but these require additional packaging and do not offer the added benefits of a bubble-free syringe, such as enhanced dosing accuracy and safety as well as reduced waste due to the elimination of a product drip at the needle when the tip cap is removed.³


As prefilled syringes continue to find favor as an alternative to vials for many of

today's parenteral products, reduced gas bubble filling should likewise become increasingly popular as an alternative to traditional filling methods and may one day become the industry standard.

REFERENCES


1. Harrison B, Rios M. Big shot: developments in prefilled syringes. *Pharm Technol.* 2007;31(3):50-56.
2. Kinney SD. Considerations on the size of the gas bubble in a prefilled syringe. Paper presented at the PDA Universe of the Prefilled Syringe Show in Berlin, Germany, November 27-28, 2007.
3. Kinney SD. Innovative Solutions Seminar. New Brunswick, NJ, October 30, 2007.

FIGURE 6



The data demonstrates that smaller gas bubbles and stoppers with larger H_{sb} reduce the risk of stopper movement exceeding $1/5 H_{sb}$.

FIGURE 7



Gas bubbles in traditionally filled syringes, like the syringe on the bottom in this photo, can cause product to drip from the needle when the needle sheath or tip cap is removed. In a bubble-free syringe, like the one pictured on the top, there is no drip, decreasing waste and improving dosing accuracy and safety.

BIOGRAPHIES

Dr. Shawn D. Kinney, President of Hyaluron Contract Manufacturing (HCM), founded HCM in 1999 to provide aseptic manufacturing and filling services to the pharmaceutical, biotech, and medical device industries. Dr. Kinney earned his PhD in Chemistry from the University of Massachusetts at Amherst, a Masters in Medicinal Chemistry from Northeastern University, and a BS in Chemistry from the University of Massachusetts at North Dartmouth. Dr. Kinney has worked at Anika Therapeutics, Wyeth-Ayerst, and Millipore and has more than 20 years of experience in the pharmaceutical industry. He has extensive experience in the development of sterile formulation and filling processes, including viscous and difficult-to-fill products. Prior to founding HCM, he was responsible for the sterile formulation and filling of hyaluronate into prefilled syringes in his role as VP of Operations at Anika Therapeutics. Recently, Dr. Kinney has pioneered a new technology in online vacuum filling and stoppering (Bubble-Free Filling[®]) and has been granted a patent. He continues to oversee HCM's expansion and leadership in the aseptic contract manufacturing industry. He can be reached at shawn@hyaluron.com or (781) 270-7900, ext. 218.

Dr. Andrea Wagner is the Vice President of Business Development at HCM, a position she has held for 7 years. Prior to joining HCM, she was employed by the New Jersey Institute of Technology in the capacity of Senior Scientist in a national training program. Simultaneously, she worked as a Manager at Thermo Fisher Scientific as a Manager in business development of pharmaceutical applications for their XRF Analyzers. After earning her PhD in Toxicology, she managed a center devoted to innovative testing technologies in the Chemistry Department at Tufts University in Massachusetts. Dr. Wagner also earned her MS in Analytical Chemistry and her BS in Chemistry. She can be reached at andrea@hyaluron.com or (781) 270-7900, ext. 106.

Christian W. Phillips is the Director of Process Engineering, at HCM. Mr. Phillips has 14 years of experience in R&D, Process Development, Tech Transfer, and Manufacturing environments suited for the introduction of novel biotherapeutics and generics, including fill/finish applications. Prior to HCM, Mr. Phillips was employed by Transkaryotic Therapies (now Shire HGS). Mr. Phillips earned his BS in Biology from St. Michael's College and is the co-inventor with Shawn Kinney of HCM's Bubble-Free Filling[®] technology. He can be reached at cphillips@hyaluron.com or (781) 270-7900, ext. 181.

ATTACHMENT B-4



Search WorldCat

[Advanced Search](#) [Find a Library](#)

[<< Return to Search Results](#)

[Cite/Export](#)

[Print](#)

[E-mail](#)

[Share](#)


[Permalink](#)

[Add to list](#)

[Add tags](#)

[Write a review](#)

Rate this item: 1 2 3 4 5



Drug delivery technology.

Publisher: Montvile, NJ : Drug Delivery Technology, LLC

Edition/Format: Journal, magazine : Periodical : English [View all editions and formats](#)

Rating: (not yet rated) [0 with reviews - Be the first.](#)

Subjects: [Drug delivery systems -- Periodicals.](#)
[Drug Delivery Systems.](#)
[Biological Transport.](#)
[View all subjects](#)

More like this [User lists](#) [Similar Items](#)

Get a Copy

[Find a copy in the library.](#)

Search this publication for other articles with the following words:

Find a copy online

Links to this item

[drug-dev.com](#)
Includes issues for later title

Find a copy in the library

Enter your location:

Submit a complete postal address for best results.

Displaying libraries 1-6 out of 45 for all 5 editions (Maryland, USA)

Show libraries holding [just this edition](#)

« First < Prev 1 2 3 Next > Last »

Library	Held formats	Distance	
1. Library of Congress Washington, DC 20540 United States	Journal / Magazine / Newspaper	22 miles MAP IT	Library info Ask a librarian Add to favorites
2. National Library of Medicine Bethesda, MD 20894 United States	Journal / Magazine / Newspaper	25 miles MAP IT	Library info Add to favorites
3. George Mason University Fenwick Library Fairfax, VA 22030 United States	Journal / Magazine / Newspaper	39 miles MAP IT	Library info Add to favorites
4. Yeshiva University New York, NY 10033 United States	Journal / Magazine / Newspaper	190 miles MAP IT	Library info Ask a librarian Add to favorites

5.	Duke University Libraries Duke University Library; Perkins Library Durham, NC 27708 United States	 Journal / Magazine / Newspaper	245 miles MAP IT	Library info Ask a librarian Add to favorites
6.	North Carolina State University NC State University Libraries Raleigh, NC 27695 United States	 Journal / Magazine / Newspaper	252 miles MAP IT	Library info Add to favorites

[« First](#) [« Prev](#) [1](#) [2](#) [3](#) [Next >](#) [Last >>](#)

Details

Genre/Form:	Periodicals
Additional Physical Format:	Online version: Drug delivery technology (Online) (DLC) 2008215769 (OCoLC)232115072
Material Type:	Periodical, Internet resource
Document Type:	Journal / Magazine / Newspaper, Internet Resource
ISSN:	1537-2898
OCLC Number:	48060225
Description:	volumes : illustrations
Other Titles:	Drug delivery technology

Reviews

User-contributed reviews

[Add a review](#) and share your thoughts with other readers. Be the first.

Tags

[Add tags](#) for "Drug delivery technology.". Be the first.

Similar Items

Related Subjects: (6)

- [Drug delivery systems -- Periodicals.](#)
- [Drug Delivery Systems.](#)
- [Biological Transport.](#)
- [Technology, Pharmaceutical.](#)
- [Drug Industry.](#)
- [Drug delivery systems.](#)

User lists with this item (1)

[CUH2A periodicals](#) (83 items)

by [MTuftsCUH2A](#)

ATTACHMENT B-5



Search WorldCat

Search

[Advanced Search](#) [Find a Library](#)

[<< Return to Search Results](#)

[Cite/Export](#)

[Print](#)

[E-mail](#)

[Share](#)

[Permalink](#)

[Add to list](#)

[Add tags](#)

[Write a review](#)

Rate this item:


1

2

3

4

5



Preview this item

Drug delivery technology.

Publisher: Montvile, NJ : Drug Delivery Technology, LLC

Edition/Format: Journal, magazine : Periodical : English [View all editions and formats](#)

Rating: (not yet rated) [0 with reviews - Be the first.](#)

Subjects: [Drug delivery systems -- Periodicals.](#)
[Drug Delivery Systems.](#)
[Biological Transport.](#)
[View all subjects](#)

More like this [User lists](#) [Similar Items](#)

Get a Copy

[Find a copy in the library.](#)

Search this publication for other articles with the following words:

Search

Find a copy online

Links to this item

[drug-dev.com](#)

Includes issues for later title

Find a copy in the library

Enter your location: [Find libraries](#)

Submit a complete postal address for best results.

Displaying libraries 1-6 out of 45 for all 5 editions (United Kingdom)

Show libraries holding [just this edition](#)

[<< First](#) [< Prev](#) [1](#) [2](#) [3](#) [Next >](#) [Last >>](#)

Library	Held formats	Distance	
1. National Library of Scotland NLS Edinburgh, Scotland, EH1 1EW United Kingdom	Journal / Magazine / Newspaper	41 miles MAP IT	Library info Add to favorites
2. Glasgow Caledonian University Glasgow, G4 0BA United Kingdom	Journal / Magazine / Newspaper	46 miles MAP IT	Library info Add to favorites
3. Newcastle University, Robinson Library Tyne and Wear, Newcastle Upon Tyne, NE1 7RU United Kingdom	Journal / Magazine / Newspaper	77 miles MAP IT	Library info Add to favorites
		132 miles	Library info

4.	The British Library, On Demand The British Library, Document Supply, Boston Spa Wetherby, West Yorkshire, LS23 7BQ United Kingdom	Journal / Magazine / Newspaper	MAP IT	Add to favorites
5.	University of Liverpool, Sydney Jones Library Liverpool, L69 3DA United Kingdom	 Journal / Magazine / Newspaper	138 miles MAP IT	Library info Ask a librarian Add to favorites
6.	University of Birmingham Birmingham University Birmingham, B15 2TT United Kingdom	 Journal / Magazine / Newspaper	212 miles MAP IT	Library info Ask a librarian Add to favorites

« First < Prev 1 2 3 Next > Last »

Details

Genre/Form:	Periodicals
Additional Physical Format:	Online version: Drug delivery technology (Online) (DLC) 2008215769 (OCoLC)232115072
Material Type:	Periodical, Internet resource
Document Type:	Journal / Magazine / Newspaper, Internet Resource
ISSN:	1537-2898
OCLC Number:	48060225
Description:	volumes : illustrations
Other Titles:	Drug delivery technology

Reviews**User-contributed reviews**

[Add a review](#) and share your thoughts with other readers. Be the first.

Tags

[Add tags](#) for "Drug delivery technology.". Be the first.

Similar Items

Related Subjects: (6)

[Drug delivery systems -- Periodicals.](#)

[Drug Delivery Systems.](#)

[Biological Transport.](#)
[Technology, Pharmaceutical.](#)
[Drug Industry.](#)
[Drug delivery systems.](#)

User lists with this item (1)

[CUH2A periodicals](#) (83 items)
by [MTuftsCUH2A](#)

ATTACHMENT B-6



Search WorldCat

Search

[Advanced Search](#) [Find a Library](#)

[<< Return to Search Results](#)

[Cite/Export](#)

[Print](#)

[E-mail](#)

[Share](#)

[Permalink](#)

[Add to list](#)

[Add tags](#)

[Write a review](#)

Rate this item:


1

2

3

4

5



Preview this item

Drug delivery technology.

Publisher: Montvile, NJ : Drug Delivery Technology, LLC

Edition/Format: Journal, magazine : Periodical : English [View all editions and formats](#)

Rating: (not yet rated) [0 with reviews - Be the first.](#)

Subjects: [Drug delivery systems -- Periodicals.](#)
[Drug Delivery Systems.](#)
[Biological Transport.](#)
[View all subjects](#)

More like this [User lists](#) [Similar Items](#)

Get a Copy

[Find a copy in the library.](#)

Search this publication for other articles with the following words:

Search

Find a copy online

Links to this item

[drug-dev.com](#)

Includes issues for later title

Find a copy in the library

Enter your location: [Find libraries](#)

Submit a complete postal address for best results.

Displaying libraries 1-6 out of 45 for all 5 editions (Indiana, USA)

Show libraries holding [just this edition](#)

[<< First](#) [< Prev](#) [1](#) [2](#) [3](#) [Next >](#) [Last >>](#)

Library	Held formats	Distance	
1. Butler University Libraries Indianapolis, IN 46208 United States	Journal / Magazine / Newspaper	30 miles MAP IT	Library info Ask a librarian Add to favorites
2. Rush University Medical Center Library RUMC Library Chicago, IL 60612 United States	Journal / Magazine / Newspaper	137 miles MAP IT	Library info Add to favorites
3. University of Iowa Libraries Iowa City, IA 52242 United States	Journal / Magazine / Newspaper	298 miles MAP IT	Library info Ask a librarian Add to favorites
4. George Mason University Fenwick Library	Journal / Magazine / Newspaper	481 miles MAP IT	Library info Add to favorites

Fairfax, VA 22030 United States			
5.	University of Minnesota, Twin Cities Minneapolis, MN 55455 United States	 Journal / Magazine / Newspaper	486 miles MAP IT Library info Add to favorites
6.	National Library of Medicine Bethesda, MD 20894 United States	 Journal / Magazine / Newspaper	489 miles MAP IT Library info Add to favorites
« First < Prev 1 2 3 Next > Last >>			

Details

Genre/Form: Periodicals

Additional Physical Format: Online version:
Drug delivery technology (Online)
(DLC) 2008215769
(OCoLC)232115072

Material Type: Periodical, Internet resource

Document Type: Journal / Magazine / Newspaper, Internet Resource

ISSN: 1537-2898

OCLC Number: 48060225

Description: volumes : illustrations

Other Titles: Drug delivery technology

Reviews

User-contributed reviews

[Add a review](#) and share your thoughts with other readers. Be the first.

Tags

[Add tags](#) for "Drug delivery technology.". Be the first.

Similar Items

Related Subjects: (6)

- [Drug delivery systems -- Periodicals.](#)
- [Drug Delivery Systems.](#)
- [Biological Transport.](#)
- [Technology, Pharmaceutical.](#)
- [Drug Industry.](#)
- [Drug delivery systems.](#)

User lists with this item (1)

[CUH2A periodicals](#) (83 items)

by [MTuftsCUH2A](#)

ATTACHMENT B-7



JOURNAL

Drug delivery technology.

Montville, NJ : Drug Delivery Technology, LLC; Began in 2001; ceased with v. 10, no. 9 (Nov.-Dec. 2010).; 2001 - 2010

Library Catalog ; MMS ID 9911348263406676; ISSN 1537-2898; NLM ID 101134826

[Available at NLM General Collection \(W1 DR514BK\)](#) >



TOP

SEND TO

GET IT

DETAILS

LINKS

Send to _____



DOWNLOAD
MARC



EMAIL



PERMALINK



CITATION



ENDNOTE



EXPORT RIS



QR



EXPORT TO
EXCEL



PRINT

Get It _____

Please sign in to check if there are other options. [Sign in](#)

[BACK TO LOCATIONS](#)

LOCATION ITEMS

NLM

[Available](#) , General Collection W1 DR514BK

Summary holdings: v.2(2002)-10(2010)

Item in place (0 requests) Loanable	v. 21, no. 7 (Oct. 2021)	▼
Item in place (0 requests) Loanable	v. 21, no. 7 (Oct. 2021)	▼
Item in place (0 requests) Loanable	v. 10, no. 6-9 (2010)	▼
Item in place (0 requests) Loanable	v. 10, no. 1-5 (2010)	▼
Item in place (0 requests) Loanable	v. 9, no. 6-10 (2009) Material Type: Issue	▼

Regeneron Exhibit 1103.138
Regeneron v. Novartis
IPR2021-00816

ATTACHMENT B-8



Explore the British Library

[Explore Home](#) [Feedback](#) [Basket](#) [Request Other Items](#) [My Reading Room Requests](#) [Help](#)
[Main catalogue](#) [Available online \(beta\)](#) [Our website](#) [Explore Further](#)

1537-2898

Everything in this catalogue

[Advanced search](#)
[Back to results list](#)

Drug delivery technology.

Montville, NJ : Drug Delivery Technology, LLC, 2001-2010.

[Details](#) [I want this](#)
[Actions ▼](#)

Title: Drug delivery technology.

Other Titles: Key Title: Drug delivery technology

Subjects: [Drug delivery systems -- Periodicals](#); [Drug Delivery Systems -- Periodicals](#); [Biological Transport -- Periodicals](#); [Technology, Pharmaceutical -- Periodicals](#); [Drug Industry -- Periodicals](#);
Dewey: 615.605

Rights: Terms governing use: British Library not licensed to copy

Publication Details: Montville, NJ : Drug Delivery Technology, LLC, 2001-2010.

Language: English

Description: Began in 2001.
 -vol. 10, no. 9 (2010).

Identifier: ISSN 1537-2898; System number: 007842723

Related Titles: Later Title: Drug development & delivery
 Also issued online: Drug delivery technology (Online) 1944-818X

Notes: Current publication frequency: Nine times a year, Jan./Feb. 2010-
 Former publication frequency: Eight times a year, <Jan./Feb. 2002->
 Former publication frequency: Ten times a year, <Jan. 2006-Nov./Dec. 2009
 Citation/references note: Chemical abstracts, 0009-2258
 Additional phys. form: Available also online. Subscription required for access and full text.

Physical Description: 10 v. : ill.

Holdings Notes: Document Supply 3629.104900 Vol. 1 (2001)-v. 10, no. 9 (2010)

Shelfmark(s): Document Supply 3629.104900

UIN: BLL01007842723

Links

[Item Holdings](#)
[View record in Library Hub Discover](#)
[View record in WorldCat®](#)
[Report Catalogue Error](#)
[MARC display](#)
[Continued by: Drug development & delivery.](#)

[Back to results list](#)

 Result 1 [Next →](#)

[Terms of Use](#) [About the British Library](#) [Privacy](#) [Cookies](#) [Accessibility](#) [Contact us](#)

All text is © British Library Board and is available under a Creative Commons Attribution Licence, except where otherwise stated.



P2

ATTACHMENT B-9

no:48060225  

[Sign in](#)

[← Back to Search Results](#)


 Result 1 of 1 

1



-  Cite
-  Share
-  Save

Drug delivery technology.

 **Journal, Magazine 2001**
Montvile, NJ : Drug Delivery Technology, LLC
Began in 2001; ceased with v. 10, no. 9 (Nov.-Dec. 2010).

Access Options

 **Butler University Libraries** has v.6 (2006)-v.10 (2010)

[1 Available at 1 Location](#)

Publication:
Montvile, NJ : Drug Delivery Technology, LLC
Began in 2001; ceased with v. 10, no. 9 (Nov.-Dec. 2010).

Physical Description: volumes : illustrations

ISSN: 1537-2898, 1944-818X



Subjects:

Library of Congress Subject Headings

[Drug delivery systems Periodicals.](#)

Medical Subject Headings

[Drug Delivery Systems.](#)

[Biological Transport.](#)

[Technology, Pharmaceutical.](#)

[Drug Industry.](#)

[Periodicals.](#)

Show More 

Additional Physical Form Entry:

Online version: [Drug delivery technology \(Online\)](#) (1944-818X / 232115072)

OCLC Number/Unique Identifier: **48060225**

Language: English

Genre:

Periodicals.

Succeeding Entry:

Continued by: [Drug development & delivery](#)

Database: WorldCat

Staff View (MARC Record):

[MARC Record](#)

LCCN: 2001215705


[^ Less Item Details](#)


Availability at Butler University Libraries



Library Has: v.6 (2006)-v.10 (2010)

Science Library

 **1 Available** at this Location



Other Availability & Holdings

Other Availability & Holdings

Other Libraries Worldwide (13 Libraries)

Explore Editions & Formats

Group & Refine ▾

Sort: Library ▾

4 Editions & Formats

1

Edition:



Drug delivery technology.

Montvile, NJ : Drug Delivery Technology, LLC

Format:  Journal, Magazine

Year: 2001

Language: English

Library: Butler University Libraries and 13 Libraries Worldwide

2

Edition:





[Drug delivery technology.](#)

Montvile, NJ : Drug Delivery Technology, LLC, [2001]-

Format:  eJournal, eMagazine

Year:2001

Language:English

Library:37 Libraries Worldwide

3

Edition:



[Drug delivery technology.](#)

Montvile, NJ Drug Delivery Technology, LLC.

Format:  eJournal, eMagazine

Year:uuuu


Language:English

Library:1 Libraries Worldwide



4

Edition:



[Drug delivery technology](#)

(U.st.)

Format:  eJournal, eMagazine

Year:uuuu

Language:Undetermined

Library:No libraries hold this item

1-4 of 4



Number of Results per Page: 25 ▾

Language:

English



Brought to you by WorldCat Discovery
Copyright © 2001-2022 OCLC. All rights reserved.

4/3/22, 1:07 PM

Drug delivery technology. | Butler University Libraries

[Privacy policy](#)
[Terms and conditions](#)
[Cookie notice](#)
[Accessibility statement](#)
[ISO 27001 certificate](#)

Registry ID: 933
Institution Symbol: IIB

REL-1.264.2-224
Of258483-b0cb-4fd0-aab4-216a617d350b

Resources

[Advanced Search](#)
[Course Reserves](#)
[Send Feedback](#)

[Library Home](#)
[Off-Campus Login](#)
[Report a Problem](#)

[Search history](#)

My Account

[Sign in](#)



ATTACHMENT B-10

Downloaded from on April 3, 2022

PDA Journal
of Pharmaceutical Science and Technology



Investigating Liquid Leak from Pre-Filled Syringes upon Needle Shield Removal: Effect of Air Bubble Pressure

Edwin Chan, Yuh-Fun Maa, David Overcashier, et al.

PDA J Pharm Sci and Tech **2011**, 65 363-371

Access the most recent version at doi:[10.5731/pdajpst.2011.00759](https://doi.org/10.5731/pdajpst.2011.00759)

Regeneron Exhibit 1103.150
Regeneron v. Novartis
IPR2021-00816

Investigating Liquid Leak from Pre-Filled Syringes upon Needle Shield Removal: Effect of Air Bubble Pressure

EDWIN CHAN^a, YUH-FUN MAA^a, DAVID OVERCASHIER^b, and CHUNG C. HSU^a

^aPharmaceutical Processing and Technology Development and ^bDevice Development, Genentech ©PDA, Inc. 2011

ABSTRACT: This study is to investigate the effect of headspace air pressure in pre-filled syringes on liquid leak (dripping) from the syringe needle upon needle shield removal. *Drip tests* to measure drip quantity were performed on syringes manually filled with 0.5 or 1.0 mL of various aqueous solutions. Parameters assessed included temperature (filling and test), bulk storage conditions (tank pressure and the type of the pressurized gas), solution composition (pure water, 0.9% sodium chloride, and a monoclonal antibody formulation), and testing procedures. A headspace pressure analyzer was used to verify the drip test method. Results suggested that leakage is indeed caused by headspace pressure increase, and the temperature effect (ideal gas expansion) is a major, but not the only, factor. The dissolved gases in the liquid bulk prior to or during filling may contribute to leakage, as these gases could be released into the headspace due to solubility changes (in response to test temperature and pressure conditions) and cause pressure increase. Needle shield removal procedures were found to cause dripping, but liquid composition played little role. Overall, paying attention to the processing history (pressure and temperature) of the liquid bulk is the key to minimize leakage. The headspace pressure could be reduced by decreasing liquid bulk storage pressure, filling at a higher temperature, or employing lower solubility gas (e.g., helium) for bulk transfer and storage. Leakage could also be mitigated by simply holding the syringe needle pointing upward during needle shield removal.

KEYWORDS: Prefilled syringe, Headspace pressure, Drip test, Gas solubility, Ideal gas, Syringe fill

LAY ABSTRACT: Substantial advances in pre-filled syringe technology development, particularly in syringe filling accuracy, have been made. However, there are factors, as subtle as how the needle shield (or tip cap) is removed, that may affect dosing accuracy. We recently found that upon removal of the tip cap from a syringe held vertically with needle pointed downwards, a small amount of solution, up to 3–4% of the 1 mL filled volume or higher for filled volume of <1 mL, leaked out from the needle. This paper identified the root causes of this problem and offered solutions from the perspectives of the syringe fill process and the end user procedure. The readers will benefit from this paper by understanding how each process step prior to and during syringe filling may affect delivery performance of the pre-filled syringe device.

Introduction

Large molecules like monoclonal antibodies, proteins, and peptides need to be delivered via the parenteral route. Pre-filled syringes are now the primary container of choice for most parenteral drug delivery systems mainly for reasons that they are safe and user friendly (1). In recent years substantial advances in pre-filled syringe technology development have been made, particularly in syringe filling accuracy (2).

However, there are factors, as subtle as how the needle shield (or tip cap) is removed, that may affect dosing accuracy. We recently found that upon removal of the tip cap from a syringe held vertically with needle pointed downwards, a small amount of solution (up to 3–4% of the 1 mL filled volume) leaked out from the needle. Although holding the syringe tip downwards during needle shield removal is not recommended, this remains a significant issue affecting the overall delivery dose, especially with small fill volumes.

Correspondence author: Yuh-Fun Maa, 1 DNA Way South San Francisco, CA 94080; tel: 650-225-3499; fax: 650-742-1504; e-mail: maay@gene.com
doi: 10.5731/pdajpst.2011.00759

The same observation was previously reported by Kinney and co-workers who attributed such leakage to bubble expansion as the result of small vacuum created during tip cap removal (3). We agree that the root cause of leakage is the air bubble (or headspace) and




Figure 1

Process flow diagram of syringe filling.

that the vacuum created by tip cap removal can cause bubble expansion, thereby resulting in liquid dripping. This phenomenon, however, may be more complex. Actually, any factors capable of causing air bubble expansion may be able to induce leakage. Certainly, temperature increase (e.g., from refrigeration to an ambient environment) could cause bubble expansion simply following the Ideal Gas Law (described below). Yet, this study would go far beyond to investigate upstream process effects. Prior to filling, thawed liquid bulks are filtered (under a trans-membrane pressure) and stored in a tank pressurized under nitrogen blank for some time before second filtration (under a trans-membrane pressure) (Figure 1). Certainly, all these steps up to liquid fill can be performed under a controlled temperature and/or pressure. Thus, this study investigates whether and how the temperature and pressure history of the liquid may eventually affect headspace expansion/pressure. Furthermore, procedures of needle shield removal were assessed to better understand the leakage phenomenon. Three aqueous solutions, pure water, 0.9% NaCl, and an anti-IgE monoclonal antibody formulation, were tested in this study to understand the effect of formulation on leakage.

Materials and Methods

All experiments in this study employed 1.0 mL long 26G ½ inch staked needle syringes filled with 1.0 mL or 0.5 mL volume of pure water, 0.9% NaCl aqueous solution, or an anti-IgE monoclonal antibody aqueous solution. All solutions were 0.22 μm-filtered and stored at 2–8 °C under a pre-determined pressure. All pre-filled syringes were manufactured and manually filled in the laboratory. Two different lots of syringe barrel (pre-assembled with needle shields) were used to demonstrate reproducibility. Samples were analyzed by measuring gross weight change using an analytical balance before and after removal of the rigid needle shield. Equipment and materials used in this study are tabulated in Table I.

The following describes the processing and test procedures for pre-filled syringes manufactured for this study.

Components Sterilization

Empty syringes with 26G ½ inch staked needle (previously washed and siliconized by an external contract manufacturer), W4023/FLT stoppers, and stopper in-

TABLE I
Equipment and Materials Used in the Study

Equipment	Supplier/Model
Autoclave	Steris (Mentor, OH)/Amsco Century
Balance	Mettler Toledo AG 204 (Columbus, OH)/AG135
Digital thermometer; with Type K thermocouple	John Fluke Mfg., Inc. (Everett, WA)/Fluke 52
Pressure gauge (0 psi–30 psi) with 1-inch sanitary fitting	Anderson (Fultonville, NY)/EB029
Pressure vessel, 5 liter, stainless steel storage tank	Alloy Products Corp. (Waukesha, WI) Custom made
Stoppering tool	Becton Dickinson (Franklin Lake, NJ)/Custom made
Materials	
1 mL-long syringe with 26G × ½" staked needle	Becton Dickinson (Swedesboro, NJ)/1 MI long
Rigid needle shield (RNS)	Helvoet Pharma (Pennsauken, NJ)/FM27
Plunger stopper stopper (Flurotec coated on product-contact surface)	Becton Dickinson (Swedesboro, NJ)/W4023/FLT
Helium	Praxair (Danbury, CT), 5.0 Ultra High Purity Grade
Nitrogen	Praxair (Danbury, CT), 5.0 Ultra High Purity Grade
Vent filter, pore size: 0.2 μm, membrane: PTFE	Pall Corporation (Ann Arbor, MI)/ACRO® 50
Monoclonal antibody formulation (150 mg/mL anti-IgE, 200 mM arginine-HCl, 20 mM histidine/histidine-HCl, 0.04% polysorbate 20, pH 6.0)	Genentech (South San Francisco, CA)
Sodium chloride	J. T. Baker (Phillipsburg, NJ)
Water, distilled	Genentech (South San Francisco, CA)

sersion tools were autoclaved using a conservative ramp cycle (ramps at 1 psi/min, 30 min exposure at 121.1 °C, and 30 min drying at 2 psia) during pressurization and evacuation to minimize the chance of needle shield movement during the sterilizing process. After the cycle was complete, each syringe was visually inspected for loose needle shield.

Liquid Bulk Storage under Pressurization

A 5 L stainless steel pressure tank was assembled with a calibrated pressure gauge, a valve connected with a vent filter, and a pressure regulator connected to a gas source. Each filtered solution was individually loaded into the pressure tank and pressurized to a desired pressure (0, 10, or 20 psig) and held at 2–8 °C (cold room) for 24 h. The pressure gauge was checked periodically to ensure constant pressure was maintained.

Manual Syringe Filling and Stopper Insertion

The pressure tank was depressurized in the cold room to 0 psig by closing the gas source and opening the vent filter valve. A liquid volume of 1.0 mL or 0.5 mL was withdrawn from the pressure tank using a repeater pipette and filled into 1 mL long syringes. W4023/FLT plunger stoppers were manually inserted using a Becton Dickinson (BD) stopper insertion tool as illustrated in Appendix I. The depth of the stopper (measured from the back of the syringe flange to the back of the stopper) was positioned at 8 mm for 1 mL syringes and 24 mm for 0.5 mL syringes. This resulted in headspace height of approximately 8 mm for both configurations.

Although the majority of the syringes were filled in the cold room at 2–8 °C, some were filled at higher temperatures (15 °C and 21.5 °C) using a circulation bath

to control the liquid temperature. In that case a digital thermometer was submerged directly in the solution to monitor the actual fill temperature. All samples were stored at 2–8 °C after filling for at least 24 h to allow the headspace pressure to equilibrate.

Drip/Leakage Test

Unless otherwise specified, all filled syringes were equilibrated to ambient temperature (measured and recorded) for at least 30 min before testing. The initial syringe weight, W_{initial} , was measured. Syringes were held vertically with the needle pointing downward—except for samples tested for different rigid needle shield (RNS) removal methods—and the needle shield was then removed to allow for solution dripping from the tip of the needle on water-absorbent material (e.g., paper tissue). When the needle stopped dripping, the syringe and the needle shield were weighed together to obtain the leakage amount by taking the difference in weight before and after the drip. Finally, to determine the liquid extractable volume in each syringe, a plunger rod was inserted to eject all liquid content from the syringe. Empty syringe weight (including the needle shield), W_{empty} , was then determined, and the gross weight of the dripped solution could be calculated accordingly.

Headspace Pressure Measurement

An optical-based, non-destructive gas analyzer (Model FMS-1400P, Lighthouse Instruments) was employed to determine the headspace pressure inside sealed pre-filled syringes. Briefly, light from a near-infrared laser is tuned to match an internal absorption frequency of the water molecule and passes through a container in the headspace above the product. The amount of laser light absorbed is proportional to the water vapor concentration in the headspace, while the width of the absorption signal is related to the headspace pressure (4).

Pressure and Temperature of Gas Bubble Calculation (Ideal Gas Law)

Based on the Ideal Gas Law (eq 1), when syringes were filled at 5 °C (T_1) under ambient pressure (P_1) and then relocated to an ambient environment at use (P_2 and T_2) for drip test, the air bubble would experience volume and/or pressure increase. After the needle shield was removed, the open system allowed the volume of the air bubble to expand until the bubble




Figure 2

Graphic representation of syringe and its physical dimensional parameters used in eq 3.

pressure equilibrated with the ambient pressure ($P_1 = P_2$). Bubble expansion (V_2) displaced some solution as leakage and the expanded volume ($V_2 - V_1$) could be theoretically calculated by eq 2.

$$\frac{P_1 V_1}{nRT_1} = \frac{P_2 V_2}{nRT_2} \quad (1)$$

$$V_2 - V_1 = V_1 \times \left(\frac{T_2}{T_1} - 1 \right) \quad (2)$$

where T_1 and T_2 are known values, initial and final temperatures, respectively; and V_1 is a constant that can be calculated from known syringe physical parameters (eq 3 and Figure 2).

$$V_1 = (BH - LH_{\text{Before Drip}} - S_{\text{Height}} - S_{\text{Depth}}) \times \text{BCA} \quad (3)$$

where BH is the barrel height, $LH_{\text{Before Drip}}$ is the liquid height before removal of the needle shield, S_{Height} is the stopper total height, S_{Depth} is the stopper position measured from the back of the syringe flange to the back of the stopper, and BCA is the barrel cross-sectional area.

TABLE II
Physical Dimensions of Syringe, Components, and Liquid Fill

Parameters	1.0 mL	0.5 mL
Fill volume (mL)*	1.00	0.50
Barrel diameter (mm)	6.35	6.35
Stopper depth, S_{Depth} (mm)*	8.00	24.00
Stopper height, S_{Height} (mm)	7.85	7.85
Neck volume offset (mL)	0.04	0.04
Barrel length (mm)	54.00	54.00
Liquid height (mm)*	30.00	14.34

* Average fill volumes and stopper depths were measured for each experiment, therefore these values may vary.

Conversion of Drip Test Results into Pressure Units (Torr)

Before and after the drip test, the headspace conditions in the filled syringe are (T_1, P'_1, V_1) and (T_2, P'_2, V_2) , respectively. P'_1 represents the internal pressure of the syringe headspace before the drip test, and P'_2 represents ambient pressure or is 1 atm.; V_1 and V_2 can be calculated using eqs 3 and 4 and physical dimensions (Table II):

$$V_2 = (\text{Barrel Height} - (\text{Liquid Height}_{\text{After Drip}} - S_{\text{Height}} - S_{\text{Depth}})) \times \text{BCA}. \quad (4)$$

Once V_1 and V_2 are calculated, assuming $T_1 = T_2$, the Ideal Gas Law (eq 1) can be used to derive eq 5 and solve for P_1 :

$$P_1 = P_2 \times \frac{V_2}{V_1}. \quad (5)$$

Results and Discussion

Effect of Pressure and Temperature during Bulk Storage and Filling

Leakage was first tested on syringes manually filled with the anti-IgE antibody formulation that had been stored under N_2 blank at three different pressures: 0, 10, and 20 psig. The results are summarized in Figure 3. The ideal gas expansion of inert nitrogen, calculated using eq 2 with the temperature change from filling at 5 °C to testing at 21.5 °C, was 17 mg (the horizontal line in Figure 3) based on density of 1.06 g/L. Both 0.5




Figure 3

Effect of liquid bulk storage pressure (0, 10, and 20 psig) on leakage from syringes filled with 1-mL or 0.5-mL of anti-IgE antibody liquid formulation. Syringes tested at $t=0$ and $t=1$ month are represented by square and triangle symbols, respectively. The two fill volumes of 1.0 mL and 0.5 mL are illustrated by pink and blue color, respectively.

mL and 1.0 mL syringes leaked more than the dripping contributed by ideal gas expansion. In addition, the amount of leakage increased with increasing storage pressure, approximately 0.3 mg/psig. The 1.0 mL syringes appeared to expel more liquid, 25–33 mg (6–8 drips or 2.4–2.8% of the overall dose) than the 0.5 mL syringes, 23–29 mg (5–7 drips or 4.6–5.0% of the overall dose) over the whole pressure range. These observations could be attributed to increased gas solubility. When the storage pressure increased, it dissolved more nitrogen molecules into the solution. Some of dissolved N_2 would escape to the headspace created during filling under ambient pressure, thereby enhancing the headspace pressure. Because 1.0 mL filled syringes contained twice the liquid volume, more dissolved gas diffused from the liquid to the gaseous phase, which resulted in slightly higher headspace pressure than the 0.5 mL filled counterpart.

It is worth noting that the storage pressure effect could not explain the 0 psig storage condition where the leakage was still higher than that predicted by ideal gas expansion. Again, it is a gas solubility phenomenon and could be interpreted by the temperature-solubility relationship. Gas solubility in water generally decreases with increasing temperature. Nitrogen solubility can be predicted as a function of temperature as illustrated in Appendix II (5–8), showing that nitrogen solubility decreases from 1.7×10^{-5} (mole fraction) at 5 °C (278 °K) to 1.25×10^{-5} (mole fraction) at




Figure 4

Effect of gas species (nitrogen vs argon) on leakage from syringes filled with 1 mL or 0.5 mL of anti-IgE antibody liquid formulation. Syringes with fill volumes of 1.0 mL and 0.5 mL are represented by square and triangle symbols, respectively. The two inert gases, nitrogen and helium, are illustrated by pink and blue colors, respectively.

21.5 °C (294.5 °K). Thus, during the leakage test at ambient temperature, some nitrogen and oxygen molecules originally dissolved in the liquid during filling at 2–8 °C became insoluble and would diffuse to the headspace, which caused higher pressure and additional leakage. Note that oxygen is even more soluble than nitrogen (Appendix II).

Some pre-filled syringes were stored at 2–8 °C for 1 month as part of a stability study and tested for leakage. The results (Figure 3) were similar to the $T = 0$ condition, suggesting the additional storage time has little effect on leakage, which was primarily determined by the temperature and pressure of liquid storage, filling, and leakage test.

Effects of Gas Species

Because a soluble gas like N_2 contributed to headspace pressure increase, a less soluble gas might alleviate such an effect. As shown in Appendix II, helium is less soluble than N_2 , $\sim 0.7 \times 10^{-5}$ mole fraction, and is independent of temperature changes. Drip tests were performed on syringes filled with liquid bulks previously stored under helium at three different pressures: 0, 10, and 20 psig. It is apparent that helium caused less leakage than N_2 , and both 0.5 mL and 1.0 mL filled syringes showed little changes in leakage amount with pressure (Figure 4). Again, the 0 psig result exceeds what is predicted by the Ideal Gas Law




Figure 5

Effect of liquid bulk composition (anti-IgE antibody formulation [pink square], pure water [blue triangle], and 0.9% NaCl aqueous solution [orange diamond]) on leakage from syringes filled with 1.0 mL liquid (a) or 0.5 mL liquid (b).

and can be attributed to soluble gases (oxygen and nitrogen) that already dissolved in the liquid during storage and filling (2–8 °C). The dissolved gases could have diffused into the headspace during the leakage test at the higher ambient temperature.

Effects of Liquid Composition

Liquid salinity may influence gas solubility; higher salinity in the solution may have a tendency to reduce gas solubility (6). The anti-IgE antibody formulation contains arginine HCl, which makes the formulation slightly higher in salinity than water. In addition, a 0.9% NaCl solution was evaluated. The leakage results on these three liquids showed no clear trend of salinity effects (Figure 5a for 1.0 mL filled syringes and Figure 5b for 0.5 mL filled syringes) when all three storage pressures (0, 10, and 20 psig) were compared. This leakage phenomenon appeared to be insensitive to formulation changes given the test conditions.




Figure 6

Effect of filling temperature (5° C, 15° C, and 21.5° C) and drip test temperature (5° C [blue square] and 21.5° C [pink triangle]) on leakage from syringes filled with 1.0 mL of pure water.

Effect of Liquid Fill and Drip Test Temperature

Temperature is certainly one of the most important factors influencing the amount of leakage, particularly the temperature during liquid fill and drip test. The former represents the final equilibration condition that the liquid experiences before being sealed in the syringe. Assuming the liquid is filled and tested under the same ambient pressure, higher test temperature/lower fill temperature would result in bubble expansion and liquid leakage, but lower test temperature/higher fill temperature would cause bubble contraction and no liquid leakage. Theoretically there should be little or no leakage if fill temperature and test temperature are identical. This temperature effect takes both ideal gas expansion/contraction and gas solubility into consideration.

Syringes were manually filled with 1 mL of pure water at three temperatures, 5, 15, and 21.5 °C and tested for leakage at 5 and 21.5 °C at ambient pressure (0 psig). The results (Figure 6) confirmed that leakage can be minimized or completely avoided if the liquid fill temperature is equal to or higher than the drip test temperature, particularly filling at 21.5 °C resulting in almost no leakage. Thus, performing liquid fill at higher temperatures (if protein stability allows) is one of the most effective approaches to mitigate leakage when the needle shield is removed.

Effect of Needle Shield Removal Methods

Kinney and co-workers reported that needle shield removal creates vacuum at the tip of the needle




Figure 7

Effect of rigid needle shield removal methods on leakage from syringes containing 1.0 mL of pure water filled at 5° C and 0 psig.

which promotes leakage (3). This vacuum effect is probably inevitable. Therefore, this part of the study was to evaluate some needle shield removal procedures and identify the one having the least effect on leakage.

Syringes manually filled with 1.0 mL of pure water (under 0 psig bulk storage pressure) were tested by holding the syringe either vertically (needle tip pointing up and down) or horizontally and by carefully cutting the needle shield open (lengthwise into halves) to avoid or minimize any vacuum that may be created from pulling on the rubber part of the needle shield. As shown in Figure 7, the vertical (needle tip pointing downwards) and horizontal removal methods showed no observable differences and the amount of leakage remained high (25–27 mg). The cutting removal methods had a mild effect in reducing leakage (20–25 mg), suggesting leakage contributed by vacuum from removing the needle shield is minor. Vertically removing the needle shield with needle pointing upwards was most effective and caused almost no leakage. With the needle pointing upwards, the air bubble flowed to the top of the syringe, allowing air to vent for pressure reduction. This is the simplest solution to this leakage issue if users follow this recommendation.

Headspace Pressure Measurement

An optical gas analyzer (Model FMS-1400P, Lighthouse Instruments) was employed to directly measure headspace pressure in syringes filled with 1.0 mL of pure water that have been stored under a pressure of 0

TABLE III
Comparison of Headspace Pressure Measured Using an Optical Gas Analyzer and Derived from Drip Test (n = 5) in Syringes Filled with 1.0 mL of Pure Water

Bulk Storage	Headspace Pressure (Torr)	
	Gas Analyzer	Derived from Drip Test
0 psig	815	817 ± 4
20 psig	879	851 ± 4

psig or 20 psig prior to fill. In the meanwhile, the amount of leakage (in weight) measured by the drip test could be converted to pressure (Torr) using eqs 4 and 5 along with the physical dimensions in Table II. The results are summarized in Table III. The measured headspace pressure agreed well with what is derived from the drip test, suggesting that the drip test is a good tool for headspace pressure measurement and that headspace pressure increase is indeed the root cause of leakage.


Conclusions

Liquid leakage from the pre-filled syringe after needle shield removal is a phenomenon universal to all aqueous liquids. Other than the vacuum created during needle shield removal, we demonstrated that the root cause of leakage is an increase in headspace pressure dictated by multiple parameters, mainly the temperature and pressure history of the liquid bulk during the filling manufacturing process. Headspace pressure increase was primarily caused by ideal gas expansion and soluble gas re-equilibration between the liquid and the gas phases. We determined that performing liquid fill at a temperature close to a standard ambient temperature (~20 °C) or removing the needle shield while pointing the needle upward is most effective in minimizing leakage. Lowering liquid bulk storage/filtration pressure or using a low solubility gas (e.g., helium) for storage/filtration is also useful in alleviating headspace pressure/leakage.

Conflict of Interest Declaration

The author(s) declare that they have no competing interests.

Appendix I. Stopper Insertion Tool (not drawn to scale)



Appendix II. Solubility Profile of Different Gases in Water at 1 atm

According to Reference 7, the mole fraction solubility X_1 of the gas can be derived from the smoothing equation at each temperature:


$$\ln X_1 = A + \frac{B}{T^*} + C \ln T^*$$

where

$$T^* = \frac{T}{100 K}$$

Plugging in all the constants from the table below, a solubility profile can be plotted from 273K to 328K.

Equation Constants	He	N ₂	O ₂
A	-41.4611	-67.3877	-66.7354
B	42.5962	86.3213	87.4755
C	14.0094	24.7981	24.4526



References

- Romacker, M.; Shoenknecht, T. The Rise of Prefilled Syringes from Niche Product to Primary Container of Choice: A Short History. Presented at PDA Conference “The Universe of Pre-filled Syringes and Injection Devices,” San Diego, USA, 2008. www.pda.org/prefilled2008 (accessed August 16, 2010).
- Berends, W. Development of a Prefilled Syringe: Filling of Pre-filled Syringes. Presented at PDA Europe Conference “The Universe of Pre-Filled Syringes & Injection Devices,” Venice, Italy, 2009.
- Kinney, H.; Wagner, A.; Phillips, C. W. A rational approach to determining the maximum allowable gas bubble inside a prefilled syringe to minimize stopper movement and protect product sterility. *Drug Deliv. Technol.* **2009**, *9*, 42–47.
- Lighthouse Instruments website, FMS-1400 Head-space Pressure/Moisture Analyzer, <http://www.lighthouseinstruments.com/NewFiles/vacuum.html> (accessed August 16, 2010).
- Hamme, R.; Emerson, S. The solubility of neon, nitrogen and argon in distilled water and seawater. *Deep Sea Research Part I: Oceanographic Research Papers* **2004**, *51* (11), 1517–1528.
- Smith, N.; Kelemen, S.; Nagy, B. Solubility of natural gases in aqueous salt solutions. *Geochimica et Cosmochimica Acta* **1961**, *24* (1–2), 23–31.
- Gevantman, L. H. Solubility of Selected Gases in Water. In *CRC Handbook*, 86th ed.; CRC Press LLC: Boca Raton, Florida, 2004, pp 8-86–8-87.
- Masoudi, R.; Tohidi, B.; Danesh, A. Modelling Gas Solubility in Saline Solution and Its Importance to IOR Gas Injection. Institute of Petroleum Engineering, Heriot-Watt University: Edinburgh, UK, 2000.

APPENDIX A

JAMES L. MULLINS, PhD

Prior Art Documentation Librarian Services, LLC

205 Saint Cuthbert, Williamsburg, VA 23188

jlmullins@priorartdoclib.com

ph. 765 479 4956

Prior Art Documentation Librarian Services, LLC. (PADLS). Founded January 2018. As of April, 2022, 98 declarations have been completed for 35 law firms; four depositions scheduled, three cancelled a few days prior, and one was held, and was successful for my client.

Library Experience:

2018-present Dean Emeritus of Libraries and Esther Ellis Norton Professor Emeritus

2011 - 2017 Dean of Libraries & Esther Ellis Norton Professor

2004 - 2011 Dean of Libraries & Professor, Purdue University, West Lafayette, IN

**2000-2004 Assistant/Associate Director for Administration, MIT Libraries,
Massachusetts Institute of Technology, Cambridge, MA.**

**1996-2000 University Librarian & Director, Falvey Memorial Library. Villanova University,
Villanova, PA.**

1978-1996 Director of Library Services, Indiana University South Bend.

1974-1978 Associate Librarian, Indiana University Bloomington, School of Law.

1973-1974 Instructor/Catalog Librarian. Georgia Southern College (now University).

Teaching Experience:

**1977-1996 Associate Professor (part-time), School of Library and Information Science, Indiana
University. Subjects taught: Cataloging, Management, and Academic
Librarianship.**

Education:

The University of Iowa. Honors Bachelor of Arts in History, Religion and Political Science.

The University of Iowa. Master of Arts in Library Science.

Indiana University. Doctor of Philosophy. Concentration: Academic Library Administration.

Emphasis: Law Librarianship.

Regeneron Exhibit 1103.161

Regeneron v. Novartis

IPR2021-00816

Awards and Recognition:

2017 Wilmeth Active Learning Center/Library of Engineering and Science, Grand Reading Room, was announced by President Mitch Daniels, Purdue University, that it would be re-named the James L. Mullins Reading Room to honor his leadership and reputation in the academic library profession. September 2017. Portrait unveiled December 2017.

2017 Distinguished Alumnus Award by the School of Informatics and Computing, Indiana University, Bloomington. Given June 25, 2017.

2016 Hugh C. Atkinson Memorial Award, jointly sponsored by the four divisions of the American Library Association (ALA), June 27, 2016.

2015 ACRL Excellence in University Libraries Award, April 23, 2015.

Named Esther Ellis Norton Professor of Library Science by Purdue Trustees, December 11, 2011.

International Review Panel to evaluate the University of Pretoria Library, February 20 – 24, 2011. Pretoria, South Africa.

Publications: (selected)

A Purdue Icon: creation, life, and legacy, edited by James L. Mullins, Founder's Series, Purdue University Press, 138pp., August 2017.

“The policy and institutional framework.” In *Research Data Management, Practical Strategies for Information Professionals*, edited by Ray, J M. Purdue University Press, pp.25-44, 2014.

“DataCite: linking research to data sets and content.” In Benson, P and Silver, S. *What Editors Want: An Author's Guide to Scientific Journal Publishing*. University of Chicago Press, pp. 21-23, December 2012.

“Library Publishing Services: Strategies for Success,” with R. Crow, O. Ivins, A. Mower, C. Murray-Rust, J. Ogburn, D Nesdill, M. Newton, J. Speer, C. Watkinson. *Scholarly Publishing and Academic Resources Coalition (SPARC)*, version 2.0, March 2012.

“The Changing Definition and Role of Collections and Services in the University Research Library.” *Indiana Libraries*, Vol 31, Number 1 (2012), pp.18-24.

“Are MLS Graduates Being Prepared for the Changing and Emerging Roles that Librarians must now assume within Research Libraries?” *Journal of Library Administration*. Volume 52, Issue 1, 2012, p. 124-132

Baykoucheva, Svetla. What Do Libraries Have to Do with e-Science?: An Interview with James L. Mullins, Dean of Purdue University Libraries. *Chem. Inf. Bull.* [Online] 2011, 63 (1), 45-49. <http://www.acscinf.org/publications/bulletin/63-1/mullins.php> (accessed Mar 16, 2011).

“The Challenges of e-Science Data-set Management and Scholarly Communication for Domain Sciences and Technology: a Role for Academic Libraries and Librarians,” chapter in, *The Digital Deluge: Can Libraries Cope with e-Science?*” Deanna B. Marcum and Gerald George, editors, Libraries Unlimited/Teacher Ideas Press, 2009. (a monograph publication of the combined proceedings of the KIT/CLIR proceedings).

“Bringing Librarianship to e-Science,” *College and Research Libraries*. vol. 70, no. 3, May 2009, editorial.

“The Librarian’s Role in e-Science” *Joho Kanri (Journal on Information Processing and Management)*, Japan Science and Technology Agency (formerly Japan Information Center of Science and Technology), Tokyo, Japan. Translated into Japanese by Taeko Kato. March 2008.

The Challenge of e-Science Data-set Management to Domain Sciences and Engineering: a Role for Academic Libraries and Librarians,” KIT (Kanazawa Institute of Technology)/CLIR (Council of Library and Information Resources) International Roundtable for Library and Information Science, July 5-6, 2007. Developments in e-science status quo and the challenge, The Japan Foundation, 2007.

“An Administrative Perspective,” Chapter 14, *Proven Strategies for Building an Information Literacy Program*, Susan Curzon and Lynn Lampert, editors, Neal-Schuman Publishers, Inc., New York, 2007. pp. 229-237.

Library Management and Marketing in a Multicultural World, proceedings of the IFLA Management and Marketing (M&M) Section, Shanghai, China, August 16-17, 2006, edited. K.G. Saur, Munchen, Germany, June 2007. 390 pp.

Top Ten Assumptions for the Future of Academic Libraries and Librarians: a report from the ACRL Research Committee, with Frank R. Allen and Jon R. Hufford. *College & Research Libraries*, April 2007, vol.68, no.4. pp.240-241, 246.

To Stand the Test of Time: Long-term Stewardship of Digital Data Sets in Science and Engineering. A report to the National Science Foundation from the ARL Workshop on New Collaborative Relationships: the Role of Academic Libraries in the Digital Data Universe. September 26-27, 2006, Arlington, VA. p.141. <http://www.arl.org/bm~doc/digdatarpt.pdf>

“Enabling Interaction and Quality in a Distributed Data DRIS,” *Enabling Interaction and Quality: Beyond the Hanseatic League*. 8th International Conference on Current Research Information Systems, with D. Scott Brandt and Michael Witt. Promoted by euro CRIS. Leuven University Press, 2006. pp.55-62. Editors: Anne Garns Steine Asserson and Eduard J. Simons.

"Standards for College Libraries, the final version approved January 2000," prepared by the ACRL College Libraries Standards Committee (member), *C&RL News*, March 2000, p.175-182.

"Standards for College Libraries: a draft," prepared by the ACRL College Libraries Section, Standards Committee (member), *C&RL News*, May 1999, p. 375-381.

"Statistical Measures of Usage of Web-based Resources," *The Serials Librarian*, vol. 36, no. 1-2 (1999) p. 207-10.

"An Opportunity: Cooperation between the Library and Computer Services," in *Building Partnerships: Computing and Library Professionals*. Edited by Anne G. Lipow and Sheila D. Creth. Berkeley and San Carlos, CA, Library Solutions Press, 1995. p. 69-70.

"Faculty Status of Librarians: A Comparative Study of Two Universities in the United Kingdom and How They Compare to the Association of College and Research Libraries Standards, " in *Academic Librarianship, Past, Present, and Future: a Festschrift in Honor of David Kaser*. Englewood, Colorado; Libraries Unlimited, 1989. p. 67-78. Review in: *College & Research Libraries*, vol. 51, no. 6. November 1990, p. 573-574.

Presentations: (Representative)

“How Long the Odyssey? Transitioning the Library and Librarians to Meet the Needs and Expectations of the 21st Century University,” David Kaser Lecture, School of Informatics & Computing, Indiana University, Bloomington, IN, November 16, 2015.

Presentation at University of Cape Town, Cape Town, South Africa, August 20, 2015.

“The Challenge of Discovering Science and Technology Information,” Moderator, International Federation of Library Associations (IFLA) Science and Technological Libraries Section Program, Cape Town, South Africa, August 18, 2015.

“An Odyssey in Data Management: Purdue University,” International Federation of Library Associations (IFLA) Research Data Management: Finding Our Role – A program of the Research Data Alliance, Cape Town, South Africa, August 17, 2015.

Presentation at University of Pretoria, Pretoria, South Africa, August 11, 2015.

Co-Convener with Sarah Thomas, Harvard University, at the Harvard Purdue Symposium on Data Management, Harvard University, Cambridge, MA, June 15-18, 2015.

“Strategic Communication,” panel discussion on the Director's role and perspective on library communications at Committee on Institutional Cooperation (CIC) Center for Library Initiatives (CLI) Annual Conference, University of Illinois Urbana-Champaign, May 20, 2015.

“Issues in Data Management,” panel discussion moderated by Catherine Woteki, United States Undersecretary for Research, Education & Economics at 20th Agriculture Network Information Collaborative (AgNIC) Annual Meeting in the National Agricultural Library, Beltsville, MD, May 6, 2015.

“Active learning/IMPACT & the Active Learning Center at Purdue University,” Florida Institute of Technology, Melbourne, FL, February 11, 2015.

“Science+art=creativity: libraries and the new collaborative thinking,” panel moderator, International Federation of Library Associations (IFLA) 80th General Conference and Assembly, Lyon, France, August 19, 2014.

“Purdue University The Active Learning Center—A new concept for a library,” Association of University Architects 59th Annual National Conference, University of Notre Dame, South Bend, IN, June 23, 2014.

“Big Data & Implications for Academic Libraries,” keynote speaker, Greater Western Library Alliance (GWLA) Cyber-infrastructure Conference, Kansas City, MO, May 28, 2014.

“Research Infrastructure,” panel moderator, Association of Research Libraries (ARL) 164th Membership Meeting, Ohio State University, Columbus, OH, May 7, 2014.

“An Eight Year Odyssey in Data Management: Purdue University,” International Association of Scientific and Technological University Libraries (IATUL) 2013 Workshop Research Data Management: Finding Our Role, University of Oxford, UK, December 2013.

“Purdue University Libraries & Press: from collaboration to integration,” Ithaka Sustainable Scholarship, The Evolving Digital Landscape: New Roles and Responsibilities in Higher Education, libraries as publishers, New York, New York, October 2013.

“Tsinghua and Purdue: Research Libraries for the 21st Century,” Tsinghua University, Tsinghua, China, August 2013.

“Purdue Publishing Experience in the Libraries Publishing Coalition,” Association of American University Presses Annual Meeting, Press-Library Coalition Panel, Boston, Massachusetts, June 21, 2013.

“Indiana University Librarians Day: Purdue University Libraries Ready for the 21st Century,” Indiana University Purdue University Indianapolis (IUPUI), June 7, 2013.

“Purdue University Libraries and Open Access; CNI Project Update,” Coalition for Networked Information, San Antonio, TX, April 5, 2013.

Memorial Resolution, honoring Joseph Brannon, to the Board of the Association of College & Research Libraries, Seattle, WA, January 2013.

“An overview of sustaining e-Science collaboration in an Academic Research Library—the Purdue experience,” Duraspace e-Science Institute webcast, October 17, 2012.

“The Role of Libraries in Data Curation, Access, and Preservation: an International Perspective,” Panel Moderator, 78th General Conference and Assembly, International Federation of Library Associations, Helsinki, Finland, August 15, 2012.

“21st Century Libraries,” moderator of First Plenary Session, International Association of Technological University Libraries 33rd Annual Conference, Singapore, June 4, 2012.

“Planning for New Buildings on Campus,” panel presenter, University of Calgary Building Symposium on Designing Libraries for the 21st Century, Calgary, Alberta, Canada, May 17, 2012.

“Data Management and e-Science, the Purdue Response.” Wiley-Blackwell Executive Seminar-2012, Washington, DC, March 23, 2012.

“An overview of Sustaining e-Science Collaboration in Academic Research Libraries and the Purdue Experience.” Leadership & Career Development Program Institute, Association of Research Libraries (ARL). Houston, TX, March 21, 2012.

“An overview of Data Activities at Purdue University in response to Data Management Requirements.” Coalition for Academic Scientific Computation (CASC). Arlington, VA, September 8, 2011.

“Getting on Track with Tenure,” Association of College and Research Libraries (ACRL) Research Program Committee. Washington, DC, June 26, 2011.

“Integration of the Press and Libraries Collaboration to Promote Scholarly Communication,” Association of Library Collections & Technical Services (ALCTS) Scholarly Communication Interest Group – American Library Association, New Orleans, Louisiana, June 25, 2011.

“Cooperation for improving access to scholarly communication,” with N. Lossau (Germany), C. Mazurek (Poland), J. Stokker (Australia), panel moderator and presenter, Second Plenary Session, International Association of Scientific and Technological University Libraries (IATUL) 32nd Conference 2011, Warsaw, Poland. May 29-June 2, 2011.

“Riding the Wave of Data,” STM Annual Spring Conference 2011. Trailblazing & transforming scholarly publishing 2011. Washington, D.C., April 28, 2011.

“Confronting old assumptions to assume new roles: physical and operational integration of the Press and Libraries at Purdue University,” keynote speaker, 2011 BioOne Publishers & Partners Meeting. Washington, D. C., April 22, 2011.

“Are MLS Graduates Being Prepared for the Changing and Emerging Roles that Librarians must now assume within Research Libraries?” University of Oklahoma Libraries Seminar, March 4, 2011, Oklahoma City, Oklahoma.

“The Future Role of University Librarians,” the University of Cape Town, South Africa, February 25, 2011.

“New Roles for Librarians: the Application of Library Science to Scientific/Technical Research – Purdue University – a case study. International Council for Science and Technology (ICSTI); Ottawa, Canada. June 9, 2009.

“Reinventing Science Librarianship: Models for the Future,” Association of Research Libraries / Coalition for Networked Information. October 16-17th, 2008, Arlington, VA. Moderator and convener of Data Curation: Issues and Challenges.

“Practical Implementation and Opportunities Created at Purdue University,” African Digital Curation Conference, Pretoria, South Africa, (live video transmission), February 12, 2008.

Keynote speaker. “*Scholarly Communication & Academe: The Winter of Our Discontent*,” XXVII Charleston Conference on Issues in Book and Serial Acquisition, Charleston, South Carolina. November 8, 2007.

Keynote speaker. “*Enabling Access to Scientific & Technical Data-sets in e-Science: a role for Library and Archival Sciences*,” Greater Western Library Alliance (GWLA), Tucson, Arizona. September 17, 2007. A meeting of library directors and vice presidents for research of member institutions.

“*The Challenge of e-Science Data-set Management to Domain Sciences and Engineering: a Role for Academic Libraries and Librarians*,” KIT (Kanazawa Institute of Technology)/CLIR (Council of

Library and Information Resources) International Roundtable for Library and Information Science, July 5-6, 2007. Invited to participate by the Deputy Librarian of Congress.

International Association of Technological University Libraries (IATUL), Stockholm, Sweden. June 8, 2007. Invited paper, *Enabling International Access to Scientific Data-sets: creation of the Distributed Data Curation Center (D2C2)*.

“A New Collaboration for Librarians: The Principles of Library and Archival Sciences Applied to the Curation of Datasets,” Symposium of the Libraries and the College of Engineering, University of Louisville, April 6, 2007.

“Purdue University Libraries: Through Pre-eminent Innovation and Creativity, Meeting the Challenges of the Information Age,” Board of Trustees, Purdue University, February 15, 2007.

ARL Workshop on New Collaborative Relationships: The Role of Academic Libraries in the Digital Data Universe, September 26-27, 2006, Arlington, VA. Invited participant.

NARA and SDSC: A partnership. A panel before the National Science Foundation, June 27, 2006. Arlington, VA. Invited participant.

“Kaleidoscope of Scientific Literacy: fusing new connections,” with Diane Rein, American Library Association, Association of College and Research Libraries, Science & Technology Section, Annual Conference, New Orleans, June 26th, 2006.

“Leadership for Learning: Building a Culture of Teaching in Academic Libraries – an administrative perspective,” American Library Association, Association of College and Research Libraries, Instruction Section, Annual Conference, New Orleans, June 25th, 2006.

“Building an interdisciplinary research program in an academic library:

how the Libraries’ associate dean for research makes a difference at Purdue University,” International Association of Technological University Libraries (IATUL), Porto, Portugal, May 23rd, 2006.

“Enabling Interaction and Quality in a Distributed Data DRIS,” *Enabling Interaction and Quality: Beyond the Hanseatic League*. 8th International Conference on Current Research Information Systems, with D. Scott Brandt and Michael Witt. Promoted by euro CRIS, Bergen, Norway, May 12th, 2006, Brandt, and Witt presented in person

“Interdisciplinary Research,” with D. Scott Brandt, Coalition for Networked Information (CNI) Spring Meeting: Project Briefing, Washington, D.C., April 3rd, 2006.

“An Interview with Purdue’s James Mullins,” a podcast submitted by Matt Pasiewicz, on *Educause Connect*, http://connect.educause.edu/James_L_Mullins_Interview_CNI_2005

“Managing Long-Lived Digital Data-sets and their Curation: Interdisciplinary Policy Issues,” Managing Digital Assets Forum, Association of Research Libraries (ARL), Washington, D.C., October 28th, 2005.

“The Odyssey of a Librarian.” Indiana Library Federation (ILF), District 2 Meeting, South Bend, Indiana. October 4th, 2005.

"New College Library Standards," Standards Committee Presentation, ALA, Chicago, July 7, 2000. SUNY Library Directors, Lake George, New York. *“The College Library Standards: a Tool for Assessment.”* April 5, 2000.

Tri-State College Library Association, *Finding You Have Talents You Never Knew You Had*, Penn State Great Valley, March 25, 2000.

Using Web Statistics, American Library Association, New Orleans, June 24, 1999.

Keynote speaker at the JSTOR Workshop, January 29, 30, 1999. University of Pennsylvania, Philadelphia, PA.

"The New Standards for Electronic Resources Statistics," Society of Scholarly Publishers, Washington, D.C., September 17, 1998.

"Evaluating Online Resources: Now that you've got them what do you do?," joint presenter with Chuck Hamaker, LSU, at the NASIG Conference, Boulder, Colorado. June 1998.

"What Employers Are Looking for in New Librarians?" Pennsylvania Library Association, Philadelphia. September 26, 1997.

"The Theory of Matrix Management" panel presentation of the Comparative Library Organization Committee of the Library Organization and Management Section of the Library Administration and Management Association, a division of the American Library Association, Annual Meeting, Chicago, June 24, 1990.

Professional Involvement: (summary of recent emphasis)

The focus for my professional involvement and research has moved recently toward managing massive data-sets. This has resulted in working with faculty in the sciences and technology to determine how librarians can collaborate in managing, curating, and preserving data-sets for future access and documentation. This has included various speaking opportunities as well as participation in planning with the National Science Foundation (NSF) on ways in which librarians can be integrated more completely into the funded research process. Participation in the Kanazawa Institute of Technology/Council of Library Resources Roundtable was particularly rewarding and provided new opportunities to share with international colleagues the issues surrounding data-set management. I was

the champion for the creation of the Distributed Data Curation Center (D2C2) at Purdue University (<http://d2c2.lib.purdue.edu/>)

Throughout my career, beginning with my dissertation, I have been actively involved with assessing and evaluating libraries. In the fall of 1999, I contacted twenty-two academic library directors to determine whether the need was also felt by others. The response was overwhelmingly affirmative. This resulted in a meeting at ALA Midwinter, January 2000. A formal meeting followed at Villanova University in April 2000. As convener, I helped to form the University Libraries Group (ULG), modeled after the Oberlin Group for college libraries. The ULG is made up of university libraries that support diverse wide-ranging programs through doctoral level and have a level of support that places them in the top tier of academic institutions. A few of the member libraries, along with Villanova, are William and Mary, Wake Forest, Lehigh, Carnegie-Mellon, Tufts, Marquette, Miami of Ohio, and Southern Methodist. In 1994 appointed to the Standards Committee, College Section, Association of College and Research Libraries. During the next six years, the Committee concentrated on changing the focus of the standards from quantitative analysis of input and output factors to emphasis on assessment of the outcome. Culmination of the work was a re-issue of the *Standards for College Libraries* in 2000. The knowledge gained through my work experience enabled me to formulate the changes needed in the standards. This work allowed for close collaboration with accrediting agencies, both professional and regional. During this same time another focus emerged, the impact of digital resources. Through my work on the JSTOR Statistics Task Force, standards were developed on the collection of use of electronic databases. This Standard was later adopted in 1998 by the International Consortium of Library Consortia (ICOLC). In 2002, the American Library Association appointed me to serve as the liaison to the Marketing and Management Section of the International Federation of Library Associations (IFLA).

Professional Service: (representative list)

Nominations Committee, Association of Research Libraries (ARL), 2016.

Steering Committee, Scholarly Publishing and Academic Resources Coalition (SPARC), 2016 – 2017.

“Excellence in Library Services,” Chair, Review Team, University of Hong Kong, Hong Kong, August 24-27, 2015.

Chair, Management Advisory Board, 2015-2017; Member, Scientific Advisory Board, arXiv, Cornell University, 1/1/2013 – present.

Advisory Board for the Wayne State University School of Library and Information Science, July 2012 – present.

Advisory Board for Microsoft Academic Search, 2012 – 2015. Redmond, WA.

Transforming Research Libraries, a Strategic Direction Steering Committee of the Association of Research Libraries (ARL), 2012-2015.

Science and Technology section, representing ARL, International Federation of Library Associations (IFLA), Chair, 2013 – 2017; Member, 2011 to present.

Member of University of Pretoria, South Africa, Library Review Committee. August 2013.

Co-chair, Local Arrangements Planning Committee for 2013 Conference, Association of College and Research Libraries (ACRL), a division of the American Library Association (ALA).

Association of Research Libraries Leadership & Career Development Program Mentor, 2011-2017.

e-Science Task Force, Association of Research Libraries. July 2006 – present. Chair, October 2011 – October 2012.

Board of Directors, International Association of Technological University Libraries (IATUL). January 2008 – December 2014.

Midwest Collaborative for Library Services (MCLS); Board Member, October 2010 – December 2012.

Chair, Library Directors, Committee on Institutional Cooperation (CIC), July 2010 – June 2012.

Board of Directors, Association of Research Libraries (ARL); October 2008 – October 2011.

Scholarly Communication Steering Committee, Association of Research Libraries (ARL) 2008-2011.

Editorial Board, *College and Research Libraries*, Association of College and Research Libraries, American Library Association. January 2008 – December 2014.

Chair, Organizing Committee for IATUL Conference 2010, June 21-24, 2010, Purdue University, West Lafayette, Indiana/Chicago, Illinois.

Conference Planning Committee for National Conference of the Association of College and Research Libraries, 2009, Seattle, Washington.

Research Committee, Association of College and Research Libraries, ACRL, division of ALA. 2002-2007, chair, 2005-2007.

Association of Research Libraries, Search and Screen Committee, Executive Director. March – January 2008.

Center for Research Libraries, Board of Directors. April 2006 – April 2012.

Academic Libraries of Indiana, Board of Directors, 2004 – present. Vice-president, 2005-2007. President, 2007- 2009.

ALA Representative to the International Federation of Library Associations (IFLA), Marketing and Management (M&M) Section, initial term 2003-2007, re-appointed for second term, 2007-2011.

Invited to represent Research Libraries at the ACRL/3M Wonewok Retreat to assess Marketing of Academic Libraries, October 2002.

Hugh A. Atkinson Award Committee, LAMA Representative, ALA, 2001-2005.

Program Committee, Library Administrators and Management Association (LAMA), a division of ALA. 1996-2001.

ACRL, Standards and Accreditation Committee, a division of ALA. Liaison to RBMS Section of ACRL. 1997-2002.

Elected to the Executive Committee of LAMA, LOMS, a division of the American Library Association, 1998-2000. Nominated as Chair/Elect for 2003 – 2005.

Columbia University Press Advisory Committee. 1996 - 2000.

LITA/LAMA Conference Evaluation Committee, Pittsburgh, Pennsylvania, October 1996.

"New Learning Communities," Coalition for Networked Information, Indianapolis. November 19-21, 1995. Facilitator for invitational, national conference committed to developing collaborative learning and teaching techniques, involving librarians.

Planning Committee-Evaluation. LITA/LAMA 1996 Conference, Pittsburgh. This first conference, to be held jointly between two divisions of ALA, will focus on new technologies within libraries.

Indiana Cooperative Library Services Authority (InCoLSA), elected to Executive Committee, April 1991, served as President in 1993-94. InCoLSA is a statewide network of academic, public, school, and special libraries that supports library cooperation for cataloging, interlibrary loan, collection development and application of new technologies.

Governor's Conference on Libraries and Information Services. Served on Planning Committee, Academic Libraries Representative, appointed by the Governor to represent academic libraries in Indiana, Chair, Finance Committee, April 1989-July 1991.

Indiana Library Endowment Foundation Board, 1984-92. Charter Member, 1984, President, 1988-1992. 2004-2005.

University Service: (Summary)

Served on search and screen committees for senior positions including chancellor, dean, and directors; most recently I have been asked to serve on the search committee for the provost of Purdue University.

At MIT service included the Library Council & appointment to the Administrative Council by President

Vest, 2001-2003 & Member of the Faculty Committee on the Library System. At Purdue appointed by the President to the Search Committee for the Provost, October 2007 to May 2008; member of the Capital Projects Committee, and IT Operational Oversight Committee as senior academic dean, 2008-2014.

Global Council, Global Policy Institute, 2012 – 2016.

Academic Program Excellence and Rankings (APER) project team, 2014.

Representative of the Academic Deans on the Re-engineering Business Operations, Purdue University, 2016 –

Academic Deans Council chaired by Provost – 2004 – 2017.

University Promotion and Tenure Committee – 2006 – 2017.

"Outstanding Team Award, Electronic Reserve Project," served as Chair, recognition awarded by the President of Villanova University to one team who made an outstanding contribution to the operations of the University, selected by a committee of administrators, faculty, and staff. Awarded September 9, 1999.

Nominated for the IUSB Lundquist Award, 1995 & 1996. The Lundquist award is given to faculty who have "exhibited excellence in teaching, scholarly or artistic achievement, and diversified relevant service..."